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Cell-based regenerative medicine therapies (RMTs) hold great potential for the 
treatment of a wide range of injuries and disease. There are several concerns which 
hinder the translation of RMTs to the clinic, an important one being our lack of 
understanding of how the cells behave following administration. To address this, we 
need to be able to track the cells using non-invasive imaging techniques. A further 
problem is that in some applications, a large proportion of the implanted cell 
population will die shortly after delivery, reducing the efficacy of the therapy. A 
potential solution is to encapsulate the cells in hydrogels that provide a supportive 
environment for cell survival, and that help to protect the cells from the host’s immune 
system. However, before using this approach in the clinic, it is necessary to be able to 
monitor the behaviour of the hydrogels in animal models to ensure their safety and 
monitor their rate of degradation. 
In this study, novel contrast agents have been explored for the in vivo tracking of 
mesenchymal stromal cells (MSCs) and encapsulating hydrogels with fluorescence 
and photoacoustic imaging techniques. The two types of contrast agents that have been 
assessed in the project are polymer-stabilised nanoparticles prepared by 
nanoprecipitation and nanodiamonds.  These nanoparticles have been prepared with 
perylene diimide (PDI) derivatives, a class of organic dyes with high absorptivity and 
photostability.  
For cell-tracking with photoacoustic imaging, a near-infrared (NIR) absorbing PDI 
derivative was prepared with absorption at ~710 nm. PDI nanoparticles were prepared 
by nanoprecipitation with our novel star hyperbranched block copolymer stabiliser 
(DEAMA50-c-DEGDMA2)-b-(OEGMA80). These nanoparticles were shown to be 
III 
 
effective contrast agents for photoacoustic imaging whilst also having limited 
cytotoxicity and good cellular uptake in MSCs. The NIR-absorbing PDI nanoparticles 
were also investigated for their ability to label cell-encapsulating hydrogels. MSCs 
were seeded in collagen hydrogel constructs that had been labelled with PDI 
nanoparticles. The labelled hydrogels could be visualised with both fluorescence and 
photoacoustic imaging and the nanoparticles had limited cytotoxicity. However, 
further work is required to prevent nanoparticles leaching out of the hydrogels over 
time.  
Nanodiamonds (NDs) have been investigated for cell tracking with fluorescence 
imaging techniques due to their high biocompatibility. PDI-NDs were prepared and 
compared with commercial fluorescent NDs with nitrogen-vacancy (NV) defects, and 
it was found that particle aggregation hindered the efficacy of PDI-NDs. NV NDs with 
a particle size of 90 nm appeared as superior contrast agents for the labelling of MSCs, 
exhibiting high fluorescence intensity, limited aggregation and excellent cellular 
uptake.  
The experiments conducted herein have highlighted 90 nm NV NDs as effective 
contrast agents for cell tracking with fluorescence imaging. Additionally, polymer 
stabilised NIR-absorbing PDI nanoparticles can be effectively visualised in MSCs 
with photoacoustic imaging techniques. These probes can be used to determine the 
mechanism of action of cells expressing the firefly luciferase reporter, to 
simultaneously monitor the viability of administered cells using bioluminescence 
imaging in order to aid the design of safe and efficacious cell-based RMTs. 
Furthermore, preliminary work herein has highlighted the potential of using PDI 
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Chapter 1: Introduction 
 
1.1 Regenerative Medicine Therapies  
In recent years, cell-based regenerative medicine therapies (RMTs) have been 
extensively explored for their ability to restore cells/tissue/organs which have been 
damaged by disease or trauma.1 Broadly, cell-based RMTs include stem cells, 
progenitor cells and stromal cells; however, the definition has been extended to any 
cell-based therapy which has the capacity to regenerate.2 Stem cells have two specific 
properties: the capacity to self-renew through cell division, and the ability to 
differentiate into specialised cell types.3, 4 They can be categorised based on their 
ability to differentiate, where unipotent, multipotent and pluripotent stem cells are able 
to differentiate into one, multiple or all cell types within a mature organism, 
respectively.  
RMTs could offer a solution to the problems associated with organ and tissue 
transplants, such as limited donor supply and organ rejection.1, 5 Although significant 
advances have been made to reduce the rejection of organs by immunosuppression, 
this is not always effective and can cause detrimental side effects. Therefore, if 
successful, RMTs could avoid the reliance on donors, and by using autologous cells it 
could be possible to circumvent rejection issues.  
One of the most widely-used and successful RMTs are hematopoietic stem cells from 
bone marrow or umbilical cord blood, used for the treatment of leukaemia and other 
blood disorders.6 Many advances in the regenerative medicine field have looked at 
exploring cell-based treatments for renal, cardiovascular and neurodegenerative 
diseases.7-10 Although bone marrow transplants have been used for over 50 years, it 
was not until the first human embryonic stem cell line (hESC) was established in 1998 
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that the stem cell field began to rapidly expand.11 The derivation of the first hESC line 
gave rise to much optimism because these cells are pluripotent and have the ability to 
generate all cell types in the adult human.12 However, there are several ethical concerns 
around the use of ESCs, namely because their procurement requires the destruction of 
the human embryo, and also undifferentiated ESCs pose a risk of tumour formation.13 
Hence, this stimulated research into RMTs derived from adult sources, such as 
mesenchymal stromal cells (MSC) which is a type of multipotent progenitor cell that 
can be derived from bone marrow and other tissues, including adipose tissue and 
umbilical cord.14 
MSCs have an ability to differentiate into different cell types, including fat, bone and 
cartilage, and have promising immunomodulatory properties.15 Although at first it was 
thought that administered MSCs could differentiate in vivo to replace injured cells,  it 
is now widely thought that their main therapeutic effect is via paracrine factors that 
stimulate immunomodulation and other repair processes.16   MSCs are of particular 
interest due to their potential use as an autologous treatment. Despite this, there is a 
high variation in clinical outcomes, possibly due to factors such as age and weight, and 
so allogenic therapies from young, healthy donors are also being explored.17  
1.1.1 Limitations and Safety Concerns 
Despite the high volume of research into RMTs, there are many safety concerns which 
hinder their clinical translation. Unlike pharmacological therapies, cell-based RMTs 
are capable of persisting and proliferating in the body, with the potential to migrate to 
other organs.18 As previously mentioned, some administered RMTs have resulted in 
tumour formation, inherent of their rapid cell division, particularly for ESCs.13, 19 In 
addition to this, there are adverse side effects reported relating to immunogenicity.20  
These risks, combined with inconsistency in therapeutic outcomes based on 
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demographic factors, mean that while many cell-based RMTs have been tested in 
clinical trials, only a few have been found to be effective.  
Aside from safety concerns, there are many questions around the efficacy of RMTs. 
The lack of safety and efficacy data for RMTs can be attributed to a lack of 
understanding of their mechanism of action.  The ability to track the fate and 
biodistribution of administered cells in vivo will aid the translation of RMTs by 
providing invaluable information on cell survival, migration and mechanism of action, 
as well as addressing the aforementioned safety concerns.  
1.1.2 Cell Delivery 
Encapsulation of RMTs within protective polymer matrices, such as hydrogels, has 
been found to increase cell survival.21, 22 The polymer matrix offers novel benefits, 
such as limiting immunogenicity by protecting the cells from immune system 
components, whilst allowing the diffusion of nutrients.23, 24 Furthermore, constructs 
can be designed to mimic the extracellular matrix (ECM) to enable 3D cell growth and 
regulate differentiation.25 Hydrogels are defined as swollen 3D networks of polymers 
held together by physical or chemical crosslinking.26 The polymers can be either 
natural or synthetic, although the former is preferred for cell encapsulation due to 
biocompatibility.27  
Hydrogel scaffolds are of particular interest for cell delivery in spinal cord injury 
(SCI). RMTs have been widely explored as treatments for SCI and early clinical trial 
data has demonstrated some regenerative effects through increased sensory and 
locomotor function.28-31 Despite this, trials associated with SCI are still in their infancy 
as optimisation of the cell administration process is required to increase cell viability.32 
For instance, improved methods are needed to enable precise delivery of cells to the 
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required location and to prevent adhesion to the spinal surface and cell sedimentation; 
these problems could potentially be addressed through encapsulating the cells in 
hydrogels.33, 34 Furthermore, the mouldable structure can easily adapt to fit the space, 
and injectable hydrogels can facilitate a less invasive route of administration compared 
to surgical treatments.35, 36 
There are many different materials being explored as hydrogel constructs for SCI.37 
Alginate hydrogels have been investigated for cell delivery in SCI and it has been 
found that the addition of fibronectin, a component of the ECM, enhanced the 
regenerative effect of administered schwann cells.38 Hence, hydrogels that are able to 
mimic the ECM are of great significance for cell delivery in SCI.39, 40 Collagen is a 
major component of the ECM and has been employed in hydrogel development for 
cell delivery and tissue engineering applications.41, 42 Moreover, collagen hydrogel 
constructs were used to encapsulate neural cells for the treatment of SCI where the 
collagen matrix enabled astrocyte growth over an extended time frame.32  
There are several factors to consider when selecting suitable materials and designing 
hydrogel constructs for cell delivery including: (i) cell migration, (ii) cell survival, (iii) 
cell proliferation and (iii) the degradation rate of the hydrogel material. Hence, the 
ability to monitor cell release and hydrogel fate in vivo will aid the design of 
encapsulated RMTs. 
1.1.3 Tracking of RMTs 
Animal models help researchers obtain more information on the safety and efficacy of 
RMTs. Ex vivo imaging strategies have been developed together with histological 
analyses in order to confirm the biodistribution of MSCs in post-mortem samples.43 
However, this method does not allow tracking of administered cells with time, and 
5 
 
hence, non-invasive preclinical imaging technologies are preferred because they 
provide the capacity for researchers to monitor the same animal at various time 
points.44  
In order to track cells in vivo, they must either be engineered to contain reporter genes 
that code for proteins which exhibit a traceable signal, or labelled with probes. Using 
genetically engineered cells can be advantageous as it circumvents some of the 
problems associated with probes, such as signal dilution; i.e. when cells are labelled 
with probes, the signal is diluted 50% with each cell division. Furthermore, as it is the 
probe that is being imaged, there is a risk that the probe could be released from the cell 
and taken up by host cells, leading to false positive results.  
Despite this, there are several limitations to the reporter gene approach, including the 
complex genetic engineering protocols with related safety concerns and the potential 
immunological response.45, 46 Furthermore, there have been significant advances in 
probe chemistry over recent years which has seen the development of a wide range of 
biocompatible nanoparticles ideal for cell tracking.47 Both the reporter gene and probe 
approaches are useful in different applications and can also be used simultaneously for 
dual imaging capabilities.48  
When encapsulating cells in protective matrices, it is important to be able to track cell 
release in order to optimise the construct material and cell delivery process. In addition 
to this, it is also useful to be able to monitor the integrity of the hydrogel constructs in 
vivo to observe fragmentation and degradation.27 Hydrogels can be engineered to 
provide contrast with bioimaging techniques, either by chemical modification of the 
polymers used to prepare the gel or by incorporation of contrast agents upon gel 
assembly.49-51 Furthermore, being able to distinguish between the labels of the cells 
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and hydrogel would enable simultaneous tracking of cell release and gel integrity in 
vivo.  
 
1.2 Bioimaging Techniques and Probes 
The five main types of pre-clinical imaging techniques include nuclear imaging, 
magnetic resonance imaging (MRI), optical (including fluorescence and 
bioluminescence), ultrasound and photoacoustic imaging (PAI). A summary of the 
imaging capabilities of each technique can be found in Table 1.1. Furthermore, 
significant developments have been made to design contrast agents for each of the 
bioimaging techniques. Some of the contrast agents used for the tracking of cell-based 
RMTs are shown in Figure 1.1.  









Nuclear Imaging  1-2 mm Seconds-minutes No limit 
MRI 40-100 µm Minutes-hours No limit 




Ultrasonography >30 µm Seconds-minutes 3-4 cm 




Figure 1.1: Summary of the five main bioimaging techniques utilised for cell tracking 
and the common contrast agents employed. Nuclear imaging modalities include 
positron emission tomography (PET) and single photon emission computed 
tomography (SPECT) with associated radionucleotide metal contrast agents. Magnetic 
Resonance Imaging (MRI) contrast agents are gadolinium chelates, superparamagnetic 
iron oxide nanoparticles (SPION) and perfluorocarbons (PFC). Photoacoustic (PA) 
probes include gold nanoparticles (AuNP), semiconducting polymer nanoparticles 
(SPN) and small molecules. Bioluminescence imaging (BLI) utilises luciferase 
enzymes and fluorescence imaging probes include fluorescent proteins, carbon-based 
materials, such as nanodiamonds (ND) and quantum dots (QD). Probes capable of 
providing ultrasound contrast are microbubbles and perfluorocarbons (PFC). 
1.2.1 Nuclear Imaging 
Nuclear imaging includes positron emission tomography (PET) and single photon 
emission computed tomography (SPECT), where the signal comes from measuring the 
decay of a radionucleotide. Contrast agents for PET/SPECT include unstable atoms 
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which release particles through radioactive decay to reach a more stable form. For 
PET, a positron is emitted which collides with a free electron to form a positronium; 
this decays by annihilation to form a  pair of gamma rays which are detected by the 
scanner.53 In contrast, SPECT tracers emit gamma radiation directly and are detected  
using rotating gamma cameras and a collimator; hence SPECT has lower sensitivity.54  
Contrast agents for PET are based upon unstable isotopes, where the most common 
PET tracers contain fluorine-18 or zirconium-89. PET has been widely used in the 
clinic for imaging tumours using the 18F-fluorodeoxyglucose (18FDG) radiotracer.55, 56 
The glucose aspect of 18FDG enables accumulation at tumour sites which is thought to 
be due to the high metabolic rate of cancer cells, making 18FDG an excellent marker 
for tumours. The half-life of 18F (t1/2 = 110 min) is significantly longer than other 
common radioactive isotopes such as 13C (t1/2 = 20 min); however, 
89Zr is the most 
suitable for cell tracking, with a half-life of 78 hr.57, 58  
PET/18FDG can be a useful tool for assessing the biodistribution and homing of stem 
cells within the early phase of administration, thus enabling optimisation of the dosing 
and delivery method.59 In one study, PET/18FDG was specifically used to quantify 
myocardial retention and evaluate the possible different delivery methods when 
administering cardiac-derived stem cells in a rodent models.60 The widespread use of 
18FDG makes it the obvious choice for cell labelling; however, the short half-life limits 
its utility and hence more recent research has focussed on other isotopes, such as 89Zr- 
(t1/2 = 78 hr) and 
111In-based radiotracers (t1/2 = 2.8 d).
61-64 
Nuclear imaging has also been used for monitoring hydrogel delivery and retention in 
mice.51 Alginate-based hydrogels have been prepared by utilising the SPECT tracer, 
111In, as an ionic crosslinker. MSCs were encapsulated in the hydrogels for cardiac 
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repair which could be visualised with SPECT, thus demonstrating the feasibility of 
monitoring hydrogel retention in vivo with nuclear imaging.  
The main benefits of PET/SPECT are the high sensitivity and unlimited penetration 
depth. However, the imaging time window is limited to the half-life of the 
radionucleotide and the spatial resolution is poor without co-localisation with 
computed tomography (CT) or magnetic resonance imaging (MRI).45 In addition to 
this, there are safety concerns associated with over-exposure to radiation.65  
1.2.2 Magnetic Resonance Imaging  
One of the main advantages of MRI in bioimaging is the lack of ionising radiation. 
MRI works by monitoring the spin alignment of water protons in the direction of an 
applied magnetic field. Hydrogen nuclei precess at a particular frequency which is 
disturbed upon introduction of a perpendicular radio frequency pulse.66 When this 
pulse is removed, protons return to their aligned state through equilibration of the net 
magnetisation and this process is called relaxation. Protons in different 
tissues/fats/organs relax to different extents resulting in the complex greyscale images 
observed in MRI.67 The high sensitivity of the technique to soft tissue has seen the use 
of MRI in imaging the brain and spinal cord, as well as assessing cardiac function and 
tumour detection.68-70  
There are two mechanisms of proton relaxation: longitudinal (T1) and transverse (T2) 
and hence there are two types of contrast agent for MRI. T1 contrast agents are 
commonly based on gadolinium (III) ions, a paramagnetic lanthanide species with 7 
unpaired electrons.71 Gd alters relaxation properties of protons through an interaction 
with the protons in local water molecules. This mechanism is thought to involve 
changes in the water exchange rate in the gadolinium coordination sphere and water 
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diffusional correlation time, as described by Solomon, Bloembergen and Morgan 
(SBM) theory.72, 73 Gd-based contrast agents are used in the clinic; however, as 
elemental Gd is toxic, organic multidentate ligands are required to reduce 
transmetallation. An example of this is FDA-approved Dotarem® where the DOTA 
macrocycle (1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid) chelates the 
Gd(III) ions.74 
Significant efforts have been made to develop Gd-based probes for cell tracking as the 
Gd-chelates alone have unfavourable cellular uptake and cytotoxicity. One approach 
was to incorporate Gd complexes into mesoporous silica nanoparticles (MSN) for the 
tracking of human MSCs.75 The probes showed excellent cellular internalisation and a 
sufficient loading of Gd was achieved which enabled in vivo MRI for 14 days. Another 
approach linked a Gd-chelate to rhodamine particles using a dextran polymer for the 
tracking of neural stem cells.76 A Gd-chelate has also been covalently attached to 
chitosan hydrogels for monitoring gel degradation with MRI.77  
Superparamagnetic iron oxide nanoparticles (SPION) are T2 contrast agents which are 
more widely used for biomedical applications due to their low cytotoxicity and ease of 
synthesis.78, 79 Particularly for cell tracking applications, their superior cellular uptake 
and biocompatibility has meant they are more widely investigated compared to Gd-
based tracers. SPIONs are colloidal suspensions of magnetite (Fe3O4) or maghemite 
(γ-Fe2O3), usually with a polymeric coating to prevent aggregation.
80, 81 Dextran is the 
most common coating for SPIONs, where it has been shown that the surface charge 
can be tailored, by incorporating the diethylaminoethyl (DEAE) group, to improve 
cellular uptake and negate the need for transfection agents.82 These DEAE-Dextran-
SPIONs could effectively be used to label macrophages where hepatic localisation was 
observed in vivo.83 Furthermore, SPIONs have been used to label cellulose/silk fibroin 
11 
 
hybrid hydrogels;84 this enabled monitoring of hydrogel integrity with MRI without 
affecting the proliferation rate of encapsulated MSCs for applications in cartilage 
regeneration.  
1.2.2.1 Fluorine-19 MRI 
There are several advantages of 19F which make it suitable as an MRI contrast agent, 
including relatively high sensitivity (83% of 1H), 100% natural abundance and there 
is relatively low amount of 19F in biological tissue; hence, 19F MRI essentially allows 
background-free visualisation of 19F probes.85-87 Furthermore, the most common 
contrast agent, perfluorocarbons (PFC) have been extensively explored as blood 
substitutes and now many are available as 19F probes, for example commercially 
available CelSense.88-90  
PFCs are linear or cyclic carbon molecules where all of the protons have been 
substituted by fluorine atoms and the strong C-F bond renders PFCs chemically inert. 
They are extremely hydrophobic and hence PFC nanoemulsions have been 
developed.91 Surfactants are used to stabilise the nanoemulsion which can also impart 
desirable surface properties to promote cellular uptake.86  
Examples of PFCs used in cell tracking include perfluoropolyether (PFPE), 
perfluorooctylbromide (PFOB) and perfluoro-15-crown-5-ether (PFCE).92  PFCs has 
been encapsulated in poly(lactic-co-glycolic acid) (PLGA) nanoparticles as efficient 
19F probes for dendritic cell tracking.93 Furthermore, the manipulation of the 
nanoparticle ultrastructure enabled control over the in vivo clearance rate, where multi-
core particles produced fast-clearing highly sensitive 19F probes thus minimising local 
retention time and associated safety concerns.94 Fluorinated PLGA nanoparticles have 
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also been developed as multimodal probes;95, 96 the particles can be tracked with 19F 
MRI and could also be loaded with dyes for optical or photoacoustic contrast. 
MRI techniques are widely used in the clinic due to unlimited penetration depth and 
minimal safety concerns associated with the lack of ionising radiation. However, the 
high temporal resolution means that image acquisition takes much longer which is 
intensive work in preclinical studies where multiple animals are required.  
1.2.3 Optical Imaging 
The two main types of optical imaging used for the tracking of cell-based RMTs in 
small animals are bioluminescence and fluorescence.44 Both techniques involve the 
detection of light emitted from a cell which expresses a reporter gene or has been 
labelled with a probe. The widespread use of optical imaging techniques in cell 
tracking is owed to their high sensitivity and low cost.  
1.2.3.1 Bioluminescence Imaging 
In BLI, the light detected has been biochemically emitted by a luciferase enzyme. The 
enzyme can be found in a variety of organisms where the North American firefly 
(Photinus pyralis) has been most extensively studied, however luciferase is also found 
in certain bacteria, insects and fish.97, 98 BLI is therefore particularly useful for 
monitoring the biodistribution of luciferase-expressing cells in rodent tissues and 
organs, as it generates a high signal-to-noise ratio and hence high sensitivity.99 One of 
the main factors which prevents the clinical translation of this technique, is the need 
for a substrate such as luciferin (the substrate for Firefly luciferase).100 BLI also suffers 
from poor spatial resolution and a limited penetration depth, as well as an inability to 
visualise particular organs due to light scattering.101  
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Live animal imaging can be non-invasively carried out by engineering cells with 
bioluminescent reporter genes that encode a luciferase. Luciferase is the generic term 
for a group of enzymes which catalyse the oxidation of a substrate. In the case of 
Firefly luciferase, which is the luciferase most commonly used for small animal 
imaging, the substrate is  luciferin, which emits  light in the presence of oxygen, Mg2+ 
and ATP.102  Firefly luciferase converts D-luciferin into oxyluciferin, resulting in light 
emissions at 562 nm (Figure 1.2). 
 
Figure 1.2: The conversion of D-luciferin to oxyluciferin by firefly luciferase in the 
presence of oxygen and ATP 
BLI has been a useful tool for tracking the fate of administered cells in vivo to monitor 
cell migration and survival.101 Generally, cells are first genetically engineered to 
express luciferase before being administered into rodent models.103 The dependence 
of luciferase on oxygen and ATP metabolism means that BLI will only detect cells 
which are alive, where other techniques may show both alive and dead cells.44 BLI has 
been used for the tracking of neural progenitor cells to assess engraftment and 
migration in order to optimise the timing of administration after spinal cord injury in 
mice.104 Similar studies have been carried out to assess cell survival and migration in 
rodents of a wide variety of administered cells including cardiac progenitor cells, 
MSCs, and ESCs.105-107 In most cases, BLI could be corroborated by ex vivo 
histological analysis.  
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1.2.3.2 Fluorescence Imaging 
Fluorescence imaging can be carried out on cells modified with reporter genes to code 
for fluorescent proteins, or cells which have been labelled with fluorescent probes. The 
proteins/probes absorb light of a particular wavelength and emit light, typically of a 
longer wavelength.108 The excitation and emission wavelengths are specific to a 
particular protein/probe and the difference between them is known as the Stoke’s shift. 
The efficiency of a fluorophore is described by the quantum yield (Φ), as shown in 




  (Equation 1.1) 
Similar to BLI, fluorescence imaging has high sensitivity; however, the spatial 
resolution and penetration depth inhibits routine use in the clinic and makes it difficult 
to image internal organs in rodents. One of the many advantages of fluorescence 
imaging is the capabilities for high contrast. There is an optical window at 700-900 
nm where the light-absorbing molecules in tissue, such as fat, water, melanin and 
haemoglobin, have the lowest absorption coefficient.110 Hence contrast agents can be  
designed to absorb within the optical window to enable deeper light penetration as less 
light is absorbed by endogenous absorbers. 
Cells can be transfected with fluorescent reporter genes which encode for fluorescent 
proteins. Common examples include green fluorescent protein (GFP) and red 
fluorescent protein (RFP) which fluoresce at 509 nm and 618 nm, respectively.47 
Significant progress in genetic engineering has enabled the development of GFPs with 
improved properties, such as enhanced brightness and stability, as well as the 
development of  GFP-like proteins of different colours.111 Far-red and near-infrared 
(NIR) fluorescent proteins have been developed, such as Katushka2S which enabled 
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small animal whole body imaging with minimal background signal due to its  
absorbance peak being within the optical window.112  
Fluorescent probes have been widely explored for cell tracking applications, in 
particular quantum dots (QDs). QDs are semiconducting nanoparticles which have 
interesting optical and electronic properties owing to quantum confinement. Hence, 
their properties are dependent upon particle size, shape and surface chemistry.113, 114 
QDs have many advantages including resistance to photobleaching, high molar 
extinction coefficient, broad spectrum absorbance, and high resistance to 
degradation.115 Furthermore, QDs have been prepared with absorption/fluorescence in 
the NIR region to increase signal-to-noise ratio.116  
QDs have been made from a variety of materials including CdSe, CdS, CdTe, InP, 
carbon and silicon nanoparticles.117-120 One of the hurdles in the development of QD 
for cell tracking is cytotoxicity, and hence it is common for QDs to be coated to 
improve biocompatibility. CdSe QDs were found to be cytotoxic due to surface 
oxidation leading to the release of Cd2+ ions.121 It was found that the cytotoxic effect 
was significantly reduced when CdSe QDs were coated with ZnO or bovine serum 
albumin.  Furthermore, the circulation lifetime of core-shell CdSe-ZnS QDs can be 
increased by surface modification with long poly(ethylene glycol) (PEG) chains for 
whole body fluorescence imaging of mice.122  
Organic dyes have also been developed as fluorescent probes for cell and gel tracking, 
in particular cyanine dyes. IRDye 800CW is a cyanine derivative which has been 
incorporated into hyaluronan hydrogels to monitor hydrogel integrity in vivo with 
fluorescence imaging techniques.123 IRDye 800CW was covalently attached to thiol 
groups included in the modified hyaluronan macromolecules. By monitoring the 
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fluorescent signal of the dye, hydrogel degradation could be assessed and it was found 
that the rate of degradation could be controlled by changing hydrogel concentration.  
Indocyanine green (ICG) is a tricarbocyanine dye with emission around 800 nm, well 
within the optical window. In addition to this, ICG has the significant advantage of 
already being FDA-approved for use in humans with only a few rare cases of adverse 
side effects.124 ICG has been successfully used for tracking MSCs with both NIR 
fluorescence and photoacoustic imaging.125 Despite this, there are a number of 
disadvantages to the use of ICG in cell tracking; it has relatively weak fluorescence 
and low photostability so must be imaged within 10 hours.126 Hence, rylene 
derivatives, in particular perylene diimides (PDI), are another class of organic dyes 
which have emerged as fluorescent probes due to their bright fluorescence, high 
quantum yield and high photostability.127, 128 
Carbon-based materials, including graphene, carbon nanotubes (CNTs), fullerenes, 
carbon dots and nanodiamonds (NDs), have more recently been investigated due to 
their interesting optical properties which are can be exploited for cell tracking. 
Generally, graphene and CNTs require a surface coating in order to improve 
biocompatibility, and fullerene derivatives have issues with solubility.129-132 Carbon 
dots are a relatively new class of material which are being explored for cell and 
organelle tracking.133, 134  
NDs have been shown to have high fluorescence intensity and also extremely low 
cytotoxicity, thus offering an advantage over other carbon-based materials and 
QDs.135-137 NDs are defined as a dense network of sp3 hybridised carbon atoms which 
give a rigid structure thus resulting in high chemical inertness. Defects can be 
introduced to the diamond structure which can alter the optical properties of the NDs, 
where the most common are nitrogen-vacancy defects, NV0 and NV-.138 Furthermore, 
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the surface chemistry of the NDs can be exploited for the attachment of targeting 
ligands, drug molecules and dyes thus rendering NDs ideal candidates for theranostic 
applications.139-141  
Although there are examples of cell tracking with fluorescence imaging, the utility of 
the technique is hampered due to photon scattering in biological tissue, limiting the 
penetration depth. Despite this, fluorescent imaging can still provide useful 
information in cell tracking experiments; for instance, the intra-organ distribution of 
administered cells can be quickly and easily confirmed after in vivo experiments by 
imaging the dissected organs after animal sacrifice. NDs have been shown to be 
excellent candidates for this due to their high stability under physiological conditions, 
which was confirmed by fluorescence imaging in mice after 37 days.142 Moreover, 
NDs could be detected during ex vivo histological analysis where it was also shown 
that high doses (up to 75 mg/kg body weight) did not cause toxicity. 
1.2.4 Ultrasound Imaging 
Ultrasound imaging is another bioimaging technique that does not require ionising 
radiation and has other advantages, including excellent spatial and temporal 
resolution.52 Furthermore, ultrasound can be used at the bedside and hence is one of 
the most wide-spread and cost efficient imaging modalities. Images are generated as 
sound waves are attenuated/reflected/scattered by tissue and ultrasound has been a 
useful tool for guided stem cell delivery.143 The most common ultrasound contrast 
agent is a gas-filled microbubble.52, 144, 145 Microbubbles are most commonly used in 
diagnostics, in particular for contrast enhancement during echocardiograms; however, 
they are also being explored as drug carriers for therapeutic applications.146, 147  
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Many studies have focussed on  improving the efficacy of microbubbles by stabilising 
the gas-liquid interface with lipids, polymers and proteins.148 The use of PFCs as the 
internal gas phase has also been shown to stabilise microbubbles and hence many of 
the commercially available microbubbles have a fluorinated gas core.149, 150 This 
research has opened up opportunities to explore the use of ultrasound for cell 
tracking;151-153 this field had previously been hindered by microbubble instability 
making long-term imaging a challenge. More recently, PLGA particles containing 
liquid PFCs have been shown to enable ultrasound contrast for long-term imaging of 
dendritic cells with ultrasound and 19F MRI.154  
1.2.5 Photoacoustic Imaging  
Photoacoustic imaging (PAI) combines the advantages of optical imaging with 
ultrasound, whereby light is converted to sound waves via the photoacoustic effect, as 
demonstrated in Figure 1.3. A laser is irradiated on a sample and photon absorption 
causes an increase in the transient temperature, resulting in thermoelastic expansion 
and ensuing relaxation. This produces sound pressure waves which are detected by an 
ultrasound transducer. An image can then be reconstructed based on the amplitude of 
the wave and the time it takes to hit the detector.155 The conversion of light to sound 
waves presents a significant advantage in terms of penetration depth as phonons are 
scattered approximately three orders of magnitude less than photons.156  
PAI has a penetration depth of up to 4-5 cm in biological tissue which is significantly 
deeper than optical imaging (Table 1.1). Furthermore, PAI has other advantages, such 
as higher spatial resolution and the capacity for tomographic imaging means that it is 
easier to locate cells in the body; therefore, PAI is suited to imaging internal organs of 
intact small animals.44 One drawback of the technique is that it is difficult to image the 
lungs due to the presence of air.18  
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Different biological tissues have different absorption, thermal and elastic properties 
and hence the resultant sound waves have different amplitudes and reach the detector 
at different times, thus giving information on depth and tissue characteristics. As with 
optical imaging, strong absorbers, such as lipids, melanin and haemoglobin, have a 
strong photoacoustic signal and thus exogenous absorbers, including gold 
nanoparticles and organic dyes, are designed to absorb in the NIR region to improve 
sensitivity.  
 
Figure 1.3: Schematic representation of the principles of the photoacoustic effect. 
1.2.5.1 Multispectral Optoacoustic Tomography (MSOT) 
MSOT is a type of PAI where tissues can be excited at multiple wavelengths.157 Images 
can then be spectrally unmixed so that different absorbers in the tissue can be detected 
and visualised separately. One example of this is using PAI to monitor blood 
oxygenation; haemoglobin and oxyhaemoglobin are endogenous absorbers with 
different spectral absorption which can be distinguished by MSOT.158 Furthermore, as 
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well as endogenous absorbers, MSOT can simultaneously detect and spectrally unmix 
exogenous absorbers, such as reporter genes, NIR dyes and gold nanoparticles.159, 160 
MSOT can be used for small animal imaging; multiple cross-sectional images can be 
acquired in sequential steps which can then be used to build up a 3D image of animal 
or target tissue/organ. In cell tracking, this enables an understanding of the 
biodistribution of labelled cells across the whole body. MSOT can also be used for 
real-time tracking of pharmacokinetics, for example to analyse the accumulation or 
clearance of an exogenous absorber in a specific location.18 MSOT has been used for 
dynamic imaging of mice to assess the biodistribution of multiple exogenous 
absorbers;161 the clearance of indocyanine green from systemic circulation was 
observed along with the uptake of IRDye 800CW carboxylate in separate regions of 
the kidney. This demonstrated the high-resolution in vivo imaging capabilities of 
MSOT for tracking the fate of multiple exogenous absorbers in real-time. 
The multispectral unmixing capabilities of MSOT are ideal for cell tracking 
applications in order to distinguish the absorption of labelled cells from endogenous 
absorbers. Furthermore,  a study was carried out where cells were administered and 
tracked by simultaneously detecting multiple exogenous absorbers: gold nanorods and 
reporter genes.48 MSCs co-expressing BLI reporter luciferase and NIR fluorescent 
protein iRGP720 were labelled with gold nanorods; the nanorods highlighted the 
immediate distribution of the cells and were cleared after 15 days, whereas the NIR 
reporter gene could be detected up to day 40. The absorbance of each of the exogenous 
absorbers could be distinguished enabling effective short- and long-term 
biodistribution studies.  
Distinguishing between multiple absorbers is useful for tracking and distinguishing 
between multiple cell types. Furthermore, different exogenous absorbers could be used 
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to label cells and encapsulating hydrogels, enabling the simultaneous tracking of cell 
and hydrogel fate in vivo, thus making MSOT the ideal imaging modality for the 
present study.  
1.2.5.2 Photothermal Therapy (PTT) 
Another significant application of the photoacoustic effect is PTT. In this case, light is 
converted to heat in order to cause cell death.162 Hence, PTT shows strong promise as 
a non-invasive treatment for cancer as photothermal absorbers can be designed to 
target and enhance the generation of heat at tumour sites.163 The careful design of 
photothermal probes can minimise the effect on healthy tissue, thus limiting side 
effects. Advances in the progress of photothermal absorbers are extremely relevant 
when considering photoacoustic (PA) probes for cell tracking, as they share a common 
goal to develop particles capable of high photoacoustic efficiency.  
 
1.3 Photoacoustic Probes 
Exogeneous PA contrast agents include NIR reporter genes and nanoparticles, the 
latter of which can be categorised based on how they interact with light.159 Some 
nanoparticles absorb light via surface plasmon resonance (SPR), where optical 
absorption is dependent on the physical dimensions of the material, for example, gold 
nanorods. The second type of PA nanoprobes involve light absorbing organic dyes, 
such as cyanine or perylene dyes. 
1.3.1 Reporter Genes 
Genetically encoded florescent proteins which absorb in the far-red and NIR region of 
the spectrum can also been utilised in PAI due to their strong light absorption.164-166 
For example, iRFP can be used as a PA probe as it has an extremely high molar 
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extinction coefficient (105,000 M-1 cm-1) and low quantum yield (6%), with excitation 
and emission spectra in the NIR region.167 Furthermore, the fluorescent properties 
provide additional capacity for ex vivo fluorescence imaging.168  
The genetically encoded enzyme, tyrosinase, has also been investigated for generating 
PA contrast.169, 170 Tyrosinase catalyses the reaction of cellular tyrosine into the 
pigment eumelanin, which has broad absorption and high photostability.171 A study 
was carried out where mammalian cells encoded with the tyrosine reporter gene could 
be detected with PAI for up to 7 weeks, thus suggesting the potential for these probes 
in longitudinal studies.172 Despite these advances, overall reporter genes tend to have 
relatively low PA contrast and hence nanoparticle probes have been much more widely 
explored.44  
1.3.2 Gold Nanoparticles 
Gold nanoparticles (AuNP) absorb light due to surface plasmon resonance (SPR); SPR 
is a phenomenon which describes the collective oscillation of conduction electrons on 
the surface of a metal due to propagation of an electromagnetic wave when photons 
are absorbed.173 This results in an enhanced magnetic field at the surface, which is 
extremely sensitive to changes in the surrounding environment and hence AuNPs have 
been widely utilised in biosensing and diagnostics.174, 175 Spherical 5 nm AuNPs are 
red (λmax= 520 nm); however this is highly dependent on the composition, size, shape, 
inter-particle distance and surrounding environment.176 Hence these properties can be 
tailored to the desired application, i.e. to absorb in the optical window to create a highly 
sensitive PA probes.  
Spherical AuNPs have limited use for PAI due to weak NIR absorbance, and hence, 
other morphologies have been investigated, including Au nanorods, nanoshells and 
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nanocages (Figure 1.4).177 Modifications in the size, shape, dimensions and 
surrounding environment of such nanoparticles causes a shift in the SPR, which in turn 
alters the absorption profile.178  
 
Figure 1.4: The most common AuNP shapes and morphologies. 
Au nanoshells comprise a dielectric silica core with a surrounding conductive, gold 
shell where the absorption and scattering properties can be controlled by altering both 
the core and shell size.179 The nanoshells have high NIR absorbance and photostability 
and the gold surfaces of the nanoshell can be exploited for anchoring of polymers to 
increase uptake and biocompatibility.180 Nanoshells have been widely explored in 
cancer imaging and PTT.181-183  
Au nanorods are another class of AuNP which have seen wider use in targeting cellular 
receptors due to their smaller particle sizes (>100 nm).177 They are prepared by seed 
mediated growth methods which have been developed to enable control over the size 
and aspect ratio (i.e. ratio of length to width).184 For example, nanorods were 
synthesized with dimensions of 45 nm x 15 nm which resulted in an absorption peak 
at 810 nm. The relevant antibody was then conjugated to the surface for targeting of 
prostate cancer cells.185 The Au nanorods enabled effective detection of selected 
tumour cells using PAI with high sensitivity compared to non-tumour cells in vitro. 
Au nanorods have been used for the tracking of cells in vivo using PAI.186 As 
previously mentioned, AuNP properties are dependent on the inter-particle distance 
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and hence it has been found that endocytosis results in the tight packing of nanorods, 
leading to plasmon coupling.187, 188 Coating Au nanorods with silica has provided a 
solution to his problem by sterically hindering the close proximity of the particle 
without affecting the optical absorption.189 This enabled the successful tracking of 
MSCs in vivo with MSOT to give high sensitivity without affecting MSC viability or 
differentiation properties. It has also been found that coating Au nanorods with silica 
can increase cellular uptake 5-fold with limited effect on the viability, proliferation or 
pluripotency of MSCs.190   
Au nanocages consist of porous, hollow structures of cuboidal symmetry where their 
intense signal can be attributed to their large absorption cross-section.191 Au nanocages 
are prepared by the galvanic replacement of HAuCl4 with Ag templates where altering 
the molar ratio Ag:Au  enables the peak absorption to be tuned within the visible-NIR 
region.192 Au nanocages have made significant advances as probes for PTT, for 
example in targeting breast cancer.193, 194 As well as this, the hollow structure can be 
exploited for drug delivery and cancer therapeutics.195 PEG-coated nanocages 
effectively enhanced the contrast of blood for PAI of the cerebral cortex of mice.196 
Human MSCs labelled with Au nanocages could be effectively detected in a 
glioblastoma mouse model using PAI.197 Dual wavelength scanning enabled 
simultaneous imaging of the MSCs and endogenous absorbers in the tumour 
vasculature. 
The surface chemistry of AuNPs is widely explored which has hence further expanded 
their biomedical applications. Commonly, thiol groups have been attached to the 
surface of AuNP for the anchoring of a wide variety of molecules. For example, 
functional thiolates have been shown to be effective in stabilising gold nanoparticles 
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by incorporating groups such as PEG.198 As well as this, surface functionalisation has 
enabled applications of AuNPs in gene and drug delivery to be explored.199  
1.3.3 Quantum Dots 
QDs have previously been discussed as fluorescent probes however the optical 
properties have also been explored for PAI. For example, copper selenide and copper 
sulphide have absorbance in the NIR region and have been used for sentinel lymph 
node mapping in mice with PAI.200, 201 Despite this, the PA detection limit is much 
better for AuNPs, as QDs generally have much lower absorption in the NIR region.202 
Several methods have been explored to improve the PA sensitivity of QDs, where one 
idea is to design integrated QD-Au nanoprobes.203 Although the PAI signal is not as 
high as AuNPs, QDs could be used as hybrid contrast agents enabling both PAI and 
fluorescence imaging.204 
1.3.4 Carbon-Based Materials 
Nanosized reduced graphene oxide sheets have been shown to have high NIR 
absorption for PTT and PAI.205 NIR absorbance was increased 6-fold when the 
reduced graphene oxide sheets were functionalised with PEGylated polymer chains, 
which also improved the stability of the contrast agents in biological medium.206 
Similarly, reduced graphene oxide nanosheets have been functionalised with bovine 
serum album (BSA) which were found to be effective theranostic contrast agents for 
PAI/PTT in mice.207 Several studies have shown that coating Au nanorods with 
reduced graphene oxide layers can strongly amplify the photoacoustic signal compared 
to non-coated and silica coated Au nanorods.208, 209 
CNTs have also been widely explored as photoacoustic probes.210, 211 Similarly to 
graphene, most of the literature has focussed on the design of photoacoustic probes for 
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targeting applications or PTT.212 This can be attributed to the large surface area and 
ease of functionalisation of graphene and CNTs.209 Despite the high NIR absorption, 
CNTs often require a coating to reduce toxicity. Gold-plated CNTs provide a novel 
solution to this problem whilst also providing high contrast.213 CNTs were prepared 
with a diameter of 1.5-2 nm and a thin gold layer (4-8 nm) was deposited on the 
surface; changes in both the dimensions of the CNTs and the thickness of the gold 
enabled control over the absorbance properties. Small molecule dyes, such as ICG, can 
also be conjugated to the surface to enhance photoacoustic signal.214  
There are few examples of NDs in photoacoustic imaging, possibly due to their high 
quantum yield. NDs can be engineered with structural defects which alter the 
absorption properties. Nitrogen-vacancy (NV) defects are the most common defects 
which result in high fluorescence across the visible spectrum however more recently 
silicon-vacancy (SiV) defects have demonstrated NIR absorbance.215, 216 A more 
common approach to obtain a ND-based PA probe is to attach NIR-absorbing moieties 
to the surface. Examples include attaching small molecules such as cyanine dyes to the 
surface; however, Au-ND nanocomposites have also been explored.217 It has been 
hypothesized that combining NDs with Au enables energy transfer from the NDs to 
the Au clusters resulting in increased PA signal compared to AuNPs.218  
1.3.5 Semiconducting Polymer Nanoparticles 
Semiconducting polymer nanoparticles (SPN) are made up of electronically and 
optically active semi-conducting polymers and have been explored in electronic 
devices, photovoltaics and sensors.219-221 The unique semi-conducting properties come 
from the π-conjugated backbone of the polymers where a decrease in hydrophobicity 
is achieved through formulating into nanoparticles.222 One of the key advantages of 
SPNs is that they are organic and biologically inert thus making them ideal for 
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biomedical applications.223 This together with their high brightness, excellent 
photostability and versatile surface modification have propelled research into 
applications of SPNs in biological sensing applications, therapeutics and 
bioimaging.224-227  
In PAI, two NIR-absorbing SPNs developed for photovoltaic applications were 
assessed for contrast enhancement in mice and their performance was compared with 
gold nanorods.228 It was found that amplitude of the PA signal was much higher than 
for gold nanorods of the same concentration, thus suggesting dose levels could be 
reduced. SPNs have also been shown to be effective probes for tracking stem cells 
with PAI. Furthermore, the structural versatility of the SPNs opens the door to 
activatable probes for real-time monitoring of stem cell behaviours i.e. cell 
differentiation.229  
1.3.6 Cyanine Dyes 
Cyanine dyes have been previously discussed as fluorescent probes however they have 
also been explored as PA contrast agents. One example is IRDye 800CW carboxylate 
which has been used to visualise renal clearance in mice with MSOT.161 The NIR-
absorbing dye is water soluble and hence its capacity for monitoring renal function has 
been further developed for assessing the efficacy of kidney therapies in vivo with 
MSOT.230  
More commonly, indocyanine green (ICG) has been utilised for PAI due to its 
absorption in the NIR region (Figure 1.5). Furthermore, ICG has limitations for 
fluorescence imaging due to having a low quantum yield which is ideal for PAI where 
light energy is converted to acoustic waves.209 An extra benefit of ICG is that it is 




Figure 1.5: Chemical structure of ICG. 
One of the drawbacks of ICG is low photostability; the half-life of ICG in the blood 
stream is only several minutes and hence research efforts have focussed on trying to 
improve this. One approach looked at trapping ICG in MSNs which improved the 
stability of the dye and performances as a PA probe.231, 232 Photonic explorers for 
biomedical use by biologically localized embedding (PEBBLE) technology has also 
been explored for tackling the problems associated with ICG.177 The technology was 
originally utilised in sensing and therapeutic applications however entrapment of ICG 
in an organically modified silicate matrix was shown to stabilise the dye against 
aggregation, whilst retaining the high absorption.233 Furthermore, encapsulation of 
ICG in nanoparticles opens up opportunities for surface functionalisation with 
targeting moieties.  
ICG has also been encapsulated in PFC-loaded PLGA nanoparticles.95 PFC-based 
particles have been investigated as contrast agents for 19F MRI however the 
incorporation of ICG opens up opportunities for multimodal imaging. The probe 
combined the ease and sensitivity of PAI with the penetration depth and quantitative 
analysis of 19F MRI for applications in cell tracking and lymph node detection. 
Moreover, these particles are approved for a clinical cell tracking trial hence 
demonstrating the feasibility for clinical translation.  
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1.3.7 Perylene Diimide 
Rylene dyes have also been exploited for the high absorption properties, where 
perylene diimide (PDI) derivatives have gained traction in PAI due to absorption in 
the NIR region (Figure 1.6).234 Whilst the majority of research has focussed on 
photovoltaic and electronic applications, their high stability (thermal and photo) and 
unique electronic and optical properties are of great interest for bioimaging 
applications.235, 236  
 
Figure 1.6: General structure of PDI. 
The high molar extinction coefficient and photostability makes PDI stand out from 
other probes for PAI applications.159 PDI dyes also have strong fluorescence and have 
been used in fluorescence sensing applications.237, 238 Despite this, the high 
absorptivity of PDI derivatives means that they can still provide effective PA contrast. 
Furthermore, for cell tracking applications, the fluorescence properties provide 
additional capacity for ex vivo fluorescence imaging.  
The strong absorbance is derived from the electron dense perylene core where core 
expansion causes a red-shift in absorbance, albeit at the expense of solubility.239 
Furthermore, PDI is highly versatile compound where modification of the perylene 
core or imide groups can alter the physical properties (Figure 1.6). Modification at the 
bay and ortho positions have a significant effect on the wavelength of absorbance, 
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where electron-donating groups, such as pyrrolidine and pyrrolidinone, shift the 
absorption to the NIR region.240 However, modification at the imide position has a 
greater effect on solubility.  
The synthesis of PDI derivatives has been widely explored in the literature. Starting 
from commercially available PTCDA, multiple PDI derivatives can be synthesized 
with a range of absorption profiles.236, 237 The tunability of PDI is highly beneficial for 
MSOT, where spectral unmixing capabilities can be utilised. In principle, two PDI 
derivatives with different peak absorption could be detected and distinguished with 
MSOT, opening up opportunities for tracking of multiple PDI-based probes in one 
experiment.  
A drawback of PDI derivatives is that they suffer from poor solubility and hence PDI 
nanoparticles offer a novel advantage.241 Nanoparticles have been extensively 
explored in drug formulation where nano-sizing provides an effective way to improve 
water solubility.242, 243 Particle sizes of 10-1000 nm result in a high surface/volume 
ratio meaning that the properties of the material are defined by the surface. As a result, 
surface moieties are usually introduced to stabilise nanoparticles, preventing 
aggregation and improving bioavailability.244  
PDI nanoparticles have been explored as PA probes for deep tumour imaging in 
mice;245 the unique properties, including extraordinarily high photostability, low cost 
and ease of modification highlighted the potential of PDI-based probes for PAI. 
Further to this, the same group demonstrated the capabilities of PDI-based probes for 
identifying early thrombus and targeted PTT.246, 247 Throughout all of these studies, 
the probes were found to have limited cytotoxicity thus demonstrating the potential for 
PDI-based probes in cell tracking.  
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PDI nanoparticles have also been developed as dual PAI and PET imaging probes by 
labelling the nanoparticles with 64Cu.248 These particles were coating in PEG to 
increase biocompatibility and effectively used for lymph node mapping and cancer 
imaging. Further to this, another study developed theranostic PDI nanoparticles 
containing an anticancer drug, to enhance the generation of reactive oxidative species 
(ROS), and a ROS activatable near-infrared dye (IR790s). The probe was able to have 
a chemotherapeutic effect whilst also allowing for real-time monitoring of ROS 
generation through ratiometric PAI, at excitation wavelengths of 680 nm and 790 nm 
for PDI and IR790s dye, respectively.249  
 
1.4 PDI Nanoparticles for Tracking of Encapsulated RMTs 
PDI-based probes stand out as excellent PA contrast agents due to their high molar 
extinction coefficient and photostability. The versatile chemistry of PDI allows for 
tuneable optical properties and hence multiple PDI derivatives can be prepared with 
different peak absorption wavelengths. In principle, these derivatives could be 
employed to prepare two different sets of nanoparticles; these nanoparticles can then 
be used to label cells and hydrogels separately for the simultaneous tracking of cell 
biodistribution and hydrogel integrity with MSOT. The spectral absorbance of the two 
sets of nanoparticles could be unmixed enabling distinction between the labelled cells 
and labelled hydrogel in vivo.  
PDI derivatives also exhibit strong fluorescence which is a useful property for 
designing cell and gel tracking probes. For in vitro cell studies, it is important to be 
able to assess the cellular uptake of the nanoparticles, in particular flow cytometry is 
a useful tool for detecting labelled cells based on their fluorescence properties. 
32 
 
Furthermore, fluorescence microscopy of labelled cells can provide qualitative data on 
labelling efficiency and the ability to visualise labelled gels with in vitro fluorescence 
imaging is also of great importance.  
In preclinical studies, the fluorescence properties of the probes could be utilised for ex 
vivo imaging and histology, which are commonly carried out post-mortem to 
corroborate in vivo imaging data. It is worth noting that in some cases, it can be 
difficult to detect probes ex vivo due to signal dilution over the timescale of the 
experiment. Hence, high doses of nanoparticles could circumvent this problem which 
may be achieved by using particles with extremely low cytotoxicity. Hence, honing 
the high biocompatibility of nanodiamonds (NDs) by combining them with PDI could 
be the ideal solution. 
When designing probes for labelling encapsulated RMTs, there are several factors 
which must be considered. The probes must exhibit high signal so that imaging can be 
carried out at depth in vivo and the signal can still be detected even with dilution from 
cell proliferation. Furthermore, probes must be biocompatible and have limited 
cytotoxicity. For cell labelling, it is important to optimise parameters such as cellular 
uptake and retention. When designing probes to label gels, considerations include the 









1.5 Aims  
The purpose of this work is to investigate the performance of perylene diimide-based 
nanoprobes for the in vivo tracking of administered mesenchymal stromal cells and 
encapsulating collagen hydrogels with multispectral optoacoustic tomography and 
fluorescent imaging. The aims are as follows: 
1. To synthesize a near-infrared absorbing perylene diimide derivative that can 
be prepared into nanoparticles to efficiently label cells and enable their 
detection with multispectral optoacoustic tomography.  
2. To assess whether near-infrared absorbing perylene diimide nanoparticles can 
efficiently label cell-encapsulating hydrogels to enable their detection with 
multispectral optoacoustic tomography. 
3. To develop nanoprobes comprising a perylene diimide derivative and 
nanodiamonds for cell labelling to enable cells to be visualised with 
fluorescence imaging.  
The probes investigated herein will be assessed for their photoacoustic and fluorescent 














Chapter 2: Synthesis of Near-Infrared Absorbing Perylene 
Diimide Nanoparticles for Cell Labelling 
2.1  Introduction 
Rylene dyes are characterised as a framework of naphthalene units linked at the peri-
positions, where perylene, terrylene and quarterrylene are the first in the series (Figure 
2.1). Rylene diimides are a novel class of materials which consist of a rylene core with 
a π-accepting six-membered dicarboxylic imide at each end.250 These dyes have been 
investigated for their intense light absorption properties, owed to their highly aromatic 
and electron dense core, particularly in the dye and pigment, electronic and 
photovoltaic industries.239, 251, 252 Rylene diimide derivatives, particularly naphthalene 
diimide and perylene diimide, have gained significant interest due to their ease of 
modification, low cost, high chemical and thermal stability and high absorption.234  
 
Figure 2.1: Chemical structure of rylene dyes. 
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2.1.1 Perylene Diimide  
Perylene-3,4,9,10-tetracarboxylic dianhydride (PTCDA, Figure 2.2) is a commercially 
available, low-cost starting material which can be easily modified into various PDI 
derivatives.253  PTCDA is a red dye with poor solubility in water and other common 
solvents; however, chemical modification can alter both absorption maxima and 
solubility properties. Functionalisation at the bay position predominantly affects the 
optical properties whereas forming the diimide and exploring different imide 
substituents generally has a greater effect on solubility.239 
 
Figure 2.2: Chemical structure of perylene-3,4,9,10-tetracarboxylic dianhydride 
(PTCDA). 
2.1.2 Synthesis of Near-Infrared Absorbing Perylene Diimide Derivatives 
2.1.2.1 Core Expansion 
Core expansion of the perylene core has shown to cause a bathochromic shift in peak 
absorption, albeit at the expense of reducing solubility.254, 255 Terrylene, quarterrylene, 
pentarylene and hexarylene diimide derivatives have been synthesized where an 
absorption shift of around 100 nm is seen as the core size is increased by one 
naphthaline unit.254 An increase in molar extinction coefficient (ε) was also observed 
with larger rylene diimide derivatives. 
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The synthesis of terrylene and quarterrylene diimides is usually carried out via a 
coupling reaction from the monoimide, followed by dehydrogenation, or an alternative 
route is a one-pot fusion from the respective monoimides.254  Higher rylene diimide 
derivatives are much less common due to their more complex synthesis and their lower 
solubility arising from strong π-π stacking.256 
2.1.2.2 Imidization 
Reactions of PTCDA with aliphatic amines and anilines at the imide position have 
been carried out with high yield in the dye and pigment industry for some time.257 The 
simple condensation reaction is commonly carried out under reflux and inert 
atmosphere in N-methyl-2-pyrrolidinone with acetic acid for 6 hours.258, 259 More 
recently, a green chemistry approach has been adopted where the imidization process 
can be carried out under hydrothermal conditions, without the need for organic 
solvents or catalysts.260 
Many PDI derivatives suffer from poor solubility due to their planar aromatic structure 
resulting in strong π-π stacking. Hence it was found that attaching bulky alkyl or aryl 
groups to the imide position can increase solubility by disrupting the planarity of PDI, 
in particular tert-butyl groups or long-chain secondary alkyl groups (swallow-tail 
substituent).257, 261 N-substituted PDI derivatives such as these, have good solubility in 
chlorinated solvents; however, more hydrophilic groups are required to obtain water-
soluble PDI derivatives. Imidization with sulfonic acid moieties, crown ethers, 
cyclodextrin and polyglycerol dendrons have been reported although these PDI 
derivatives do not exhibit NIR absorbance.128, 257     
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2.1.2.3 Bay Functionalisation 
Bay modification can allow for extension of the perylene π-system, which in turn 
affects the peak absorption. Hence, the bromination of PDI derivatives at the bay 
position was a crucial building block for the development of NIR-absorbing PDI 
derivatives.236, 237 Typically, bromination of the perylene core has been carried out 
under harsh conditions using concentrated sulfuric acid with heating producing a 
mixture of the 1,6- and 1,7-isomers, where consequent recrystallisation or column 
chromatography has been used to obtain a pure yield.262  
Alternative routes to bromination of PDI derivatives have been explored in order to 
avoid the use of concentrated acids. Mild conditions of PDI bromination have been 
reported using excess bromine in dichloromethane however it was found that the imide 
groups affect the reactivity at the bay position.263 Bulkier groups disrupt π-π stacking 
of PDI derivatives, thus increasing reactivity. Therefore, when dimethyl pentyl groups 
were at the imide position, the reaction proceeded after 2 days at 22-24 °C; however, 
the reaction of a PDI derivative containing cyclohexyl imide groups required 4 days 
under reflux. Milder conditions result in a mixture of mono- and disubstituted 
brominated PDI derivatives. Indirect routes to bromination have also been explored to 
avoid harsh conditions and have been employed herein.236, 237 
Modifying the bay positions at the perylene core with hydrophilic substituents, such 
as poly(ethylene glycol) or peptide chains, can also increase the solubility albeit at the 
expense of NIR absorption.264 Thus it was found that attaching electron-donating 
amines, such as pyrrolidinyl or piperidinyl groups, to the perylene core causes a red 
shift towards the NIR region.127, 236 The red-shift is much more pronounced in 
disubstituted derivatives.263, 265 It was found that there was a greater red shift with 
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pyridinyl groups compared to piperidinyl due to short C-N bond length and greater sp2 
character of the nitrogen hybrid orbital.240 
2.1.2.4 Recent Advances in Perylene Diimide Synthesis  
More recent methods have investigated attachment of substituent groups at two 
positions in the perylene core, which has shown to cause a large red-shift. A facile, 
metal-free approach to annulation of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) to 
PDI has been established whereby DBU can act as both a reactant and catalyst to yield 
a derivative with absorbance at 750-800 nm.266 Another recent approach has involved 
thionation of the carboxylic acid groups causing a red-shift of approximately 50-100 
nm.267 
2.1.3 Applications of Perylene Diimide 
PDI derivatives, as well as other rylene dyes, have been historically used in the dye 
and pigment industry and played a significant part in the industrial revolution.252 They 
have predominantly been used as dyes in the industrial textile colourants, in red/black 
shades, but more recently, they have been developed as pigments, e.g. Pigment Violet 
29.235, 254, 268 The high stability, particularly photostability and stability against the 
weather, makes PDI derivatives ideal materials for coatings.  
More recent times has seen the evolution of these materials into ‘functional dyes.’ In 
particular, the electron-accepting character of PDI derivatives has led to interest for 
electronic and photonic applications, such as organic field-effect transistors (OFET), 
organic thin-film transistors (OTFT) and organic photovoltaic cells (OPV).235, 251, 269, 
270 The ease of modification and versatility of PDI derivatives, combined with control 
of stacking in the solid state, is advantageous compared to fullerenes which are 
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predominantly used as n-type semiconductors in solar cells.257, 262 Hence, PDI 
derivatives offer greater ease and ability of tuning the band gap. 
2.1.3.1 Biomedical Applications 
One of the key properties of PDI derivatives for biomedical applications, which is the 
focus of the present study, is the ease of modification to tune the absorption 
wavelength to the near-infrared (NIR) region (700-1000 nm). This is ideal for 
biomedical applications as NIR attenuation in tissues is relatively low,166, 271 and so 
suggests that PDI-based probes could be efficiently detected when administered in 
vivo, with minimal background signal from the body or endogenous fluorophores. 
Hence, PDI-based probes are being explored for applications in cell tracking.  
Photoacoustic imaging (PAI) is a useful imaging tool for tracking the fate and 
biodistribution of administered cells (stem cells, progenitor cells and other types of 
therapeutic cells), in order to aid the design of regenerative medicine therapies.189, 190 
Contrast agents for PAI have been designed to absorb >650 nm to increase signal-to-
noise and also to enable them to be distinguished from endogenous absorbers such as 
haemoglobin and water.166 Gold and cyanine dyes have previously been investigated 
as PAI contrast agents, as discussed in Chapter 1. 174, 189, 190, 233 PDI exhibits high 
photostability compared to cyanine dyes and greater ease of tunability in optical 
absorbance compared to gold nanoparticles. Therefore, these significant advantages 
have prompted research into PDI-based probes for PAI. 
In parallel with PDI-based probes for PAI, there is also reason to suggest that PDI 
could be utilised in photothermal therapies (PTT). Also based on the photoacoustic 
effect, PTT has been exploited for the treatment of cancer where tumour ablation can 
be caused by thermal stress induced by laser excitation. NIR-absorbing agents are ideal 
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for selective targeting, thus minimising the effect on healthy cells.163 At present, 
research into this area has involved gold nanoparticles or carbon-based materials, such 
as carbon nanotubes;193, 272, 273 however, there is clear potential for  NIR-absorbing 
probes in these type of applications, particularly with increasing interest in so-called 
theranostics (agents capable of therapeutic and diagnostic effects). 
2.1.4 PDI-Based Probes 
PDI-based nanoparticles offer superior properties which can improve the 
bioavailability, stability and signal intensity when compared to the free PDI dye.178 
PDI-based nanoparticles have previously enabled deep brain tumour photoacoustic 
imaging in mice.245 We have published a study investigating the use of PDI-based 
nanoparticles for tracking the fate and biodistribution of mesenchymal stromal cells 
(MSC) in vivo with multispectral optoacoustic tomography (MSOT).274  
MSOT is a form of PAI imaging whereby multiple wavelengths can be scanned and 
unmixed. This allows the effective detection of various light absorbing molecules to 
be distinguished. Hence, the ability to control the absorption wavelength of PDI 
derivatives opens up the capacity of multiple PDI-based contrast agents to be imaged 
simultaneously with MSOT. This would be particularly useful in cell tracking if more 
than one cell type was used, e.g. MSC and macrophages, or for tracking cells and 
encapsulating hydrogels simultaneously. 
2.1.5 Aims 
The present study will investigate the potential of perylene diimide nanoparticles as 
probes for tracking administered regenerative medicine therapies with multispectral 
optoacoustic tomography. The aims are as follows:  




using a multistep synthesis from commercially available perylene-3,4,9,10-
tetrecarboxylic dianhydride (PTDCA).  
2. To prepare near-infrared absorbing perylene diimide nanoparticles via 
nanoprecipitation with our novel star hyperbranched block copolymer 
(SHBP)275 or poly(vinyl alcohol) (PVA) as a stabiliser. 
3. To label mesenchymal stromal cells with perylene diimide nanoparticles and 




















All reagents were used as received from the manufacturer. Perylene-3,4,9,10-
tetrecarboxylic dianhydride (PTDCA, 97%), bromobutane (99%), butanol (99.8%, 
1,8-diazabicyclo[5.4.0]undec-7-ene (DBU, 98%), potassium hydroxide (≥85%), 
sodium bisulfite (≥99%), sodium sulfate (≥99%), p-toluenesulfonic acid monohydrate 
(99%), cyclohexylamine (≥99%), N-methyl-2-pyrrolidinone (99.5%), pyrrolidine 
(≥99%) and poly(vinyl alcohol) (MW 9-10K, 80% hydrolysed) were purchased from 
Sigma Aldrich. All solvents were HPLC grade VWR. Bromine (99.6%) was from 
Acros chemicals. The star hyperbranched block copolymer (DEAMA50-c-
DEGDMA2)-b-(OEGMA80) was prepared by Dr Ulrike Wais.
275 
2.2.2 Characterisation Methods 
1H NMR spectra were recorded using a Bruker Fourier 300HD NMR spectrometer 
(400 MHz) and spectroscopic data was obtained using a Vertex 70 Fourier Transform 
Infrared (FTIR) Spectrometer (Bruker). A Cary 5000 UV-Vis-NIR Spectrometer 
(Agilent) was used to measure absorption spectra of PDI derivatives in CH2Cl2 or 
CHCl3 (50 µg/ml) and PDI nanoparticles in water (0.15 mg/ml PDI). A Malvern 
Zetasizer Nano and associated Zetasizer software were used to determine information 
about the particles in aqueous suspension using dynamic light scattering (DLS). This 
included (i) the hydrodynamic diameter of the particles, which is the effective diameter 
of a particle calculated from the diffusion coefficient, (ii) the polydispersity index, 
which is a measure of the heterogeneity of sizes of particles, and (iii) zeta potential, 
which measures the electrical potential at the slipping plane. Samples were first diluted 
(25 µg/ml PDI) and consequently sonicated for 10 minutes prior to DLS analysis. 
Images of particles were acquired with a Hitachi S4800 Scanning Electron Microscope 
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(5 kV). One drop of nanosuspension was placed on SEM stub and left for the liquid to 
evaporate before coating with chromium. 
2.2.3 Synthesis of Perylene Diimide Derivatives 
2.2.3.1 Synthesis of Perylene-3,4,9,10-tetrabutylester (compound 1a) 
Brominated PTCDA (compound 2) was prepared following an established route by 
Sengupta et al. with small modifications. Briefly, perylenetetracarboxylic dianhydride 
(PTCDA, 4 g, 10 mmol), bromobutane (20 g, 0.146 mol), BuOH (13 g, 0.175 mol), 
DBU (15 g, 0.100 mol) and acetonitrile (ACN, 160 ml) were refluxed at 100 °C for 
18hr. The cooled reaction was then filtered, washed with methanol and purified by 
recrystallization in boiling BuOH. The pure orange compound 1a was isolated in 93% 
yield. 1H NMR (CDCl3, TMS): δ: 8.36 (d, 4H), 8.08 (d, 4H), 4.33 (t, 8H), 1.80-1.77 
(m, 8H), 1.50-1.47 (m, 8H), 0.99 (t, 12H). UV-vis (DMSO): 448 nm, 470 nm. 
2.2.3.2 Synthesis of 1,7-Dibromoperylene-3,4,9,10-tetracarboxytetrabutylester 
(compound 1b) 
Compound 1a (4 g, 6.13 mmol) and KOH (2 g, 14 mmol) were stirred in CH2Cl2 (50 
ml). Bromine (4 ml) was added dropwise and the reaction was stirred at room 
temperature for 24hr. A saturated aqueous solution of NaHSO3 was then added 
dropwise with stirring. The organic layer was then washed three times with water and 
dried over sodium sulfate. The crude orange product was a mixture of two isomers: 
compounds 1b and 1b(i). Compound 1b was isolated via double solvent 
recrystallisation from dichloromethane and acetonitrile (64% yield). 1H NMR (CDCl3, 
TMS): δ: 8.96 (d, 2H), 8.30 (s, 2H), 8.10 (d, 2H), 4.34 (t, 8H), 1.80-1.77 (m, 8H), 1.51-
1.44 (m, 8H), 0.99 (t, 12H). UV-vis (DMSO): 448 nm, 470 nm. 
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2.2.3.3 Synthesis of 1,7-Dibromoperylene-3,4,9,10-tetracarboxylic dianhydride 
(compound 2) 
Compound 1b (3 g, 3.75 mmol), p-toluenesulfonic acid monohydrate (3.6 g, 19 mmol) 
and toluene (105 ml) were refluxed at 100 °C for 30hr. The reaction was then cooled, 
filtered and washed with methanol and water. The dried product was then refluxed at 
75 °C in CHCl3 (150 ml) for 3hr to obtain the pure product in 83% yield. 
1H NMR 
could not be measured due to the extremely low solubility of compound 1b. UV-vis 
(DMSO): 495 nm, 524 nm. 
2.2.3.4 Synthesis of N,N’-Dicyclohexyl-1,7-dibromoperylene-3,4,9,10-
tetracarboxy diimide (compound 3) 
Compound 2 (1.5 g, 2.78 mmol), cyclohexylamine (0.8 g, 8.1 mmol), acetic acid (0.9 
g, 15.0 mmol) and N-methyl-2-pyrrolidinone (30 ml) were refluxed at 85 °C under a 
N2 atmosphere for 6hr. The resulting red precipitate (compound 3) was filtered, 
washed with methanol and dried in an oven. The final yield was 42%. 1H NMR 
(CDCl3, TMS): δ: 9.48 (d, 2H), 8.85 (s, 2H), 8.67 (d, 2H), 5.05-4.99 (m, 2H), 2.59-
2.53 (d, 8H), 1.93-1.25 (m, 12H). UV-vis (CH2Cl2): 492 nm, 525 nm 
2.2.3.5 Synthesis of N,N’-Dicyclohexyl-1,7-di(pyrrolidinyl)perylene-3,4,9,10-
tetracarboxy diimide (compound 4) 
Compound 3 (500 mg, 0.71 mmol) was dissolved in pyrrolidine (26 ml, 317 mmol) 
and stirred a 70 °C under an Ar atmosphere for 48hr. The reaction mixture was then 
poured into 10% hydrochloric acid solution (25 ml) before liquid extraction in 
dichloromethane was carried out three times. The blue-green product (compound 4) 
was dried over magnesium sulfate, filtered and dried in a vacuum oven. The resulting 
product was purified by silica gel column chromatography (CH2Cl2/hexane, 40/1, v/v) 
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giving a final yield of 14.2%. 1H NMR (CDCl3, TMS): δ: 8.47 (s, 2H), 8.41 (d, 2H), 
7.74 (d, 2H), 5.13-5.00 (m, 2H), 3.83-3.71 (m, 4H), 2.89-2.77 (m, 4H), 2.66-2.54 (m, 
4H), 2.12-1.86 (m, 8H), 1.76-1.70 (m, 4H), 1.57-1.25 (m, 12H). UV-vis (CH2CL2): 
448 nm, 650 nm, 710 nm.  
2.2.4 Preparation of PDI Nanoparticles via Nanoprecipitation 
2.2.4.1 Star Hyperbranched Block Copolymer (SHBP) Stabiliser 
A solution of NIR PDI (compound 4) in acetone was prepared at a concentration of 1 
mg/ml. A second solution was the prepared with SHBP (DEAMA50-c-DEGDMA2)-b-
(OEGMA80) in acetone (2 mg/ml). In some cases, the polymer solution was diluted 
further with acetone so that PDI:polymer ratios of 1:1, 2:1 and 3:1 were achieved. The 
PDI and polymer solutions (2 ml of each) were added dropwise to water (8 ml) with 
stirring. The reaction was stirred for 24hr to allow the acetone to evaporate, yielding a 
clear, blue-green aqueous nanoparticle suspension. 
2.2.4.2 Poly(vinyl alcohol) Stabiliser (PVA) 
Nanoparticles were also prepared with PVA as a stabiliser using a slightly different 
method as PVA is soluble in water. PVA (80 mg) was dissolved in 8 ml water, where 
consequently 2 ml of PDI/acetone solution (1 mg/ml) was added. The reaction was 
also stirred for 24hr to yield a clear, green aqueous nanoparticle suspension. 
2.2.5 Cell Culture 
The murine mesenchymal stromal cell line (MSC) D1 (ATCC) was used for all in vitro 
cell studies. MSCs had previously been modified by a member of our group (Dr 
Taylor, Murray Lab) to express firefly luciferase and ZsGreen under the control of the 
constitutive promoter, EF1α.276, 277 MSCs were cultured in 6 cm or 10 cm tissue culture 
dishes (Greiner CELLSTAR®) in high glucose Dulbecco’s Modified Eagle Medium 
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(DMEM, Sigma Aldrich) containing 10% fetal bovine serum (FBS, Sigma Aldrich), 
1% non-essential amino acids (Sigma Aldrich) and 2 mM L-glutamine (Gibco). Cells 
were incubated at 37°C and 5% v/v CO2 and passaged with 1% trypsin-EDTA (Sigma 
Aldrich) when they reached 90% confluence. 
2.2.6 In Vitro Cell Studies 
2.2.6.1 Cell Viability 
CellTiter-Glo® Luminescent Cell Viability Assay (Promega) was used according to 
the manufacturer’s guidelines. MSCs were seeded in triplicate at a density of 2x104 
cells/well in a 96-well plate and left to attach and grow for 24hr. After this, the medium 
was replaced with 200 µl fresh medium containing various concentrations of PDI 
nanoparticles (PDI concentration 0-40 µg/ml). Cells were incubated for a further 24hr 
before carrying out the assay. The principle is based on the detection of ATP released 
from lysed cells which reacts with luciferin/luciferase, leading to light emission at 562 
nm. Cell viability was measured as the amount of ATP released from treated cells as a 
percentage of the ATP released from the control. Luminescence measurements were 
taken with a µ–Quant Microplate reader (BioTek). 
2.2.6.2 Flow Cytometry 
Flow cytometry was used to assess the cellular uptake and fluorescence properties of 
the PDI nanoparticles. MSCs were seeded at a density of 2x105 cells/well (24-well 
plate) and incubated for 24hr. After this, the medium was aspirated and replaced with 
fresh medium containing nanoparticles of varying concentrations (0-25 µg/ml). After 
a further 24hr, cells were resuspended in PBS (1x) and kept on ice ahead of analysis. 
Flow cytometry was carried out using a BD FACSCalibur™ (BD Biosciences) with a 
488 nm laser wavelength and a long pass FL3 filter (670 nm). When appropriate, 
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threshold values for side scatter (SSC), front scatter (FSC) and FL3 were altered 
relative to the control to exclude unwanted events. 10,000 events were counted and the 
data was analysed with Flowing Software 2.5.1 (Turku Bioscience Centre). 
2.2.6.3 Confocal Fluorescence Microscopy 
Confocal fluorescence microscopy was employed to visualise and determine the 
location of PDI nanoparticles in MSCs. MSCs were seeded in 8-well chamber slides 
(Ibidi µ-Slide 8-well) at a density of 2x104 cells/well. After 24hr labelling with 
nanoparticles (25 µg/ml), samples were fixed with 4% paraformaldehyde (PFA, Sigma 
Aldrich).  Cells were permeabilised with Triton-X (0.1 %v/v, Sigma Aldrich) and 
stained with 4′,6-diamidino-2-phenylindole (DAPI, 1:1000, Thermo Fisher) and Alexa 
Fluor™ 488 phalloidin (1:50, Invitrogen).  Images were acquired with a Zeiss LSM 
800 Airyscan confocal using 405 nm, 488 nm and 640 nm diode lasers and 63x oil 
objective. Z-stack images were obtained using a step size of 0.34 μm and the master 
gain of the PMT was set to 700 mV. Images were analysed in ImageJ (FIJI). 
2.2.7 Multispectral Optoacoustic Tomography  
2.2.7.1 Preparation of Phantoms 
Agar phantoms were prepared for imaging with multispectral optoacoustic 
tomography (MSOT). 20 ml syringes were used as moulds by removing the end and 
pulling the plunger out. With the handle of the plunger taped to a surface, a straw (ends 
sealed) was suspended in the middle of the syringe and secured with tape in order to 
create a hole in the phantom for loading samples. Next, intralipid (1.03 ml, Sigma 
Aldrich) was heated in a water bath whilst agar (0.75 g, Sigma Aldrich) was added to 
50 ml of water and heated in a microwave. The solution was shaken and intralipid was 
added. The agar mixture was then poured into the syringe moulds and left to set for 30 
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minutes. Once set, the straws were removed and phantoms were stored in a small 
amount of water in the fridge to be used the following day. 
2.2.7.2 Imaging 
The nanoparticle suspensions were put in clear plastic straws and sealed at either end. 
The straws were then inserted into agar phantoms, covered in ultrasound gel and placed 
in the water bath (25°C) of the MSOT inVision System (iThera). A single slice was 
imaged at 660-1000 nm in 5 nm intervals. The following reconstruction parameters 
were utilised: backprojection 25mm(res:75µm), 50 kHz-6.5 MHz-IR and images were 
















2.3 Results  
NIR-absorbing PDI was prepared from the commercially available starting material, 
perylenetetracarboxylic dianhydride (PTCDA, compound 1), as shown in Figure 2.3. 
Firstly, PTCDA was brominated at the C1 and C7 positions of the aromatic core to 
form compound 2, following a slightly modified version of a method reported by 
Sengupta et al.237 Consequently, imide substitution resulted in compound 3 and then 
the bromine atoms were substituted by pyrrolidine groups to cause a red-shift in 
absorption to the NIR region (compound 4), based upon a protocol developed by Sukul 
et al.236  
 
Figure 2.3: Synthetic scheme to produce NIR-absorbing PDI from PTDCA.236, 237 
2.3.1 Synthesis of brominated PTCDA  
The bromination of PTCDA has been reported in several publications.235, 259, 263 The 
method used in this study was carried out via a 3-step process to yield the 
regioisomerically pure brominated PTCDA, whilst avoiding harsh conditions and 
minimising safety risks. Firstly, the anhydride groups were opened to produce a 
tetraester derivative (compound 1a) followed by bromination at the bay area 
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(compound 1b). The dianhydride was then reformed under acidic condition to yield 
brominated PTCDA (compound 2), as depicted in Figure 2.4.  
 
Figure 2.4: Synthesis of brominated PTCDA.237 
2.3.1.1 Synthesis of Perylene-3,4,9,10-tetrabutylester (compound 1a) 
The synthesis of compound 1a proceeded under ambient conditions with 1,8-
diazabicyclo(5.4.0)undec-7-ene (DBU) acting as a catalyst to give a 93% yield. The 
1H NMR spectra confirmed the presence of the alkyl chains with new upfield peaks; 
1.80-1.77 ppm, indicated the methylene group attached to the oxygen atom, 1.50-1.47 
ppm for the methylene chain and 0.99 ppm was the terminal methyl group (Figure 2.5). 
The downfield peaks can be attributed to the proton environments at the perylene core. 
FTIR also confirmed the transformation from anhydride to ester functionality with a 
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shift in wavenumber from 1756 to 1720 cm-1 and the occurrence of a new stretch at 
2867 cm-1 indicating the methylene groups (Figure 2.6). 
 
Figure 2.5: 1H NMR of perylene-3,4,9,10-tetrabutylester (compound 1a) in CDCl3. 
 




















Figure 2.6: FTIR spectra of starting material, PTCDA and perylene-3,4,9,10-
tetrabutylester (compound 1a). 
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An increase in solubility was also observed with the addition of the alkyl chains; 
PTCDA has extremely low solubility however compound 1a was soluble in 
chlorinated solvents. Compound 1a is orange in colour, compared to red PTCDA, 
which corresponded to peaks at 448 and 470 nm in the UV-vis spectrum, shown in 
Figure 2.7.  















Figure 2.7: UV-vis spectrum of perylene-3,4,9,10-tetrabutylester (compound 1a) (0.05 
mg/ml DMSO). 
2.3.1.2 Synthesis of 1,7-Dibromoperylene-3,4,9,10-tetracarboxytetrabutylester 
(compound 1b) 
The formation of compound 1b involved the addition of excess pure bromine to 
compound 1a dissolved in dichloromethane in the presence of potassium carbonate. 
The reaction proceeded at room temperature over 24hr, before quenching with sodium 
bisulfite. Bromination of the bay region of PDI generally resulted in the formation of 
the 1,6- and 1,7-regioisomers in a 2:1 ratio. The regioisomers were separated by 
double-solvent recrystallisation in dichloromethane/acetonitrile over 3 days.  
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The success of the reaction was confirmed by 1H NMR, where peaks associated with 
aromatic hydrogen atoms, at 8.96 and 8.10 ppm were shifted downfield (Figure 2.8). 
A new singlet peak at 8.30 ppm indicated the hydrogen atoms next to the bromine. The 
NMR indicated there was some of the 1,6-regioisomer even after recrystallisation; the 
peaks at 8.96 and 8.30 ppm have smaller peaks which were slightly downfield.237 This 
was not considered to be a problem for the current application as the regioisomers have 
the same absorbance maxima (Figure 2.9).  
 
Figure 2.8: 1H NMR of 1,7-dibromoperylene-3,4,9,10-tetracarboxytetrabutylester 
(compound 1b) in CDCl3. 
There was little change in the FTIR spectrum however the presence of new stretches 




















Figure 2.9: UV-vis spectrum of 1,7-dibromoperylene-3,4,9,10-tetracarboxy 
tetrabutylester (compound 1b) in DMSO (0.05 mg/ml). 
2.3.1.3 Synthesis of 1,7-Dibromoperylene-3,4,9,10-tetracarboxylic dianhydride 
(compound 2) 
The anhydride groups were reintroduced under acidic conditions to yield brominated 
PTCDA (compound 2) with an 83% yield. The solubility of compound 2 is extremely 
low (as for PTCDA) and hence an NMR spectrum could not be obtained. The FTIR 
spectrum confirmed the reformation of the anhydride from the ester with a shift in the 
carboxyl peak from 1718 to 1764 cm-1 (Figure 2.10). Additionally, there is no longer 
a stretch at 2867 cm-1 for the methylene groups.  
The low solubility and deep red colour of brominated PTCDA (compound 2), similar 
to that of PTCDA, suggested the reaction had been successful. This was confirmed 
with UV-vis analysis with peaks at 495 and 524 nm (Figure 2.11); this was possible as 
























Figure 2.10: FTIR spectra of 1,7-dibromoperylene-3,4,9,10-tetracarboxy 
tetrabutylester (compound 1b) and brominated PTCDA (compound 2). 


















Figure 2.11: UV-visible spectra of 1,7-dibromoperylene-3,4,9,10-tetracarboxy 




2.3.2 Synthesis of NIR-absorbing PDI 
N,N’-Dicyclohexyl-1,7-di(pyrrolidinyl)perylene-3,4,9,10-tetracarboxy diimide was 
synthesized from brominated PTCDA, following the scheme in Figure 2.4.236  Firstly, 
the dianhydride was converted to a diimide group with cyclohexyl substituent 
(compound 3). Following this, the bromine atoms at the bay position were substituted 
for pyrrolidine groups to increase electron density in the perylene core, resulting in a 
red shift in absorption to the NIR region (compound 4).  
2.3.2.1 Synthesis of N,N’-Dicyclohexyl-1,7-dibromoperylene-3,4,9,10-
tetracarboxy diimide (compound 3) 
The anhydride groups were first converted to imides with cyclohexyl substituents. 1H 
NMR identified a small new peak at 5.05-4.99 ppm indicating the two hydrogen atoms 
bond to C1 of each cyclohexyl ring, which each have four adjacent hydrogen atoms 
resulting in the multiplet splitting (Figure 2.12). The doublet peak at 2.59-2.53 ppm 
and the multiplet at 1.93-1.25 ppm correspond to the other hydrogen atoms in the 
cyclohexyl ring.  
FTIR was again a good indicator of the success of the reaction as stretches reappeared 
around 2800-3000 cm-1 due to the presence of methylene groups in the cyclohexyl 
ring, shown in Figure 2.13. Additionally, the carboxyl peak is shifted to a lower 
wavenumber of 1650 cm-1, characteristic of the imide compared to the previous 
anhydride group. The UV-vis profile was similar to that of brominated PTCDA 
(compound 2), thus further iterating the limited impact of imide substitution on the 





Figure 2.12: 1H NMR of N,N’-dicyclohexyl-1,7-dibromoperylene-3,4,9,10-
tetracarboxy diimide (compound 3) in CDCl3. 
 




















Figure 2.13: FTIR spectra of brominated PTCDA (compound 2) and the N,N’-
dicyclohexyl-1,7-dibromoperylene-3,4,9,10-tetracarboxy diimide (compound 3). 
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Figure 2.14: UV-vis spectrum of N,N’-dicyclohexyl-1,7-dibromoperylene-3,4,9,10-
tetracarboxy diimide (compound 3) in DCM (0.05 mg/ml). 
2.3.2.2 Synthesis of N,N’-Dicyclohexyl-1,7-di(pyrrolidinyl)perylene-3,4,9,10-
tetracarboxy diimide (compound 4) 
The next stage of the reaction was the critical step to attain NIR absorption by 
substituting the bay functionalised bromine atoms for pyrrolidine groups. The 1H 
NMR showed new multiplet peaks at 3.83-3.71 ppm and 2.89-2.77 ppm which can be 
attributed to the proton environments in the pyrrolidine ring (Figure 2.15). There was 
very little change in the FTIR spectrum other than in the fingerprint region, which 
suggested the C-Br bond was no longer present (Figure A2, Appendix).  
Ultimately, the success of the reaction was confirmed with UV-vis, where a peak at 
700 nm was observed, as shown in Figure 2.16, and colour of compound was dark 
green/blue. The substitution of bromine for pyrrolidine groups resulted in a red shift 
of 175 nm into the NIR region, making PDI derivative 4 ideal for in vivo imaging, as 




Figure 2.15: 1H NMR of N,N’-Dicyclohexyl-1,7-di(pyrrolidinyl)perylene-3,4,9,10-
tetracarboxy diimide (compound 4) in CDCl3. 

















Figure 2.16: UV-vis spectra of N,N’-dicyclohexyl-1,7-dibromoperylene-3,4,9,10-
tetracarboxy diimide (compound 3) and N,N’-dicyclohexyl-1,7-




2.3.3 Preparation of PDI Nanoparticles via Nanoprecipitation with Star 
Hyperbranched Block Copolymer Stabiliser  
PDI derivative 4 (N,N’-dicyclohexyl-1,7-di(pyrrolidinyl)perylene-3,4,9,10-
tetracarboxy diimide) was formulated into nanoparticles because of the NIR 
absorbance and the improved solubility afforded by the cyclohexyl group at the imide 
position. A nanoprecipitation method was used as it is a facile way to prepare stable 
nanoparticles using various stabilisers. The stabiliser used in this method is a novel 
star hyperbranched block copolymer (SHBP), (DEAMA50-c-DEGDMA2)-b-
(OEGMA80), which was previously developed by our group as a pH sensitive stabiliser 
to prepare hydrophobic drug nanoparticles (Figure 2.17).275  
 
Figure 2.17: Structure of the star hyperbranched block copolymer (DEAMA50-c-
DEGDMA2)-b-(OEGMA80).
275 
PDI 4, referred to as PDI from here onwards, and SHBP were first dissolved in acetone, 
as it is miscible with water. Each solution was then added dropwise to water and the 
reaction was left overnight for the acetone to evaporate, as shown in Figure 2.18. This 




Figure 2.18: Schematic of nanoparticle formation via nanoprecipitation with SHBP 
stabiliser. 
2.3.3.1 PDI-SHBP Nanoparticle Characterisation 
The ratio of PDI to SHBP stabiliser was varied by keeping the amount of PDI constant 
and changing the amount of stabiliser in order to optimise stability; nanoparticles with 
PDI:stabiliser ratios of 1:1, 2:1 and 3:1 were prepared. 
The PDI nanoparticles were analysed with using Dynamic Light Scattering (DLS) 
techniques to assess the particle size. The DLS results are represented as the number 
particle size distribution as this considers the spherical shape of the nanoparticles and 
Mie scattering. Analysis of a dilute suspension of nanoparticles with DLS resulted in 
similar particles sizes of ~150-170 nm, where the particle size distribution for the 1:1 
ratio is shown in Figure 2.19. The DLS graphs for the other particles with 2:1 and 3:1 
ratios were similar (Figures A3 and A4, Appendix).   
The DLS data is summarised in Table 2.1. The polydispersity index was slightly larger 
with the highest amount of stabiliser (1:1 ratio) however the zeta potential was similar 






















Figure 2.19: Number particle size distribution of PDI-SHBP nanoparticles (PDI:SHBP 
1:1) measured using DLS. The different colours represent 3 measurement scans with 
DLS. 











1:1 147 ± 45 0.358 -7.0 ± 3.2  
2:1 172 ± 45 0.258 -9.0 ± 3.6 
3:1 168 ± 55 0.266 -8.2 ± 3.5 
 
Analysis of the PDI nanoparticle suspensions with UV-vis spectroscopy resulted in 
similar profiles however the molar extinction coefficient (ε) decreased as the amount 
of stabiliser was reduced (Figure 2.20). PDI nanoparticles with PDI:SHBP ratio of 1:1, 
2:1 and 3:1 had molar extinction coefficients of 7,906, 7,383 and 5,789 M-1 cm-1, 
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respectively. The peak positions were similar to the free dye at 440, 655 and 710 nm 
(Figure 2.16). Unexpectedly, the absorbance of the peaks at 665 and 710 nm are more 
similar in intensity, compared to the free dye where the peak at 700 nm is more 
pronounced.  





































Concentration (mM)  
Figure 2.20: UV-vis spectroscopy of aqueous PDI-SHBP nanoparticle suspensions 
with various ratios of PDI to SHBP, showing the (a) UV-vis spectrum at a 
concentration of 0.15 mg/ml and (b) the calibration curve of absorbance at 700 nm for 
a range of nanoparticle concentrations.  
SEM images showed small, spherical nanoparticles as well as some aggregates and 
rod-like structures, as shown in Figure 2.21. A similar result was observed with 
PDI:SHBP ratios of 2:1 and 3:1 (Figure A5, Appendix). As the nanoparticles had the 
required optical properties and stability, the few rod-like structures were not 
considered a problem. 
Overall, the different sets of PDI nanoparticles prepared with SHBP stabiliser seem 
quite similar in terms of particle size and morphology; however, a higher molar 
extinction coefficient was observed with increased amounts of stabiliser. All three sets 





Figure 2.21: SEM images of PDI-SHBP nanoparticles (PDI:SHBP 1:1) prepared by 
nanoprecipitation method 
2.3.4 In vitro Evaluation of PDI Nanoparticles with SHBP Stabiliser 
Mesenchymal stromal cells (MSC) were labelled with PDI nanoparticles and tested in 
vitro to assess their biocompatibility and cellular uptake. 
2.3.4.1 The Effect of PDI-SHBP Nanoparticles on Cell Viability 
Firstly, the CellTiter® Glo assay was used to assess the viability of MSCs dosed with 
varying concentrations of PDI nanoparticles (0-40 μg/ml). Cells were seeded at a 
density of 2x104 cells/well and incubated for 24hr. After this, the media was aspirated, 
and fresh media was added containing nanoparticle suspension. Cells were left for a 
further 24hr to allow uptake of nanoparticles.  
Cell viability is measured as the amount of ATP produced from cells dosed with 
nanoparticles, compared to untreated cells. The amount of ATP produced in the 
untreated cells acts as the positive control and so ATP generation from treated cells is 
quoted as a percentage of the control, as shown in Figure 2.22.  
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Figure 2.22: The effect of PDI-SHBP nanoparticles on ATP production in 
mesenchymal stromal cells. Cells were seeded at a density of 2x104 cells/well and 
nanoparticle dosing was for 24hr (n=3). Cell viability in dosed cells is measured as a 
percentage of untreated cells.  
It was found that all types of PDI nanoparticles prepared with the SHBP stabiliser had 
a limited effect on cell viability up to a concentration of 15 µg/ml. However, at higher 
dosing concentrations, cell viability decreased the most when the highest amount of 
stabiliser was used (1:1). PDI nanoparticles with the lowest amount of stabiliser (3:1) 
were found to have a minimal effect on cell viability even at 40 µg/ml. 
2.3.4.2 Assessing Cellular Uptake of PDI-SHBP Nanoparticles with Flow 
Cytometry 
As it appeared that PDI nanoparticles were well-tolerated by MSCs, it was then 
essential to confirm that they had been efficiently taken up. Flow cytometry is a 
commonly used technique for analysing cell characteristics, in this case fluorescence 
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intensity. Flow cytometry was carried out on live cell suspensions in PBS, after 24hr 
labelling with PDI nanoparticles of various concentrations (0-25 µg/ml).  
Figure 2.23 shows the results for PDI nanoparticles prepared with a PDI:SHBP ratio 
of 1:1, however a similar trend was seen for the other ratios (Figure A6, Appendix). 
There was a relatively large shift from untreated cells to the lowest dosing 
concentration and fluorescence intensity increased with increasing concentration. For 
all dosing concentrations, the percentage of the cell population that was labelled was 
>92% (Figure A7, Appendix). 



















Figure 2.23: Live cell flow cytometry of MSCs in PBS labelled with PDI-SHBP 
nanoparticles (PDI:SHBP 1:1) where the percentage of cells positive was >92% for all 
concentrations. Fluorescence intensity was measured using FL3 filter (670 LP) and 
10,000 events were counted. 
When comparing the three types of nanoparticles in more detail, it appeared that uptake 
increased with increasing amounts of stabiliser; the highest uptake was seen with 
PDI:SHBP of 1:1 and the lowest uptake was with the 3:1 ratio (Figure 2.24). This was 
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seen at all dosing concentrations; however, it is worth noting that the difference in 
fluorescence intensity is relatively small.  

















Figure 2.24: Live cell flow cytometry of MSCs in PBS labelled with PDI-SHBP 
nanoparticles (15 µg/ml). Fluorescence intensity was measured using FL3 filter (670 
LP) and 10,000 events were counted. 
2.3.4.3 Assessing Cellular Uptake of PDI-SHBP Nanoparticles with Confocal 
Fluorescence Microscopy 
Confocal laser imaging was used to visually assess cell viability and uptake of PDI 
nanoparticles into MSCs. MSCs were labelled for 24hr with PDI nanoparticles prior 
to fixing with 4% PFA. Cells were then stained with DAPI and AlexaFluor® 488 
phalloidin to show the nucleus and actin cytoskeleton, respectively. Multiple images 
were taken at different focal planes and combined to form z-stack images with a greater 
depth of field.  
The images show that the PDI nanoparticles are within the cells, likely residing in 
endosomes and lysosomes (Figure 2.25).  The z-stack imaging highlighted that 
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particles were inside cells and not just associated with the cell surface. During imaging, 
some rod-like structures were also observed; however, these were seen when other 
ratios of stabilisers were used, as for SEM imaging (Figure 2.21). Smaller, spherical 
nanoparticles were much more abundant than rods. Confocal images for nanoparticles 
prepared with PAI:SHBP ratio of 2:1 and 3:1 can be found in Figure A8 in the 
Appendix. 
  
Figure 2.25: Confocal fluorescence image of MSCs, showing PDI-SHBP nanoparticles 
(PDI:SHBP 1:1, red) residing within cells (15 µg/ml). Cells were fixed and stained 
with DAPI (blue nuclei) and AlexaFluor ® 488 phallodin (green, actin cytoskeleton). 
The left image (a) is more representative of the whole view where spherical 
nanoparticles where abundant whereas the right image (b) shows rod-like structures. 
Overall for PDI-SHBP nanoparticles, it was found that cell viability decreased with 
increasing amounts of stabiliser suggesting PDI-SHBP nanoparticles with a 
PDI:SHBP ratio of 3:1 were the least cytotoxic; however, >80% of cells were viable 
for all sets of nanoparticles at a labelling concentration of 15 µg/ml. Furthermore, cells 




fluorescence intensity in flow cytometry experiments. This coupled with the high 
molar extinction coefficient observed in UV-vis spectroscopy pose the nanoparticles 
with PDI:SHBP ratio of 1:1 as a promising candidate for detecting cells with MSOT.   
2.3.5 Preparation of PDI Nanoparticles via Nanoprecipitation with 
Poly(Vinyl Alcohol) Stabiliser 
The PDI nanoparticles were also prepared with PVA stabiliser to see if the type of 
stabiliser had any effect on the properties of the probes. The nanoprecipitation method 
was slightly adapted with PVA due to its good solubility in water. The process was 
similar to that described in Figure 2.18 but PVA was first dissolved in water before 
adding the PDI solution (acetone) dropwise and again, leaving overnight for 
evaporation. The mass ratio of PDI:PVA was 1:40 as this had yielded a stable green-
blue nanosuspension previously in our group.278  
2.3.5.1 PDI-PVA Nanoparticle Characterisation 
The nanoparticles were analysed with DLS and the number particle size distribution is 
shown in Figure 2.26. The particle size was 116 ± 36 nm and the polydispersity index 
was 0.195. The zeta potential was measured at -2.7 ± 2.7 mV. The UV-vis profile was 
identical to that of PDI nanoparticles prepared with the SHBP stabiliser however the 
molar extinction coefficient was slightly higher at 8240 M-1 cm-1 (Figure 2.27).  
PDI-PVA nanoparticles were also imaged with SEM and both rod-like structures and 
small spherical nanoparticles could be visualised (Figure 2.28). Imaging of these 
nanoparticles, along with SHBP nanoparticles (1:1, 2:1 and 3:1 ratios), resulted in 
similar amounts of rod-like structures in the SEM images. This suggests that it is 
possibly dependent on the method parameters rather than the stabiliser. 
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Figure 2.26: Number particle size distribution of PDI-PVA nanoparticles measured 
using DLS. The different colours represent 3 measurement scans with DLS. 
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Figure 2.27: UV-vis spectroscopy of aqueous PDI-PVA nanoparticle suspensions, 
showing the (a) UV-vis spectrum at a concentration of 0.15 mg/ml and (b) the 





Figure 2.28: SEM image of PDI-PVA nanoparticles 
2.3.6 In vitro Evaluation of PDI Nanoparticles with PVA Stabiliser 
PDI-PVA nanoparticles were also assess for their biocompatibility and uptake into 
MSCs. 
2.3.6.1 The Effect of PDI Nanoparticles on Cell Viability 
The CellTiter-Glo® assay was once again used to assess the effect of the nanoparticles 
on cell viability. The same protocol was carried out as for the nanoparticles prepared 
with SHBP stabiliser, where MSCs were dosed (0-40 µg/ml) for 24hr ahead of the 
assay. The results showed that PDI-PVA nanoparticles had a limited effect on cell 
viability up to the highest concentration of 40 µg/ml, as shown in Figure 2.29. 
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Figure 2.29: The effect of PDI-PVA nanoparticles on ATP production in MSCs. Cells 
were seeded at a density of 2x104 cells/well and nanoparticle dosing was for 24hr 
(n=3). Cell viability in dosed cells is measured as a percentage of untreated cells. 
2.3.6.2 Assessing Cellular Uptake of PDI-PVA Nanoparticles with Flow 
Cytometry 
The cellular uptake of PDI-PVA nanoparticles was assessed using flow cytometry and 
confocal fluorescence microscopy. Similar to PDI-SHBP nanoparticles, there was a 
significant increase in fluorescence compared to untreated cells and fluorescence 
intensity increased with increasing concentration (Figure 2.30). The percentage of the 
cell population labelled was >80% for all concentrations (Figure A7, Appendix). The 
uptake and fluorescence intensity of PVA-stabilised nanoparticles was compared to 
SHBP-stabilised nanoparticles in Figure 2.31. This highlighted that SHBP-stabilised 
nanoparticles with a PDI:SHBP ratio of 1:1 had slightly higher fluorescence intensity.   
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Figure 2.30: Live cell flow cytometry of MSCs in PBS labelled with PDI-PVA 
nanoparticles where the percentage of cells positive was >92% for all concentrations. 
Fluorescence intensity was measured using FL3 filter (670 LP) and 10,000 events were 
counted. 


















Figure 2.31: Live cell flow cytometry of MSCs in PBS labelled with PDI nanoparticles 
at a concentration of 15 µg/ml. Fluorescence intensity was measured using FL3 filter 
(670 LP) and 10,000 events were counted. 
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2.3.6.3 Assessing Uptake of PDI-PVA Nanoparticles with Confocal Fluorescence 
Microscopy 
Confocal fluorescence microscopy was also carried out to visually assess the uptake 
of PDI-PVA nanoparticles into MSCs. Cells were fixed and stained 24hr post-labelling 
before imaging. PDI-PVA nanoparticles (red) can be visualised inside the MSCs, 
which is consistent with endosomal location (Figure 2.32). Some small rod-like 
structures can also be seen however the nanoparticles predominantly exist as small, 
spherical dots. Again, z-stack images were taken which highlighted that particles were 
inside cells and not just associated with the cell surface.     
 
Figure 2.32: Confocal fluorescence microscope image of PDI-PVA nanoparticles (red) 
inside MSCs (15 µg/ml), where the cells were fixed 24hr post-labelling. The 
cytoskeleton (green) and nuclei (blue) have been stained with AlexaFluor 488® 




2.3.7 Imaging of PDI Nanoparticles with MSOT 
In order to assess the photoacoustic signal, the PDI nanoparticles were imaged in agar 
phantoms with the MSOT. MSOT is a type of photoacoustic imaging where multiple 
wavelengths can be used to simultaneously excite a sample and the signal is detected 
by ultrasound. The nanoparticle solutions (0.25 mg/ml) were pipetted intro clear straws 
and sealed at each end. The straw was inserted into the agar phantom before placing 
into the MSOT bath for imaging. The sample was irradiated at 710 nm, which is 
consistent with the peak absorbance of the nanoparticles, and the images of the cross-
section of the straw are shown in Figure 2.33. A strong MSOT signal was observed 
for both types of nanoparticles.  
  
Figure 2.33: MSOT images at 710 nm of PDI nanoparticle solutions in phantoms. PDI 
nanoparticles stabilised with (a) SHBP (PDI:SHBP 1:1) and (b) PVA polymers are 
shown at a concentration of 0.25 mg/ml.   
A graph of the MSOT mean pixel intensity across the wavelengths scanned is shown 




signal is high at 710 nm compared to the PBS control were there was very little signal. 
The MSOT signal was similar for both types of nanoparticles.  
 
































Figure 2.34: A graph of the MSOT mean pixel intensity at different wavelengths for 
PDI-SHBP (PDI:SHBP 1:1) and PDI-PVA nanoparticle solutions (0.25 mg/ml). PBS 












The ability to monitor the fate and biodistribution of administered cells in vivo will aid 
the design of effective RMTs. A novel, non-invasive method involved the use of PAI 
techniques, such as MSOT, which offers many benefits including high spatial 
resolution, deep light penetration and spectral unmixing.271, 279 PDI derivatives are 
ideal contrast agents for MSOT as they can be engineered to absorb in the NIR region, 
where tissue absorbance is low. In addition to this they have high photostability and 
are easily modified unlike other organic molecules, such as cyanine dyes.245 The 
tuneability of optical properties is advantageous as two different PDI derivates could 
be prepared into nanoparticles for simultaneous cell and hydrogel tracking. PDI-based 
probes have been optimised herein for the non-invasive tracking of mesenchymal 
stromal cells with MSOT.  
2.4.1 Synthesis of NIR-Absorbing PDI Derivative 
A NIR-absorbing PDI derivative (N,N’-dicyclohexyl-1,7-di(pyrrolidinyl)perylene-
3,4,9,10-tetracarboxy diimide) has been synthesized from commercially available 
PTCDA, following well-established protocols but on a larger scale.236, 237 In the present 
study, the successful synthesis of each compound has been confirmed with 1H NMR, 
FTIR and ultimately, UV-vis spectroscopy to show NIR absorbance. The process was 
repeated several times to obtain a high enough yield of the final NIR-absorbing PDI 
derivative for all experiments in this PhD project; the synthesis has previously been 
carried out in our group and has been shown to be successful.278  
In the first part of the synthesis, commercially available starting material, PTCDA, 
was brominated at the bay area following the protocol developed by Sengupta et al.237 
This involved first opening the dianhydride to form a tetrabutylester derivative 
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(compound 1a), before bay substitution (compound 1b) and then reforming the 
anhydride (compound 2). Although indirect, this method was chosen as it resulted in 
efficient disubstitution where other methods may require separation of the 
monosubstituted product.235 Alternative methods in the literature have seen greater 
regioselectivity however harsher conditions are required and so the method utilised 
herein was chosen to minimise safety risks. 
The first step was to prepare the perylene tetrabutylester (compound 1a), which 
resulted in a significant increase in solubility. Consequently, a nucleophilic aromatic 
substitution reaction was carried out to produce the 1,6- and 1,7-dibromoperylene 
tetrabutylesters (compound 1b), which could then be separated by double solvent 
recrystallisation. The 1,7-regioisomer crystallised first and the 1H NMR suggested 
there were small traces of 1,6-regioisomer. The ratio of 1,7- to 1,6-regioisomer was 
2:1 which is slightly different to the literature were multiple recrystallisation processes 
were carried out to attain higher purity.237 This was not considered a priority in the 
present study as the peak absorption wavelength was the same for the two 
regioisomers. 
The next step involved the reformation of the dianhydride to form brominated PTCDA 
(compound 2). The solubility severely decreased, owing to the loss of the 
tetrabutylester functionality, thus NMR was not possible, however the reaction was 
confirmed with FTIR. Furthermore, brominated PTCDA (compound 2) was red 
compared to the orange colour of compound 1b, which resulted in different UV-vis 
profiles further indicating the success of the reaction. 
The brominated PTCDA derivative was then used to synthesize the NIR-absorbing 
PDI derivative, N,N’-dicyclohexyl-1,7-di(pyrrolidinyl)perylene-3,4,9,10-tetracarboxy 
diimide following a protocol by Sukul et al.236 The first step was the formation of the 
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diimide with cyclohexyl substituents (compound 3). Cyclohexylamine was used as a 
reagent as cyclohexyl groups are bulky enough to disrupt π-π stacking and the resultant 
derivative can be dissolved in common solvents, such as acetone and 
dichloromethane.235  
The reaction likely proceeded via an SN2 nucleophilic substitution of one carboxyl 
group to yield the amine and a carboxylic acid at one terminus, before a second 
nucleophilic attack to the neighbouring carboxyl group. The addition of the cyclohexyl 
substituent was clear with the presence of new peaks in both the 1H NMR and the FTIR 
attributed to the aliphatic methylene groups of the cyclohexane ring. Additionally, the 
shift of the carboxyl peak to lower wavenumber is indicative of a change from 
dianhydride to diimide.  
The next step in the synthesis involved the bay substitution of the bromine atoms for 
pyrrolidine groups. Pyrrolidine was chosen due to the electron donating character of 
the amine and the short C-N bond length compared to piperidine groups, resulting in 
significant red-shift to the NIR region.240 This was realised in a peak shift from 525 
nm (compound 3) to 700 nm (compound 4) in the UV-vis spectra (Figure 2.16) and a 
colour change from red to blue/green. NIR PDI had increased solubility in acetone and 
chlorinated solvents which was ideal for nanoparticle preparation.  
2.4.2 Preparation of PDI Nanoparticles 
PDI nanoparticles were prepared using  nanoprecipitation; nanoprecipitation is a 
commonly used technique for the formulation of drug nanoparticles due to its 
simplicity and reproducibility.280 The technique has previously been investigated in 
our group for encapsulation of hydrophobic drug molecules in order to increase 
bioavailability. Nanoprecipitation was the ideal technique for preparing PDI 
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nanoparticles as NIR PDI (compound 4) is hydrophobic but has good solubility in 
acetone and so can be incorporated into the solvent phase.  
Nanoparticles were prepared with either a novel hyperbranched block copolymer 
(SHBP), (DEAMA50-c-DEGDMA2)-b-(OEGMA80), or PVA stabilisers. Acetone and 
water were used as the solvent and non-solvent phases, where PDI and SHBP could 
be dissolved in acetone however PVA had good water solubility. As acetone solutions 
are added to water, the solubility of PDI decreases causing supersaturation and 
consequently PDI molecules come together (nucleation). Polymer molecules associate 
with the interface and particles grow upon collision with neighbouring particles. As 
the acetone evaporates, nanoparticles are suspended in water. All sets of PDI 
nanoparticles were around 200 nm in size and had similar zeta potentials and UV-vis 
profiles, with a broad peak stretching into the NIR region and peak absorbance at 710 
nm (Figure 2.20). 
For PDI-SHBP nanoparticles, three ratios of PDI:SHBP stabiliser were tried: 1:1, 2:1 
and 3:1 where the amount of stabiliser was varied but the PDI concentration was kept 
constant. All of the particles had a similar particle size although the polydispersity 
index of the nanoparticles with 1:1 ratio was slightly higher. It has been shown that 
more uniform particle size distributions can be achieved if the rate of solvent phase 
addition is slowed.281 This was not the case in the present study but is a potential 
avenue for future applications where greater control may be required.  
The optical properties of the nanoparticles were investigated with UV-vis 
spectroscopy. It was found that for PDI nanoparticles with SHBP stabiliser, the molar 
extinction coefficient increased with increasing concentration of stabiliser. Despite 
this, PVA-stabilised nanoparticles had the highest molar extinction coefficient of all 
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(8240 M-1 cm-1). The morphology of the particles was assessed with SEM where small, 
spherical nanoparticles were visualised and some rod-like structures.   
2.4.2.1 In Vitro Assessment of PDI Nanoparticles 
PDI nanoparticles were evaluated in vitro in MSCs to assess cytotoxicity and cellular 
uptake. In all cases, MSCs were seeded on day 1, labelled with nanoparticles on day 2 
and the assay was carried out 24hr later on day 3. It was found that PDI nanoparticles 
had a limited cytotoxic effect on MSCs: all of the PDI nanoparticles were well-
tolerated up to concentrations of 15 µg/ml. For SHBP-stabilised nanoparticle 
suspensions, cytotoxicity increased with increasing amounts of stabiliser. Both PDI-
SHBP nanoparticles with ratio of 3:1 and PDI-PVA nanoparticles had >80% viability 
at 40 µg/ml.  
Flow cytometry was then used to assess cellular uptake and it was found that MSCs 
effectively took up the SHBP- and PVA-stabilised nanoparticles. For all sets of 
nanoparticles, fluorescence intensity increased with increasing dosing concentrations. 
When comparing the uptake between the different sets of PDI nanoparticles in Figure 
2.31, it was found that nanoparticles with PDI:SHBP ratio of 1:1 were more efficiently 
taken up by MSCs.   
Confocal laser imaging allowed visualisation of the nanoparticles within the cells, by 
exploiting their fluorescence properties. The 640 nm laser was effective in exciting the 
nanoparticles due to the broadness of the far-red to NIR peak. Imaging agreed with the 
flow cytometry data and uptake of all PDI nanoparticles was observed, with 
nanoparticles present in a large proportion of the cells.  
The nanoparticles predominantly appeared as bright, small spherical dots within the 
cells; however, a small number of large rod-like structures were observed in some 
82 
 
cases (Figure 2.25). The confocal images were consistent with SEM imaging prior to 
cell work; i.e. the rod-like structures were seen for nanoparticles prepared with SHBP 
(all ratios) and PVA stabilisers. This suggests that the formation of rod-like structures 
is due to the nanoprecipitation technique and not the type of stabiliser. This was an 
unexpected result and has not been seen in previous work by our group or in the 
literature.282, 283  
Rod formation could be investigated further by looking at each stage of the 
nanoprecipitation process in detail. In the present study, it appeared that rods were 
more reproducible and abundant for the 1:1 ratio of PDI to SHBP, however this was 
not quantified. This suggests that the rate of supersaturation may have an effect on rod 
formation. Hence further studies could be carried out to support this hypothesis, as 
well as looking at the rate of nucleation and particle growth stages. This was out of the 
scope of the present study as the nanoparticle morphology was predominantly 
spherical and the cellular uptake and NIR absorbance was optimal. Furthermore, the 
presence of the rods within the cells did not have any noticeable effect on cell viability.  
2.4.2.2 Imaging PDI Nanoparticle Suspensions with MSOT 
The photoacoustic signal of the nanoparticles was assessed by imaging the 
nanoparticle suspensions in phantoms with MSOT. Due to their higher uptake (as 
indicated by flow cytometry), SHBP-stabilised nanoparticles with a PDI:SHBP ratio 
of 1:1 were evaluated against PVA-stabilised nanoparticles. Both nanoparticle 
suspensions could be visualised when imaged at 710 nm and MSOT absorbance graphs 






An NIR-absorbing PDI derivative has been successfully synthesized and fully 
characterised with 1H NMR, FTIR and UV-vis spectroscopy. PDI nanoparticles have 
consequently been prepared by nanoprecipitation with our novel SHBP stabiliser and 
PVA stabiliser. These nanoparticles have limited cytotoxicity, good cellular uptake 
and high NIR signal in MSCs and can hence be used as probes for cell tracking with 
MSOT.  
PDI nanoparticles with SHBP stabiliser (PDI:SHBP 1:1) showed more efficient uptake 
than with the PVA-stabilised nanoparticles. This is consistent with previous work in 
our group where PDI-SHBP nanoparticles enabled the in vivo tracking of MSCs in a 
rodent model with MSOT.274, 278  In the present study, PVA-stabilised nanoparticles 
exhibited low cytotoxicity and high NIR absorbance. Furthermore, PVA has the added 
benefit of being commercially available and relatively low-cost. Both PVA- and 
SHBP-stabilised (PDI:SHBP 1:1) are viable candidates for in vivo cell tracking going 
forward. 
When comparing PDI nanoparticles to other PA probes in the literature, such as gold 
nanoparticles, the ease and simplicity of the nanoprecipitation method is a key 
advantage for clinical translation, particularly as the process does not require heat or 
harmful solvents. Moreover, the PDI synthesis is straightforward and well-established 
enabling a range of PA probes to made with different spectral absorbance wavelengths 
that have excellent photostability compared to ICG. The limited toxicity and low cost 
of the materials are further benefits over other PA probes in the literature.245  
The high MSOT signal of both PVA- and SHBP-stabilised nanoparticles has been 
demonstrated for cell tracking however it is also ideal for labelling hydrogels which 
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would allow in vivo tracking of hydrogel integrity; hence, this is the focus of chapter 




















Chapter 3: Labelling Cell-Encapsulating Hydrogels with 
Perylene Diimide Nanoparticles 
 
3.1 Introduction 
When developing regenerative medicine therapies (RMTs), it is important to consider 
the possible problems associated with the cell delivery process as the route of 
administration can affect the viability, retention, integration and functionality of 
cells.284 The most common administration route is injection (e.g., intravenous, 
intramuscular, intracardiac) and thus the mechanical stress from the needle can affect 
cell viability.285-287 Furthermore, once the cells have been administered, there are 
problems such as uneven settling and clumping and subsequent cell death may lead to 
macrophage infiltration.32 These problems could contribute to a reduction in efficacy 
for RMTs and hence encapsulating cells in a protective polymer matrix offers a novel 
solution to this problem.  
Hydrogels are defined as 3-dimensional (3D) crosslinked networks of hydrophilic 
polymers, where the liquid component of the gel is water. Biocompatible hydrogels 
have been developed with natural or synthetic polymers for a variety of biomedical 
applications, including drug and cell delivery, and tissue engineering.288-290 
Encapsulation of cells in biocompatible hydrogels can increase cell survival whilst 
encouraging 3D cell growth.291  
3.1.1 Gel Materials  
Hydrogels can be categorised into physical or chemical gels. Physical gels, also known 
as reversible, are networks of polymers held together by secondary interactions, such 
as hydrogen bonds, ionic or hydrophobic forces, whereas chemical gels (irreversible) 
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involve the formation of covalent bonds.290 Methods of covalent crosslinking include 
radical polymerisation, chemical reactions of complementary groups (e.g. addition and 
condensation reactions) and enzymatically catalysed gelation.292-294 Alternately, 
physical gels can be formed by the addition of ions, changes in pH and temperature as 
well as self-assembly of amphiphilic block and graft copolymers.295-297  
Hydrogels can be synthesized from natural or synthetic polymers. The most commonly 
utilised natural polymers include alginate and collagen however, there have been 
significant advances in synthetic hydrogels to enable greater control over stability, 
strength and functionality.26 In regenerative medicine, a key consideration is the design 
of biocompatible hydrogels that mimic the extracellular matrix (ECM).25 
3.1.1.1 Synthetic Hydrogels 
Hydrogels prepared from synthetic polymers can be chemically and mechanically 
stronger than natural hydrogels which can improve durability by slowing degradation. 
Common materials include poly(ethylene glycol) (PEG), poly(lactic acid) (PLA), 
polyacrylamide (PAAm) and polyvinyl alcohol (PVA), among others.298-300  
PEG is utilised in a variety of biomedical applications due to its high biocompatibility 
and hence it is approved by the Food and Drug Administration (FDA).300 Furthermore, 
advances in PEG-hydrogels have been driven by the versatility of PEG chemistry; 
copolymerisation with other macromolecules can introduce biological moieties into 
the hydrogel structure to promote cell survival or function. An example of this is where 
PEG hydrogels containing the integrin binding peptide Arg-Gly-Asp (RGD) were 
shown to increase osteoblast viability.301, 302   
Hydrogels can also be prepared with a combination of both natural and synthetic 
polymers to tune the gel properties.303-305 For example, the addition of synthetic 
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polymer (PAAm) to methacrylated gelatin produced a superior hybrid hydrogel with 
improved performance in terms of strength, elasticity and degradation rate, thus 
expanding the applications of gelatin-based hydrogels in soft tissue engineering.306  
3.1.1.2 Natural Hydrogels 
For biomedical applications, natural polymers have been deemed more suitable due to 
them being biocompatible and biodegradable, as well as containing biologically 
recognisable moieties.307 Moreover, hydrogels prepared from natural polymers are 
mostly prepared using physical crosslinking methods, avoiding the need for toxic 
crosslinking agents.27 Table 3.1 summarises some of the most common natural 
materials used to prepared hydrogels. 
Table 3.1: Summary of common natural polymers used for hydrogels, adapted from 
reference.300 
Name Source Type Gelation 
process 
Alginate Seaweed Polysaccharide Ionotropic 
Chitosan Crustaceans Polysaccharide Ionotropic 
Hyaluronic 
acid 
ECM Polysaccharide Thermal/photo 
Collagen ECM Protein Thermal/pH 
Gelatin ECM/ collagen Protein Thermal 
 
Alginate is one of the most common natural hydrogel materials widely utilised in 
biomedical applications including wound healing, drug delivery and tissue 
engineering. Alginate is derived from seaweed and is a polysaccharide which can vary 
in composition and sequence.308 Alginate hydrogels are commonly prepared through 
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the addition of divalent ionic crosslinking agents, such as calcium ions (Ca2+).309, 310 
The widespread use of alginate hydrogels for cell encapsulation can be attributed to 
the formulation of such gels under physiological conditions having a limited effect on 
cell viability or function, as well as facile cell retrieval and a gel pore network that 
enables efficient nutrient and waste diffusion.21 Furthermore, the ionotropic 
crosslinking methods renders alginate hydrogels injectable, which offers a further 
advantage over other hydrogel materials.311   
Chitosan is a polysaccharide derived from chitin, a component of the exoskeleton of 
crustaceans. Similar to alginate, chitosan has gained traction in the biomedical field 
due to its biocompatibility and biodegradability, as well as high abundance and low 
cost.312, 313 Furthermore, chitosan has bioadhesive properties which are beneficial for 
3D cell growth. Chitosan can be covalently or ionotropically crosslinked, where the 
latter is favoured to avoid toxicity.314  
Collagen hydrogels have also been widely explored for biomedical engineering, 
particularly as collagen is the main component of ECM in mammalian tissues.300, 315 
Furthermore, bioadhesion is an important consideration for cell-based hydrogels so 
that cells can adhere to the hydrogel structure enabling 3D cell growth.316 Chitosan 
and collagen are two examples of natural polymers that inherently exhibit bioadhesion 
however, alginate hydrogels have been modified with the RGD ligand to increase cell 
adhesion properties and mimic the ECM.309, 317  
3.1.2 Use of Gels in Regenerative Medicine 
As previously mentioned, biocompatibility is a necessary property for hydrogels used 
in regenerative medicine. Moreover, the conditions of the gelation process are also an 
important consideration when designing cell-based hydrogels. Many of the chemical 
89 
 
hydrogel preparation methods include organic solvents or toxic crosslinkers and hence, 
physical gels can provide a safer option and provide opportunity for injectable in situ 
forming hydrogels.295, 296 For this, an aqueous mixture of gel precursor is administered 
via syringe and gelation occurs inside the body so hence the gelation process must 
occur under physiological conditions. Other advantages of injectable hydrogels is that 
administration is minimally invasive and the gels are mouldable, i.e. the gel construct 
can adapt to the space.318  
3.1.2.1 Tissue Engineering 
The field of tissue engineering emerged as a result of the high demand for organ 
transplants and not enough donors.319 Tissue and cell-based constructs have been 
developed for implantation, where considerations must be made to ensure the body 
accepts the engineered tissue. Traditionally, the goal was to form functional tissue 
from these constructs however tissue engineering aligns closely with the field of 
regenerative medicine, where cells and biological moieties are included to promote 
repair through the body’s own regeneration mechanisms.320 Furthermore, a 
combination of both these approaches could lead to more efficacious treatments and 
limited rejection by the body. 
Hydrogels are ideal candidates for scaffold material as they can be carefully designed 
in terms of degradation rate.321 In bone tissue engineering, scaffolds are designed as a 
template to promote bone regeneration as persistence of the graft material can have 
poor clinical outcomes and early resorption of the scaffold could destabilise initial 
bone formation.322 When designing hydrogels, combining the mechanical tailoring 
properties of synthetic polymers with biomimetic natural polymers will offer a novel 
solution in the field of tissue engineering.323  An example of this includes gelatin 
methacryloyl (GelMA) where hybrid hydrogel systems can include nanoparticles such 
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as carbon nanotubes (CNTs) to improve mechanical strength without affecting 
porosity for 3D cell growth.324, 325 
3.1.2.2 Cell Encapsulation 
Hydrogels can also be used to deliver RMTs and many of the same concepts overlap 
with tissue engineering constructs, i.e. improving cell retention and survival.326  
Encapsulating cells in a hydrogel enables protection from the host’s immune system. 
Similarly to tissue engineering constructs, hydrogels must be biocompatible, 
mechanically stable and have a porosity which allows for diffusion of nutrients.23 An 
example of this is with the encapsulation of pancreatic islet cells to treat type 1 diabetes 
using alginate-based hydrogels.327, 328 The success of islet transplantation has been 
hindered by the need for immunosuppressive regimens however it is thought that 
encapsulation offers a novel strategy to protect cells from immune system components 
whilst allowing insulin secretion.329  
The encapsulation of neuronal cells in collagen hydrogels has been extensively 
explored for spinal cord injury (SCI) and injuries to the central nervous system (CNS), 
due to its similarity to the ECM.41, 330 Furthermore, collagen gels are most commonly 
prepared by physical crosslinking where gelation can occur from changes in 
temperature or pH. This is particularly ideal for SCI or injuries to the CNS as hydrogels 
can be injected and formed in situ, offering an alternative to invasive surgeries. 
Furthermore, hydrogels can prevent cell migration to other parts of the CNS.331  
3.1.3 Fate of Gels In Vivo 
Whilst significant advances have been made to label cells and monitor release from 
hydrogels, it would also be useful to label the hydrogel. An example of the former is 
where cells have been labelled with iron oxide nanoparticles and encapsulated in 
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collagen matrices; the nanoparticles allowed for the monitor of cell release using 
magnetic resonance imaging (MRI).32, 332 Indeed, many of the probes discussed in the 
previous chapters of this thesis could be applied to tracking the release of cells from 
within a hydrogel.  
Monitoring the fate of hydrogels in vivo would aid the design of encapsulated RMTs, 
as well as having significant use in the field of tissue engineering. Furthermore, 
monitoring scaffold degradation in vivo with bioimaging techniques would enable 
non-invasive longitudinal tracking in rodent models.49, 333 Many of the biomaterials 
employed as hydrogel constructs mimic tissue and so novel probes can be used to label 
the hydrogels and provide contrast for various imaging modalities.  
Fluorescence imaging and MRI have been explored for hydrogel tracking.77, 123, 334 An 
example of this is where SPIONs were used to label cellulose/silk fibroin hydrogels.84 
Nuclear imaging has also been used where the radiometal 111In acted as a crosslinker 
for alginate hydrogels, whilst also providing contrast for in vivo nuclear imaging.51 
This enabled the tracking of hydrogel for a multitude of applications including drug 
delivery, stem cell transplantation and cardiac tissue engineering.  
To our knowledge, there are only a few examples in the literature of hydrogel tracking 
with photoacoustic imaging (PAI). One example was were gold nanoparticles were 
incorporated into an RGD-modified polypeptide hydrogel for targeted PAI.335 Another 
example was CNTs were included in poly(lactide-co-glycolide) PLGA scaffolds to 
improve the mechanical properties and provide contrast for photoacoustic (PA) 
microscopy of constructs in phantoms.50 Near- infrared (NIR) responsive hydrogels 
have also been developed for photothermal therapy (PTT) by formulating alginate gels 
with lanthanide-gold hybrid nanoparticles.336  
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Despite only a few examples, using PAI to track hydrogels has numerous advantages, 
including high spatial resolution and deep-tissue penetration.337 Furthermore, PA 
contrast agents absorb in the near-infrared (NIR) region, where tissue absorption is 
low and hence the hydrogels can be effectively visualised against the background. 
Therefore, more research into hydrogel tracking with PAI is required.  
We have demonstrated that PDI nanoparticles can be used for tracking of 
mesenchymal stromal cells (MSC) in vivo with multispectral optoacoustic tomography 
(MSOT, Chapter 2). The versatility of PDI chemistry allows tuning of the wavelength 
of absorbance of PDI derivatives. Hence, the nanoparticle platform developed in 
Chapter 2 could be utilised to prepared two sets of nanoparticles, with different PDI 
derivatives which can be spectrally unmixed. The different sets of PDI nanoparticles 
could be used to label cells and encapsulating hydrogels separately for simultaneous 
tracking with MSOT.  
3.1.4 Aims 
The purpose of the present study is to investigate the use of perylene diimide 
nanoparticles in labelling collagen hydrogels. Collagen was chosen as the material for 
the hydrogel constructs due to its biocompatibility and bioadhesive properties to 
nurture mesenchymal stromal cell growth, and also its high abundance and low cost. 
The aims of this study are as follows: 
1. To encapsulate mesenchymal stromal cells in collagen hydrogels labelled with 
perylene diimide nanoparticles. 
2. To assess the effect of collagen encapsulation on mesenchymal stromal cell 
viability and whether the inclusion of perylene diimide nanoparticles has an 
effect on this. 
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3. To image the gels in vitro with multispectral optoacoustic tomography. 
4. To determine whether cells or perylene diimide nanoparticles are migrating out 























Collagen I, rat tail was purchased from Gibco. The synthesis of NIR-absorbing PDI 
and preparation of PDI nanoparticles is detailed in Chapter 2 of this thesis.  
3.2.2 Cell Culture 
The murine mesenchymal stromal cell line D1 (ATCC) was used for all in vitro cell 
studies. All MSCs used had previously been modified by Dr Arthur Taylor (Murray 
group) to express firefly luciferase and ZsGreen, under control of the constitutive 
promoter, EF1α.276, 277 MSCs were cultured in 6 cm or 10 cm tissue culture dishes 
(Greiner CELLSTAR®) in high glucose Dulbecco’s Modified Eagle Medium 
(DMEM, Sigma Aldrich) containing 10% fetal bovine serum (FBS, Sigma Aldrich), 
1% non-essential amino acids (Sigma Aldrich) and 2 mM L-glutamine (Gibco). Cells 
were incubated at 37°C and 5% v/v CO2 and passaged with 1% trypsin-EDTA (Sigma 
Aldrich) when they reached 90% confluence. 
3.2.3 Preparation of Collagen Gels 
MSCs were encapsulated during the formation of collagen gels. The preparation of 
collagen gels (100 µl) was carried out following the manufacturer’s guidelines with a 
collagen concentration of 2 mg/ml. All reagents were kept on ice, apart from cell 
culture medium which was warmed to 37°C. In a vial with the desired number of cells 
(2x105), nanoparticle suspension (original concentration 0.25 mg/ml) and media were 
added to prepare gels with PDI concentrations of 12.5-50 µg/ml and so that the total 
volume of nanoparticle suspension and media added was 21.6 µl. After this, 10x PBS 
(10 µl) and 1N NaOH solution (1.6 µl) were added. 66.7 µl of collagen was added and 
the mixture was quickly triturated and transferred to a 96-well plate. After all gels had 
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been prepared, the plate was incubated for 30 minutes (37 °C, 5% CO2) to allow 
gelation. 100 µl of cell culture media was added to each well and the gels were left 
overnight in the incubator.   
3.2.4 Bioluminescence and Fluorescence Imaging 
Fluorescence and bioluminescence images were acquired using an IVIS Spectrum In 
Vivo Imaging System (Perkin Elmer) and analysed with Living Image software. Gels 
were removed from their original wells and the bioluminescent/fluorescent signal of 
the gel was compared to wells that the gels had previously inhabited. 
3.2.4.1 Bioluminescence imaging 
Bioluminescence imaging was used to monitor cell migration and assess cell survival 
in the gels. The MSCs expressed firefly luciferase and D-luciferin (5 mM) was added 
prior to imaging. Automatic exposure time was used, F/stop was 1 and bioluminescent 
signal was measured in radiance (p/s/cm2/sr).  
3.2.4.2 Fluorescence Imaging 
The fluorescence was measured with excitation and emission wavelengths of 710 nm 
and 750 nm, respectively and an exposure time of 45s. The fluorescent signal was 
measured in radiant efficiency (p s-1 cm-2 sr) / (µW cm-2). 
3.2.5 Multispectral Optoacoustic Tomography 
Multispectral optoacoustic tomography (MSOT) was carried out using an inVision 
256TF system (iThera Medical) to investigate the limit of detection of PDI 




3.2.5.1 Preparation of Phantoms 
Agar phantoms were prepared for in vitro imaging with MSOT. 20 ml syringes were 
used as moulds by removing the end and pulling the plunger out. With the handle of 
the plunger taped to a surface, a straw (ends sealed) was suspended in the middle of 
the syringe and secured with tape. Next, intralipid (1.03 ml, Sigma Aldrich) was heated 
in a water bath whilst agar (0.75 g, Sigma Aldrich) was added to 50 ml of water and 
heated in a microwave. The solution was shaken and intralipid was added. The agar 
mixture was then poured into the syringe moulds and left to set for 30 minutes. Once 
set, the straws were removed and phantoms were stored in a small amount of water in 
the fridge to be used the following day. 
3.2.5.2 Imaging 
The fixed gels were put in clear plastic straws, filled with PBS and sealed at either end. 
The straws were then inserted into agar phantoms, covered in ultrasound gel and placed 
in the water bath (25°C) of the inVision System (iThera). Several slices were imaged 
across the wavelength range of 660-1000 nm in 5 nm intervals in order to clearest 
images of the gels possible (1 mm step). The following reconstruction parameters were 
utilised: backprojection 25mm(res:75µm), 50 kHz-6.5 MHz-IR and images were 









MSCs were encapsulated in collagen gels labelled with NIR-absorbing PDI 
nanoparticles. The purpose of the collagen gels is to provide a protective matrix in 
order to increase cell survival when administering cells in vivo. PDI nanoparticles were 
used to label the collagen matrix so that the hydrogel integrity can be tracked in vivo 
using PAI.  
3.3.1 Preparation of Collagen Gels 
The gels were prepared with a collagen concentration of 2 mg/ml; this was chosen so 
that the gels would be rigid enough to manipulate but not too high as this could affect 
cell viability. It was observed that including MSCs in the gel causes gel contraction, a 
phenomenon that is widely documented in the literature.42, 338, 339 In the present study, 
2x105 MSCs were seeded in each collagen gel.  
The gels were labelled with PDI nanoparticles; the PDI synthesis, nanoparticle 
preparation and characterisation are detailed in Chapter 2. Briefly, NIR-absorbing PDI 
(N,N’-dicyclohexyl-1,7-di(pyrrolidinyl)perylene-3,4,9,10-tetracarboxy diimide) was 
used to prepared polymer-stabilised nanoparticles via nanoprecipitation. Nanoparticles 
were stabilised with either our novel star hyperbranched block copolymer (SHBP) or 
PVA. The structures of the PDI and the polymer stabilisers are shown in Figure 3.1.  
MSCs and nanoparticles were included with the starting materials for gel formation so 
that they could be effectively encapsulated within the collagen matrix. The two types 
of nanoparticle (SHBP- or PVA-stabilised) were compared at a range of concentrations 
(12.5-50 µg/ml) to optimise the gels in terms of PA signal and cell viability. All other 
parameters were kept consistent i.e. cell number, collagen concentration, gel size and 
incubation times. The concentration of 10x PBS and 1N NaOH was kept consistent 
98 
 
and the amount of media varied depending on the nanoparticle concentration so that 
the total volume of nanoparticle suspension and media added up to 21.6 µl.  
 
Figure 3.1: Structures of (a) SHBP stabiliser (DEAMA50-c-DEGDMA2)-b-
(OEGMA80), (b) NIR-absorbing PDI (N,N’-Dicyclohexyl-1,7-
di(pyrrolidinyl)perylene-3,4,9,10-tetracarboxy diimide and (c) poly(vinyl alcohol) 
stabiliser.  
The gels formed during the 30-minute incubation period and 100 µl of media was 
added to the top of the gels, before leaving overnight. After 24hr, the gels that 
contained MSCs had contracted, detached from the sides of the well and were floating 
in the media. These gels could easily be removed from the well using a small spatula. 
Gels which did not contain MSCs remained the same size as before the 24hr period 
and were less rigid; these control gels had to be carefully manipulated when removed 
so as to not break the gel. Gels were either moved to a new well and replenished with 
fresh media or fixed with 4% PFA and stored in PBS.  
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Gels labelled with PDI nanoparticles appeared blue in colour, whereas unlabelled gels 
were white. Due to the opaqueness of the gels, the nanoparticles and cells could not be 
visualised using a microscope without sectioning. Furthermore, the absorbance 
properties could not be evaluated with UV-vis spectroscopy due to light scattering.  
3.3.2 Investigating Cell Survival and Migration  
MSCs had been engineered to express luciferase therefore bioluminescence imaging 
could be used to investigate cell survival. Gels were prepared with 2x105 MSCs and 
imaging was carried out 24hr later. Prior to imaging, the gels were moved to a new 
well so that the bioluminescent signal of this well could be compared with the signal 
of the gel; this gave an indication of whether cells remained inside the gel or migrated 
out and adhered to the surface of the well. PBS was added to the new well and luciferin 
(5 mM) was added to this and to the media in the previous well ahead of imaging. The 
measure of photon output is displayed as radiance. 
In Figure 3.2, gels had been prepared in well 1 and moved to well 2 in a 96-well plate 
after 24hr. The lack of bioluminescent signal in well 1 suggested that cells did not 
migrate out of the gel however the gels can be clearly visualised in well 2 
demonstrating that the MSCs are viable after 24hr in the gel. The outline of the signal 
does not include the whole well which is due to gel contraction. There is no signal in 
either well for the SHBP and PVA control gels where no cells were included however 
a signal can be seen for the collagen control with MSCs; this confirms that the signal 
is due to the MSCs and not the nanoparticles.  
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Figure 3.2: Bioluminescence imaging of gels which had been prepared in well 1 and 
moved to well 2 after 24hr. Gels labelled with SHBP- and PVA-stabilised PDI 
nanoparticles (0-50 µg/ml) were imaged along with control gels, including an 
unlabelled MSC collagen gel and labelled gels (25 µg/ml) without cells. All gels 
contained 2x105 MSCs apart from the SHBP and PVA control gels. Luciferin was 
added to the wells at a concentration of 5 mM ahead of imaging.  
There was no clear trend between signal strength and nanoparticle concentration. One 
possible reason for this could have been that the stated dosing concentration was 
inaccurate due to leaching and hence this was investigated further with fluorescence 
imaging. Furthermore, the lack of correlation can be attributed to other variables which 
may affect cell survival such as timings in the gel preparation process and the moving 
of the gels. Therefore, the lack of signal for the gel labelled with SHBP-stabilised 
nanoparticles at 25 µg/ml in Figure 3.2 can be considered an anomaly. 
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In a separate experiment, gels were prepared, and bioluminescence imaging was 
carried out after 1 week to assess cell survival over a longer timescale. Gels were 
prepared as in the previous experiment and moved to a new position in the 96-well 
plate every 1-3 days. After 1 week, the gels were moved for the final time and luciferin 
was added to the gel in PBS and to the leftover media in all the previous wells. 
Figure 3.3 shows that most of the gels have a bioluminescent signal after 1 week which 
suggests that MSCs were still viable. Moreover, the lack of signal in wells that had 
previously contained the gels suggest that cells do no migrate out. A signal was 
observed in all of the gels labelled with SHBP-stabilised nanoparticles however gels 
labelled at higher concentrations of PVA-stabilised nanoparticles (37.5 and 50 µg/ml) 
did not have a bioluminescent signal in this case, suggesting that the cells may not 
tolerate the higher concentrations of PVA-stabilised nanoparticles. There is no signal 
for SHBP and PVA control gels however the collagen control can be visualised as it 
contained MSCs.  
The total flux of the gels could be quantified and is shown in Figure 3.4. For the 
unlabelled control gel which contained MSCs, the total flux was higher at 1 week than 
1 day suggesting cells were proliferating. For gels labelled with PDI-SHBP 
nanoparticles, this was the case for the majority of the gels; however, for gels labelled 
with PDI-PVA the signal was low or decreased at 1 week for gels labelled at 25, 37.5 
and 50 µg/ml. The quantified flux is averaged over three separate experiments 
suggesting that overall PDI-PVA nanoparticles have a greater cytotoxic effect when 








SHBP  PVA 
Time (days)  Time (days) 
1 4 6 7 Gel  1 4 6 7 Gel 




 Controls  
Radiance 
(p s-1 cm-2 sr) 
 
 Time (days)  
 1 4 6 7 Gel  
Collagen   
SHBP  
PVA  
Figure 3.3: Bioluminescence imaging of gels which had been prepared on day 0 and 
moved to a new well every 1-3 days. Gels labelled with (a) SHBP- and PVA-stabilised 
PDI nanoparticles (0-50 µg/ml) were imaged on day 7 along with (b) control gels 





All gels contained 2x105 MSCs apart from the SHBP and PVA control gels. Luciferin 
was added to the wells at a concentration of 5 mM ahead of imaging.  




















































Figure 3.4: Bioluminescence imaging of gels at 1-day and 1-week post-synthesis. The 
total flux of the gels was quantified and is displayed as radiance for gels labelled with 
(a) PDI-SHBP and (b) PDI-PVA nanoparticles. The results are an average of three 
experiments and the error bars are the standard error of the mean.  
3.3.3 MSOT Signal Detection 
In vitro MSOT studies were carried out using agar phantoms. The MSOT irradiates 
the sample at multiple wavelengths and the signal is detected by ultrasound; the 
intensity of the acoustic waves undergoes tomographic reconstruction to form images 
of the gels. Gels were pushed into clear plastic straws and PBS was added to avoid air 
bubbles which can cause artefacts. The ends of the straw were sealed and the straw 
was inserted into a phantom for imaging. The gels were imaged from 650-1100 nm 
and images at 710 nm are shown, as it was found in Chapter 2 (Figure 2.20) that this 
coincided with the peak absorption of PDI nanoparticles. Gels were imaged at 1-day 




Figure 3.5 shows MSOT imaging of the control gels in phantoms which had been 
imaged after 1 day. Images are shown at 710 nm, as well as a graph displaying the 
mean pixel intensity of each of the gels over the range of wavelengths scanned.  
  
 


































Figure 3.5: MSOT images at 710 nm of (a) unlabelled collagen gel and gels labelled 
with (b) SHBP-stabilised and (c) PVA-stabilised PDI nanoparticles (25 µg/ml) 1-day 
after gel preparation. A graph (d) showing MSOT mean pixel intensity of the gels vs. 






The unlabelled collagen control gel (Figure 3.5a) could not be visualised at 710 nm 
however for the nanoparticle control gels, the shape of the gels can be seen in the 
images (Figure 3.5b and 3.5c). The mean pixel intensity (related to absorbance) of the 
gel labelled with SHBP-stabilised nanoparticles is significantly higher than the 
collagen control and the gel labelled with PVA-stabilised nanoparticles (Figure 3.5d). 
MSCs were incorporated during gel preparation at a seeding density of 2x105 cells/gel 
and fixed 24hr after gel preparation for imaging with MSOT. Figure 3.6 shows the 
results for two sets of gels labelled with SHBP- or PVA-stabilised PDI nanoparticles 
at a range of concentrations (0-50 µg/ml). Images of the gels at 710 nm are shown for 
the gels labelled at a concentration of 25 µg/ml and images of all other concentrations 
can be found in the Appendix (Figures A9 and A10).  
When comparing the different concentrations for gels labelled with SHBP-stabilised 
nanoparticles, the highest concentration of 50 µg/ml gives the greatest signal however 
at all other concentrations tested the MSOT signal was relatively weak and signal 
intensity did not correlate with increasing concentration (Figure 3.6). A similar trend 
was seen for gels labelled with PVA-stabilised nanoparticles although here the MSOT 
signal was generally lower than for the gels labelled with SHBP-stabilised 
nanoparticles; this agrees with the control gels discussed in Figure 3.5. It is also worth 
noting that the signal intensity is much lower than for the nanoparticle solutions of 
equivalent concentrations (Figure 2.34, Chapter 2). This observation and the lack of 
correlation of signal with concentration was investigated further by fluorescence 















































































Figure 3.6: MSOT of gels prepared with 2x105 cells and imaged 1-day post-synthesis. 
Images of gels labelled with (ai) SHBP and (bi) PVA nanoparticles (25 µg/ml) are 
displayed, as well as graphs of MSOT mean pixel intensity vs. wavelength at different 
concentrations for (aii) SHBP and (bii) PVA labelled gels.  
The controls gels (cell only and nanoparticle only) were remade and kept in an 
incubator for 1 week with a media change every 2-3 days. After this time, gels were 
imaged with MSOT. Figure 3.7 highlights the reduction in MSOT signal of gels 









































Figure 3.7: MSOT images at 710 nm of control gels labelled with (a) SHBP-stabilised 
and (b) PVA-stabilised PDI nanoparticles (25 µg/ml) 1-week after gel preparation. A 
graph (c) of MSOT mean pixel intensity of the gels vs. wavelength is also displayed. 
Imaging was carried out on fixed gels, 1-week post-synthesis. 
The same set of gels were prepared with 2x105 MSCs seeding density. In a same 
experiment as the control, gels were kept in an incubator for 1 week and the media was 
changed every 2-3 days. The data is shown in Figure 3.8, where images at 710 nm is 
shown for gels labelled at nanoparticle concentrations of 25 µg/ml and the images with 





comparing MSOT at 1-week and 1-day timepoints, it has been observed that signal 
intensity decreases with time; this suggests that nanoparticles may be leaching out of 
the gels over time. For gels labelled with PVA-stabilised nanoparticles, there is very 
little signal compared to the collagen control after 1 week however gels with SHBP-
stabilised nanoparticles have retained some signal (Figure 3.8).  
 










































































Figure 3.8: MSOT of gels prepared with 2x105 cells and fixed 1-week post-synthesis. 






displayed, as well as graphs of MSOT mean pixel intensity vs. wavelength at different 
concentrations for (aii) SHBP and (bii) PVA labelled gels 
These findings were reproducible and repeats of the MSOT experiments are displayed 
in the Appendix (Figures A13 and A14). Again, there seemed to be no correlation 
between signal intensity and labelling concentration as it is likely that the 
concentrations stated are inaccurate due to nanoparticle leaching.   
3.3.4 Investigating Nanoparticle Leaching  
The PDI nanoparticles exhibit fluorescence at ~740 nm and so can be detected by 
fluorescence imaging. In the same experiment as with bioluminescence imaging, gels 
were prepared and after 24hr, gels were moved to a new well prior to imaging. The 
fluorescent signal output is displayed as radiant efficiency.  
Fluorescent signal was observed in all wells apart from the unlabelled collagen control 
gel, as shown in Figure 3.9, which indicated that any signal was due to the presence of 
nanoparticles. The total flux in each well was also quantified and can be found in 
Figure A15 in the Appendix. The fluorescence signal in well 1 suggested that some 
nanoparticles were not included in the gel or had leached out during the 24hr period. 
The signal in well 2 is from the gel which suggested that there were still enough 
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Figure 3.9: Fluorescence imaging of gels which had been prepared in well 1 and moved 
to well 2 after 24hr. Gels labelled with SHBP- and PVA-stabilised PDI nanoparticles 
(0-50 µg/ml) were imaged along with control gels including an unlabelled MSC 
collagen gel and labelled gels (25 µg/ml) without cells. All gels contained 2x105 MSCs 
apart from the SHBP and PVA control gels. Fluorescence imaging was carried out 
with excitation and emission filters of 710 nm and 750 nm, respectively. 
It was possible that the nanoparticles were not included in the gel in the first place and 
had settled out into the original well during the gelation process. Therefore, an 
experiment was carried out where gels were prepared, moved to a new well every 1-3 
days and covered with media before fluorescence imaging after 1 week. Any 
fluorescence signal from the now empty wells can be associated with nanoparticles 
that had migrated out of the gels and settled onto the well surface. Comparing the 
fluorescence signal from the gel and the previous wells enables an indication of the 
extent of nanoparticle leaching.  
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Figure 3.10 summarises the fluorescence imaging of the control gels, including 
collagen (with cells) as well as gels labelled with SHBP- and PVA-stabilised 
nanoparticles (without cells). The collagen control gel cannot be seen on the 
fluorescence image however the labelled gels can be visualised. Furthermore, the total 
flux of each well was quantified (Figure 3.10b) and is higher for the labelled gels whilst 
the collagen control does carry some value which can be attributed to background 
signal. These results confirm that the fluorescence signal comes from the 
nanoparticles. For the labelled gels, the fluorescence signal of the wells and gels are 
quite similar suggesting there are some nanoparticles remaining in the gels and also 
some residual nanoparticles that leached from the gel and settled on to the well surface. 
Figures 3.11 and 3.12 show the results for MSC gels labelled with SHBP- and PVA-
stabilised nanoparticles, respectively. The results show a similar trend to the 
nanoparticle control gels; fluorescence signal can be seen in the gels and in the wells. 
The total flux in each well was quantified and it was found that increasing the dosing 
concentration did not result in an increase in fluorescence intensity in the gels due to 
varied amounts of leaching from each gel (Figure 3.11b and 3.12b). There is still a 
fluorescent signal in the gel which is consistent with MSOT suggesting the gels could 
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Figure 3.10: Fluorescence imaging of gels which had been prepared in well 1 and 
moved to new wells every 1-3 days, highlighted in (a) fluorescence images and (b) a 
graph to show radiance efficiency measurement of each well. Control gels were 
imaged, including an MSC collagen gel (2x105 cells) and gels labelled with SHBP- 
and PVA-stabilised PDI nanoparticles (25 µg/ml) which did not contain MSCs. 
Fluorescence imaging was carried out with excitation and emission filters of 710 nm 
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Figure 3.11: Fluorescence imaging of gels which had been prepared in well 1 and 
moved to new wells every 1-3 days, highlighted in (a) fluorescence images and (b) a 
graph to show radiance efficiency measurement of each well. Gels labelled with 
SHBP-stabilised PDI nanoparticles (0-50 µg/ml) were imaged, and all gels contained 
2x105 MSCs. Fluorescence imaging was carried out with excitation and emission 





Gels labelled with PVA-stabilised nanoparticles 
 
PDI conc. Time (days)  




[p s-1 cm-2 sr] 
















































Figure 3.12: Fluorescence imaging of gels which had been prepared in well 1 and 
moved to new wells every 1-3 days, highlighted in (a) fluorescence images and (b) a 
graph to show radiance efficiency measurement of each well (right). Gels labelled with 
PVA-stabilised PDI nanoparticles (0-50 µg/ml) were imaged, and all gels contained 
2x105 MSCs. Fluorescence imaging was carried out with excitation and emission 






Collagen gels have been prepared as a protective matrix for the delivery of MSCs. 
Collagen was chosen as the construct material as it mimics the ECM and has 
bioadhesive properties, making it an ideal candidate for cell delivery applications in 
treating SCI.32, 316, 331 The collagen gels have been labelled with NIR-absorbing PDI 
nanoparticles for tracking hydrogel integrity in vivo with MSOT. The aims of the 
present study were to optimise the labelled gels in vitro in terms of cell viability and 
PA signal.  
The synthesis and characterisation of PDI nanoparticles is detailed in chapter 2. 
Briefly, PDI nanoparticles were prepared using a nanoprecipitation method with a 
polymer stabiliser. PVA and our novel SHBP stabiliser were used to prepare 
nanoparticles for labelling of separate gels to compare labelling efficiency and the 
effect on cell viability. A range of nanoparticle concentrations (12.5-50 µg/ml) were 
investigated to determine the optimum for achieving PA signal without affecting cell 
viability. 
The collagen gels were prepared following the manufacturer’s guidelines and gelation 
was initiated by both temperature and pH. The gel components were kept on ice prior 
to preparation as the collagen gelation is temperature-sensitive.340 The gelation process 
also includes the addition of sodium hydroxide so that hydrogen bonds can form to 
strengthen the gel. The PDI nanoparticles and MSCs were included in the gel premix, 
along with the sodium hydroxide and 10% PBS, so that they could be encapsulated in 
the matrix during gelation. Gelation occurred during the 30-minute incubation period 
after gel preparation.  
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Gels containing MSCs contracted during the 24hr period which is a phenomenon 
widely observed in the literature.42, 338, 339 The contraction results in a more rigid gel 
that can be more easily manipulated, whereas the control gels that did not contain 
MSCs were much more fragile and difficult to manipulate. A seeding density of 2x105 
was selected to enable cells to be easily visualised with bioluminescence imaging and 
to provide some rigidity so as to facilitate manipulation of the gel. Higher seeding 
densities were avoided because excessive contraction of the gel would result in an 
increase in the local concentration of PDI nanoparticles around the cells, which could 
potentially reduce cell viability. The PDI nanoparticles did not have an effect on gel 
contraction but did give the gels a blue tinge.  
3.4.1 Cell Survival and Migration 
The fate of cells in the collagen gel was monitored using bioluminescence imaging as 
the MSCs had been engineered to express firefly luciferase. Luciferin was added to 
media/PBS surrounding the gel and a bioluminescent signal was detected suggesting 
luciferin could diffuse into the gels to reach the MSCs. Experiments had to be carried 
out in duplicate to compare cell viability after 1 day and 1 week as it was not possible 
to image with the IVIS under sterile conditions.  
It was found that cells survived in all of the gels after 1 day as a bioluminescent signal 
could be detected. Conversely, there was no bioluminescent signal for any of the 
labelled control gels which did not contain MSCs. After 1 week, the cells were viable 
in the majority of gels. The bioluminescent signal of the gels could be quantified as 
total flux and it was found that the average flux increased for the unlabelled control 
gel at 1-week compared to 1-day, suggesting MSCs were proliferating. Furthermore, 
the total flux generally increased for the gels labelled with SHBP-stabilised 
nanoparticles. For the gels labelled with PVA-stabilised nanoparticles, the total flux 
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was generally low for gels labelled at 37.5 and 50 µg/ml and decreased from 1-day to 
1-week when labelled at 25 µg/ml. This suggested that the PDI-PVA nanoparticles had 
a cytotoxic effect which contradicts data in chapter 2 where PVA-stabilised 
nanoparticles were well-tolerated up to 40 µg/ml; however, mechanical forces in the 
gel will also have an effect.  
When comparing different concentrations of the same type of nanoparticle, the 
strength of the bioluminescent signal was variable. This could be caused by the lack 
of precision in the number of cells that are incorporated in the gel when making batches 
of multiple gels or problems associated with luciferin diffusing through the gel and 
reaching all the cells. Furthermore, the nanoparticle concentrations were not accurate 
due to nanoparticle leaching. Despite this, over repeats of the experiments, the 
cytotoxic effect of gels labelled with PDI-PVA nanoparticles was evident. 
It was found that MSCs did not migrate from within the collagen gel into the wells in 
the timescales used for this study. After 1 week, there was a strong bioluminescent 
signal for most of the gels however there was no signal in any of the wells that the gels 
had previously inhabited. This is consistent with the bioadhesive properties associated 
with collagen.  
3.4.2 Tracking Gels with MSOT 
The labelled gels were evaluated in vitro with MSOT using agar phantoms. Gels were 
prepared in duplicate and fixed at 1-day and 1-week timepoints for imaging with 
MSOT. All the gels could be effectively visualised with MSOT compared to the 
collagen control. The peak absorbance of the PDI nanoparticles is ~710 nm and all 
labelled gels had significantly higher MSOT mean pixel intensity at this wavelength 
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compared to the unlabelled control. This suggested the incorporation of the 
nanoparticles enabled detection of the gel with MSOT.  
The signal of gels labelled with SHBP-stabilised nanoparticles was generally much 
higher than with the PVA-stabilised nanoparticles. This is inconsistent with MSOT 
measurements of the nanoparticle solutions (Chapter 2) where similar MSOT 
absorbance was observed. Clearly, the gel structure will have an effect on this as only 
one slice of the gel is imaged and it is unclear if the nanoparticles are homogenous 
throughout the gel. Moreover, the leaching of the nanoparticles will have an effect on 
MSOT intensity. 
There was a reduction in MSOT signal intensity for both sets of gels from 1-day to 1-
week, where gels labelled with PVA-stabilised nanoparticles returned to baseline after 
1 week. The gels labelled with SHBP-stabilised nanoparticles did lose some signal 
however all gels remained above the signal of the unlabelled collagen control. This 
observation and the fact that there was no correlation between labelling concentration 
and signal intensity suggests that nanoparticles were likely leaching from the gels.  
3.4.3 Nanoparticle Leaching  
Following the MSOT data, fluorescence imaging was used to determine whether 
nanoparticles were leaching from the gels. In the same experiment as for 
bioluminescence imaging, fluorescence was measured using the IVIS at 1-day and 1-
week time points. For the 24hr experiment, the fluorescent signal of the gel was 
compared to the well that had previously held the gel. Both the well and the gel had a 
fluorescent signal however it was unclear whether nanoparticles had leached out or 
had not been incorporated in the gel in the first place, i.e. the PDI nanoparticles could 
have come out of the gel premix as the gel was forming.  
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Following this, gels were prepared and moved to new gels every 1-3 days and 
fluorescent imaging was carried out after a week. There was a fluorescent signal 
coming from all the wells that had previously held a gel that had been labelled with 
PDI nanoparticles and limited fluorescent signal for the collagen control. This 
suggested that nanoparticles leached out of the gels and settled onto the surface of the 
well. Despite this, there was still a fluorescent signal from the gel after 1 week which 
meant that some nanoparticles had remained in the gel. This is consistent with MSOT 
data where gels labelled with SHBP-stabilised nanoparticles could still be visualised 
after a week. There was a fluorescent signal from the gels labelled with PVA-stabilised 
nanoparticles after a week where no signal had been observed at this timepoint with 
MSOT. This could be due to differences in the sensitivity of the techniques in in vitro 
models, i.e. bioluminescence imaging is of the gel in a plate whereas MSOT is carried 
out in agar phantom. For animal experiments, imaging is at a greater depth and so 
MSOT is more sensitive.  
The nanoparticle leaching explains why the nanoparticle labelling concentration did 
not correlate MSOT signal intensity. It is unknown how many PDI nanoparticles 
leached at each stage so the effect of concentration on MSOT signal intensity could 
not be determined. The fluorescence imaging shows that nanoparticles leached out 
over time and so it is likely that the dosing concentrations are inaccurate however the 
extent of leaching has been difficult to quantify using this technique. A similar 
phenomenon was observed in the literature for hydrogels that were labelled with 
SPIONs;84 the MRI signal decreased over time suggesting the leaching of SPIONs.  In 
the present application, future experiments could look to explore the extent of leaching 
further by dialysing the gels and taking UV-vis absorbance measurements of the 
surrounding medium.  
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Ultimately, work would be needed to prevent nanoparticle leaching; this could be 
explored through altering the surface properties of the PDI nanoparticles to increase 
the interaction with the collagen. This could be achieved by increasing the electrostatic 
interaction between nanoparticles and hydrogels or by direct conjugation of the 
nanoparticles to the polymer. An example of this is where gold nanoparticles was 
conjugated to a synthetic polymer hydrogel via carbodiimide coupling.341  Another 
possible route is to increase the concentration of collagen which would decreased the 


















Preliminary studies herein suggest that PDI nanoparticles prepared with SHBP 
stabiliser can be used to label collagen gels for imaging with MSOT. The PDI 
nanoparticles could be used in a proof of principle experiment to assess whether it is 
possible to image the gels in vivo over the short-term. This would give insight into 
whether the gel fragments shortly after implantation. Furthermore, there is sufficient 
MSOT signal enabling gel fragmentation to be assessed for up to 1 week.   
The major drawback of the constructs is that nanoparticles appear to leach from the 
gels over time. This suggests that they would not be useful for monitoring the extent 
of gel degradation over time as it would be difficult to decipher whether a reduction in 
MSOT signal would be due to leaching or degradation. Future experiments should look 
to investigate nanoparticle leaching further and over longer timescales to find the point 
at which the gels can be no longer detected with MSOT. Ultimately, this problem will 
need to be tackled by focussing on the probe design to increase the interaction between 
















Chapter 4: Nanodiamonds as Fluorescent Probes for Cell 
Tracking 
4.1 Introduction 
Nanodiamonds (NDs) first emerged in the 1960s in the USSR, but have only attracted 
attention in the last few decades with the rise of other novel carbon-based materials.344 
The rigid diamond structure is made up of a dense network of sp3 hybridised carbon 
atoms, each with tetrahedral symmetry. Each carbon atom forms four bonds to 
neighbouring carbon atoms resulting in a lack of free valence electrons which 
contributes to the high inertness. However, as for other nanoscale materials, the 
properties of NDs are predominantly as a result of the surface chemistry.137 For NDs, 
the high surface area gives rise to properties that are different to the bulk material as 
surface carbon atoms cannot make four bonds and hence terminal groups, such as 
hydrogen and hydroxyl groups, are included to reduce unfavourable dangling bonds. 
Both the intrinsic structure (sp3 carbon network) and the surface chemistry of NDs can 
be exploited to alter material properties such as stability as well as optical and 
electronic properties. The tunability aspect, combined with their high biocompatibility 
and inexpensive large-scale synthesis, has meant that NDs are being explored for many 
potential biomedical applications.345-347  
4.1.1 The Rise of Carbon-based Materials 
Graphene, multi-walled carbon nanotubes (MWCNT) and fullerenes are among the 
most common carbon-based nanomaterials being exploited for their unique 
physicochemical properties.132, 348 Graphene is defined as a single monolayer of carbon 
atoms arranged in hexagonal lattice, or honeycomb structure, which was first isolated 
from graphite (>10 layers of graphene) in 2004 at the University of Manchester.349 The 
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novel electronic properties of graphene can be attributed to its unique 2D structure, 
where changing the amount of graphene layers allows the electronic properties to be 
manipulated.350 Other advantages, such as ease of surface functionalisation and 
processing in aqueous medium, have encouraged investigation into the possible 
biomedical applications of graphene.129, 351, 352  
MWCNTs are structures made up of multiple graphene layers rolled up, which can be 
easily functionalised to alter solubility and electronic properties.353 The direction of 
the graphene plane and the diameter of the nanotube can also be controlled to alter 
electronic properties.354 MWCNTs have been extensively explored for in vitro and in 
vivo imaging owing to their intense and tuneable optical properties, including 
photoluminescence and NIR  absorbance.131, 210 It has been found that the success of 
MWCNTs in vivo is attributed to effective surface functionalisation with 
biocompatible coatings.130, 131 
Fullerenes are caged structures made up of 60 carbon atoms, resembling a sheet of 
graphene rolled up to form a hollow sphere. The uses of fullerenes have been severely 
hampered by their lack of solubility in aqueous medium; however, functionalised 
fullerenes, such as fullerenol, have gained significant interest in the biomedical 
field.132, 355, 356   
Carbon dots, sometimes referred to as carbon quantum dots, are a relatively new class 
of carbon-based materials that have nanoparticle morphology with a particle size range 
of 2-10 nm. They can be prepared from top-down methods, from graphene, MWCNTs 
or NDs, or bottom-up approaches from carbon-based precursors.357 Carbon dots 
exhibit high fluorescence and are hence being explored in cellular imaging and 
photovoltaic applications.358  
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Studies have shown that NDs are more biocompatible than other carbon-based 
materials.132, 135, 346 This is particularly notable as NDs also share many of the 
advantages of graphene, MWCNTs, fullerenes and carbon dots, such as the unique 
optical properties, ease of surface modification and large surface area. Furthermore, 
uniquely among the other carbon-based materials, NDs show no evidence of 
photobleaching making them highly attractive for imaging applications.359 
4.1.2 Synthesis of Nanodiamonds 
Diamond can be prepared by chemical vapour deposition (CVD), high-pressure high-
temperature (HPHT) and detonation methods.137 CVD, as the name suggests, involves 
the deposition of chemical vapours onto a substrate, resulting in the formation of 
diamond films. Nanocrystalline and ultrananocrystalline films, can be prepared with 
grain sizes of 5-100 and 3-5 nm, respectively; grain size is dependent on various 
parameters, such as composition of the growth precursors, temperature, pressure and 
voltage. CVD is commonly used to prepare diamond films for sensing and coating 
applications.360 
NDs are more commonly prepared by HPHT or detonation of carbon explosives.361  
HPHT conditions are required to form NDs from graphite, in order to overcome the 
high energy barrier.136 The process generally involves irradiation and annealing, as 
well as milling techniques to achieve smaller particle sizes. The high energy process 
results in defects within the diamond structure where carbon atoms are knocked out 
resulting in vacancies. When these vacancies are near to nitrogen centres, produced by 
including nitrogen compounds in the starting material, nitrogen-vacancy (NV) defects 
are formed.137, 362 This results in unique absorbance/fluorescence properties which can 
be exploited for bioimaging.   
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4.1.2.1 Detonation NDs 
It is difficult to achieve the small particle sizes required for biomedical applications 
using the HPHT process and hence the discovery of detonation NDs was paramount.344 
Carbon explosives are detonated by the generation of a shock wave which causes high 
enough temperatures and pressures to initiate explosion; this results in conditions of 
3000–4000°C and 20–30 GPa within the chamber.137 After this, the NDs are rapidly 
cooled, by inert cooling gas or water, in order to minimise phase transformations to 
graphitic forms. It is then essential to remove impurities, such as sp2 carbon, metals, 
oxides and carbides from the chamber or starting mixture.363  
Purification usually involves treating NDs with dilute nitric acid or hydrochloric acid 
at high temperature and pressure in order to remove impurities.137, 364, 365 The non-
diamond sp2 carbon can also be oxidised with powerful liquid oxidisers, such as 
sodium peroxide.136 The purification process is usually the most expensive part of the 
ND synthesis and there is also a high environmental cost. Gas phase treatment is an 
alternative and more eco-friendly method where NDs are reacted with ozone to convert 
the sp2 carbon to CO and CO2, thus avoiding corrosive liquid oxidisers.
366, 367 The 
nature of the oxidative purification process results in oxygen containing 
functionalities, such as hydroxyl, carboxyl and anhydride groups, to present on the 
surface, terminating the dangling bonds.136, 363, 368  
4.1.2.2 Modified Nanodiamonds 
Nitrogen Vacancy (NV) Defects  
If a nitrogen atom is near to a vacancy within the ND structure, this is known as NV 
centre or defect. Some NV defects are inherent of the high energy process utilised to 
synthesize NDs however they can also be intentionally introduced to produce 
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fluorescent NDs. NV defects are caused by irradiating the NDs with high energy 
particles, such as electrons, protons or helium ions, followed by thermal annealing 
under vacuum.369, 370  
Most examples of NDs with NV defects are synthesized by HPHT though it is also 
possible to incorporate nitrogen in the detonation process. NV defects have been found 
in detonation NDs after electron irradiation and annealing, however intense and stable 
emission is only seen in the larger NDs (>30 nm).371 Detonation NDs have many 
structural defects, both intrinsic and surface associated, which may result in fewer NV 
centres. It has been confirmed that NV defects can exist in smaller detonation NDs; 
however, there are only a relatively small amount due to the particle size and hence 
there is limited detectable fluorescence.372   
There are two types of NV defects which have different fluorescence properties: the 
neutral NV0 and negative NV-.138 The NV- defect tends to be the more dominant 
product of the irradiation process which results in excitation and emission wavelengths 
of ~560 nm and 700 nm, respectively and a quantum efficiency of ~1.373, 374 These 
wavelengths are particularly useful for imaging as there is limited cell 
autofluorescence in the far-red-NIR region.  
Surface Modification 
Detonation NDs can be up to 100 nm in size, however they are typically 5 nm and 
hence very prone to aggregation.375 Various milling processes with ceramic beads can 
be used to de-aggregate the NDs, however this can result in impurities from the beads 
(ZrO2 or SiO2) and the likelihood of reaggregation is high.
376 Water-soluble salt- and 
sugar-assisted milling have also been explored to reduce contamination.377 
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Surface functionalisation provides a route to reducing ND reaggregation, where a 
simple route is from carboxylated NDs produced during the detonation process, as 
depicted in Figure 4.1.136 NDs with carboxyl groups on the surface can be isolated by 
ozone treatment, followed by hydrochloric acid to hydrolyse anhydride functional 
groups and remove metal impurities. A wide selection of gas treatments and wet 
chemistry routes have been investigated to react with the carboxyl groups, providing 
routes to attachment of proteins, polymers and various other coatings.   
 
Figure 4.1: A simplified schematic to show examples of the surface modification of 
NDs, starting from a purified sample of NDs with carboxyl groups on the surface. Gas 
treatments are shown in orange and wet chemistry routes are in blue. Adapted from 
reference.136 
It has been found that grafting poly(ethylene glycol) (PEG) to the surface of NDs can 
increase dispersibility in aqueous medium.378 Similarly, functionalising NDs with 
lysine improved stability and dispersibility in water for applications as genetic 
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carriers.379 Various surfactants have also been investigated for improving the 
dispersion of NDs, where zwitterionic lecithin resulted in optimal cellular uptake.380 
4.1.2 Biomedical Applications of Nanodiamonds 
4.1.3.1 Drug Delivery 
Extensive research into surface functionalisation of NDs has paved the way for an 
increase in biomedical applications, particularly drug delivery. For example, carboxyl 
groups on the surface of NDs  were converted to acyl chloride, followed by the addition 
of PEG and subsequent physisorption of doxorubicin (DOX), a common 
chemotherapeutic drug.381 Cellular uptake of ND-PEG-DOX was increased 2-fold 
compared to free DOX and the incorporation of PEG reduced aggregation resulting in 
increased stability. ND carriers have also been shown to overcome efflux mechanisms, 
thus increasing drug retention and efficacy.140, 382, 383 This suggests that ND carriers 
could be used to treat chemoresistant tumours. 
NDs can also be used to improve the solubility and dispersibility of hydrophobic 
drugs.137, 139 Administration of such drugs has been limited due to the use of harmful 
solvents, resulting in non-clinically relevant formulations. Therefore, novel ND drug 
carriers offer the potential to enable clinical translation of many drug candidates which 
had previously been hindered.  
4.1.3.2 Bioimaging Probes 
One of the most commonly explored fluorescent probes is quantum dots; however, 
there have been major problems with cytotoxicity and hence there is a need to develop 
coatings in order to circumvent this.373 Hence, the high biocompatibility of NDs 
combined with the fluorescence properties of the NV- defect are particularly attractive 
in bioimaging. NDs have been shown to have long fluorescence lifetime, high quantum 
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yield and low photobleaching.136, 138, 373 It should be noted that most examples of NDs 
with NV defects are generally prepared by HPHT and there is little data for 
fluorescence of detonation NDs thus far.136 
NDs with NV-defect were used to investigate sentinel lymph node mapping in a mouse 
model and fluorescent signal could still be detected 37 days post-injection 
(subcutaneous or intraperitoneal).142 This highlights the potential for long term 
imaging capabilities. Milled NDs, with mean particle size of 46 nm, have also shown 
good uptake into HeLa cells where the uptake mechanism was most likely via clathrin-
mediated endocytosis.384 In this study, it was found that NDs predominantly resided in 
endocytic vesicles; however, smaller NDs appeared to be free in the cytoplasm. This 
suggested that NDs can be used for cell labelling of mammalian cells and smaller NDs 
have high potential for biomolecule delivery.  
The widespread use of NDs with NV defects as imaging probes is inhibited due to the 
high cost associated with production and hence, the surface modification with 
fluorophores offers an alternative route.141 As for other nanoparticles, molecules can 
be added to the surface either covalently or non-covalently, i.e. physical adsorption.385, 
386 Cytochrome C (λmax = 409 nm) was immobilised on the surface of 5 nm NDs firstly 
by physical adsorption, likely via electrostatic attraction between carboxyl groups on 
the ND surface and amino groups within the protein structure.387 The resultant probe 
showed weak absorption at 409 nm which suggested that this approach was not 
successful and  thus an alternative covalent method was developed to increase the 
density and strength of attachment. Poly-L-lysine was selected to aminate the surface 
of NDs for subsequent attachment of Cytochrome C, where strong absorption at 409 
nm was demonstrated indicating more successful surface modification.  
130 
 
Hydrophobic blue fluorescent NDs have been prepared by the functionalisation of 5 
nm NDs with octadecylamine (ODA).141 The facile synthesis involved the formation 
of acid chloride groups on the ND surface followed by stirring at 90-100 °C for 96hr. 
The resultant ODA-NDs had peak excitation and emission wavelengths of 410 and 
450 nm, respectively, which was not observed for the NDs or ODA separately. This 
phenomenon has not yet been explored; however, it is hypothesized that the optical 
properties are due to the thermal degradation of the ODA chains and formation of 
aromatic structures.  
Despite the advances in NDs, fluorescence imaging for in vivo cell tracking is severely 
hampered by the limited penetration depth.44 Hence, other imaging modalities, such as 
photoacoustic imaging (PAI) are more useful for cell tracking in rodent models. In 
many cases, in vivo imaging is corroborated by ex vivo histological analysis although 
sometimes this is difficult after long timescales due to signal dilution, i.e. signal is 
diluted 50% with each cell division. Fluorescent NDs are an excellent candidate for 
labelled cells for ex vivo studies as they have extremely high biocompatibility so high 
dosing concentrations are well-tolerated. NDs. Furthermore, NDs are eventually 
cleared by excretion into the urinary tract.142 
4.1.3.3 Multimodal NDs 
Multimodal ND carriers are NDs capable of multiple functions i.e. therapy, diagnostics 
and targeting. An example of this is multimodal NDs which been prepared by 
covalently attaching paclitaxel (PTX) to the ND surface via fluorescently labelled 
oligonucleotide strands, as well as anti-epidermal growth factor receptor monoclonal 
antibodies (anti-EGFR mAb).388 The combination of PTX and mAb resulted in 
enhanced therapeutic efficacy and target specificity, where cellular uptake could be 
confirmed with fluorescence microscopy due to the labelled oligonucleotide strands. 
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This further highlights the broad range of molecules which can be loaded onto the ND 
surface and the ability to tailor the ND carrier for a desired application.  In addition to 
this, introducing a NV defect into the ND structure means that in some cases a 
fluorophore would not need to be attached, thus contributing to the impressive 
multimodal capabilities of NDs.389 This suggests that NDs could be used for 
simultaneous therapeutic and diagnostic applications (theranostics).390 
4.1.3 Perylene Diimide and NDs 
As previously mentioned, there is a high cost associated with using NDs with NV 
defect and hence attaching fluorescent dyes to the surface of NDs is another option. 
Perylene diimide (PDI) derivatives have been discussed in detail in Chapter 2 for their 
potential use in probes for multispectral optoacoustic tomography (MSOT). PDI 
derivatives also have strong fluorescence which can be utilised herein for preparing 
fluorescent NDs. The advantage of combining PDI with NDs is to hone the high 
biocompatibility of NDs which could enable high labelling concentrations for 
detecting cells in ex vivo fluorescence imaging.142 Furthermore, a NIR-absorbing PDI 
derivative could be attached to NDs for in vivo cell tracking with MSOT and 
subsequent ex vivo fluorescence imaging.  
4.1.4 Aims 
The present study will investigate the potential of various types of nanodiamonds as 
probes for cell tracking with fluorescent imaging techniques. The aims are as follows: 
1. To attach a perylene diimide derivative to the surface of detonation and high-
pressure high-temperature nanodiamonds and assess these probes in terms of 
optical properties and stability. 
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2. To label mesenchymal stromal cells with perylene diimide-nanodiamonds and 
nanodiamonds with a nitrogen vacancy defect. 
3. To assess and compare the effects of perylene diimide-nanodiamonds and 
nanodiamonds with a nitrogen vacancy defect on mesenchymal stromal cell 
viability.  
4. To confirm the uptake and fluorescent signal of the perylene diimide-




















All reagents were used as received from the manufacturer. Sodium hydroxide (≥97%), 
N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) and N-
hydroxysulfosuccinimide sodium salt (sulfo-NHS) were purchased from Sigma 
Aldrich. Detonation NDs (5-10 nm), HPHT NDs (50 nm) and NV NDs (40 nm and 90 
nm) were provided by Element Six Ltd.  N,N’-di(3,5-dicarboxylphenyl)perylene-
3,4,9,10-tetracarboxylic diimide (red PDI derivative) was synthesized by Dr Xia 
Liu.391  
4.2.2 Characterisation Methods 
A Malvern Zetasizer Nano and associated Zetasizer software were used to determine 
the hydrodynamic diameter, polydispersity index and zeta potential of particles in 
water via dynamic light scattering (DLS). Samples were diluted with water (0.1 
mg/ml) and sonicated for 10 minutes prior to DLS analysis. Images of particles were 
acquired with a Hitachi S4800 Scanning Electron Microscope (5 kV). Liquid samples 
were prepared by adding a drop of nanosuspension onto an SEM stub and leaving for 
the liquid to evaporate. Solid samples were adhered to the stub using conductive 
double-sided carbon tape. Spectroscopic data was obtained using a Vertex 70 Fourier 
Transform Infrared (FTIR) Spectrometer (Bruker); samples were dried ahead of the 
experiment. Optical properties were investigated using a μ-Quant Microplate Reader 
(BioTek) and a Fluorescence Lifetime Spectrometer (FLS) 1000 (Edinburgh 
Instruments). Samples were prepared at a concentration of 0.1 mg/ml and analysed 
using a front-face sample holder, 590 nm emission filter and excitation/emission 
bandwidths of 0.8-3 nm. Excitation wavelengths of 500 or 560 nm were used and 
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emission was measured in the range of 550-800 nm with a 1 nm step and 0.2 s dwell 
time.  
4.2.3 Surface Modification of HPHT NDs 
Carboxylic acid functional groups were introduced by oxidation of the surface of 
HPHT NDs using a well-established protocol in the literature.392 Briefly, 50 nm NDs 
(2 g) were dispersed in 80 ml acid solution (3:1 69% H2SO4/37% HNO3) and heated 
to reflux for 24hr. Once cooled, the mixture was slowly added to distilled water and 
centrifuged (4000 rpm). Particles were washed three times by centrifugation and 
consequently dried under vacuum for 24hr. 
4.2.4 Conjugation of PDI to detonation and HPHT NDs 
Optimisation of NDs as probes was carried out using a red PDI previously prepared in 
abundance in our group.391 The method of PDI conjugation was adapted from similar 
procedures in the literature.393-395 PDI (7 mg, 0.01 mmol) was dissolved in 10 ml of 
basic water (0.06 mM NaOH). EDC (26.7 mg, 0.1 mmol) and sulfo-NHS (30.2 mg, 
0.1 mmol) were added to 2 ml of the PDI solution (0.002 mmol). This was stirred at 
room temperature for 30 minutes before the addition of either detonation or HPHT 
NDs (2 ml, 0.7 wt%). This was stirred overnight and consequently washed by 
centrifugation in water. 
4.2.5 Cell Culture 
The murine mesenchymal stromal cell line D1 (ATCC) was used for all in vitro cell 
studies. MSCs had previously been modified by Dr Arthur Taylor (Murray group) to 
express firefly luciferase under the control of the constitutive promoter, EF1α.276, 277 
MSCs were cultured in 6 cm or 10 cm tissue culture dishes (Greiner CELLSTAR®) 
in high glucose Dulbecco’s Modified Eagle Medium (DMEM, Sigma Aldrich) 
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containing 10% fetal bovine serum (FBS, Sigma Aldrich), 1% non-essential amino 
acids (Sigma Aldrich) and 2 mM L-glutamine (Gibco). Cells were incubated at 37°C 
and 5% v/v CO2 and passaged with 1% trypsin/EDTA (Sigma Aldrich) when they 
reached 90% confluence. 
4.2.6 In Vitro Cell Studies 
4.2.6.1 Cell Viability 
CellTiter-Glo® Luminescent Cell Viability Assay (Promega) was used according to 
the manufacturer’s guidelines. MSCs were seeded in triplicate at a density of 2x104 
cells/well in a 96-well plate and left to attach and grow for 24hr. After this, the medium 
was replaced with 200 µl fresh medium containing various concentrations of NDs (0-
400 µg/ml). Cells were incubated for a further 24hr before carrying out the assay. The 
principle is based on cellular ATP released from lysed cells which react with 
luciferin/luciferase, leading to light emission at 562 nm. Cell viability was measured 
as the amount of ATP released from treated cells as a percentage of the ATP released 
from the control. Luminescence measurements were taken with a µ–Quant Microplate 
reader (BioTek). 
4.2.6.2 Flow Cytometry 
Flow cytometry was used to assess the cellular uptake and fluorescence properties of 
the NDs. MSCs were seeded at a density of 2x105 cells/well (24-well plate) and 
incubated for 24hr. After this, the medium was aspirated and replaced with fresh 
medium containing nanoparticles of varying concentrations (0-100 µg/ml). After a 
further 24hr, cells were resuspended in PBS (1x) and kept on ice ahead of analysis. 
Flow cytometry was carried out using a BD FACSCalibur™ (BD Biosciences) with a 
488 nm laser wavelength and a long pass FL3 filter (670 nm). When appropriate, 
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threshold values for side scatter (SSC), front scatter (FSC) and FL3 were altered 
relative to the control to exclude unwanted events. 10,000 events were counted and the 
data was analysed with Flowing Software 2.5.1 (Turku Bioscience Centre). 
4.2.6.3 Confocal Fluorescence Microscopy 
Confocal fluorescence microscopy was employed to visualise and determine the 
location of NDs in MSCs. MSCs were seeded in 8-well chamber slides (Ibidi µ-Slide 
8-well) at a density of 2x104 cells/well. After 24hr labelling with nanoparticles (50 or 
100 µg/ml), samples were fixed with 4% PFA (Sigma Aldrich).  Cells were 
permeabilised with Triton-X (0.1 %v/v) and stained with 4′,6-diamidino-2-
phenylindole (DAPI, 1:1000, Thermo Fisher) and Alexa Fluor™ 488 phalloidin (1:50, 
Invitrogen).  Images were acquired with a Zeiss LSM 800 Airyscan confocal using 
405 nm, 488 nm and 640 nm diode lasers and 63x oil objective. Z-stack images were 
obtained using a step size of 0.34 μm and the master gain of the PMT was set to 700 
mV unless it was necessary to increase the brightness to visualise certain particles. 











4.3  Results 
NDs were provided by Element 6 Ltd., prepared by either detonation of carbon 
explosives or milling of diamond powders to give aqueous suspensions with particle 
sizes ranging from 5-100 nm. The NDs investigated in this study are detonation NDs 
(5-10 nm), milled HPHT NDs (50 nm), and NV NDs prepared by detonation followed 
by HPHT treatment (40 and 90 nm). 
4.3.1 Perylene Diimide Conjugation to Detonation NDs 
Perylene diimide (PDI) was conjugated to the surface of detonation NDs via 
carbodiimide coupling to amino groups on the ND surface. The PDI-NDs were fully 
characterised and in vitro cell studies were carried out to determine their cytotoxicity, 
cellular uptake and fluorescence properties.  
4.3.1.1 Characterisation of Detonation NDs 
NDs with approximate particle sizes of 5-10 nm were used which had amino groups 
on the surface for conjugation to PDI via carbodiimide coupling. The particle size was 
confirmed to be 5-10 nm with Transmission Electron Microscopy (TEM), as shown in 
Figure 4.2.  
Dynamic Light Scattering (DLS) measurements were also carried out to determine the 
hydrodynamic diameter of the NDs. The DLS results are represented as the number 
particle size distribution as this considers the spherical shape of the nanoparticles and 
Mie scattering. The particle size of the detonation NDs was measured at 1625 ± 330 
nm (Figure 4.3) with a polydispersity index of 0.152; this suggested the detonation 





Figure 4.2: TEM image of detonation NDs with particle sizes of 5-10 nm. Images were 
taken by Dr Hripsime Gasparyan. 


















Figure 4.3: Number particle size distribution of detonation NDs in water (0.1 mg/ml). 
The different colours represent 3 measurement scans with DLS. 
The presence of amino groups on the surface of the NDs was confirmed by measuring 
the zeta potential as in aqueous medium amino groups are protonated and hence result 
in positive surface charge. The zeta potential of the aminated NDs was +23.6 ± 9.82 
mV compared to -33.4 ± 6.35 mV for non-aminated NDs (likely hydrogen or hydroxyl 




Infrared (FTIR) spectroscopy, shown in Figure 4.4; The broad stretch at 3300-3500 
cm-1 is associated with free amine groups on ND surface and the stretch at 1630 cm-1 
is also indicative of N-H bonding.  















Figure 4.4: FTIR of detonation NDs (dried) with amino group surface functionality 
(particle sizes 5-10 nm). 
4.3.1.2 PDI Conjugation 
The PDI derivative used in these fluorescent probes, shown in Figure 4.5, was 
previously synthesized by our group for optimisation of PDI-based probes.391 The 
carboxylic acid groups allow for conjugation to amino groups on the surface of 




Figure 4.5: Chemical structure of PDI derivative containing carboxylic acid 
functionality for coupling to NDs. 
The PDI derivative used has poor solubility in common solvents, including water, and 
hence basic water was used for the reaction. PDI was first dissolved in basic water 
(0.06 mM NaOH) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
(EDC) and N-hydroxysulfosuccinimide sodium salt (sulfo-NHS) were added. After 30 
minutes, NDs were added.  The reaction was stirred at room temperature overnight. 
PDI-NDs were then washed by centrifugation and resuspended in neutral water to yield 
a cloudy pink suspension. UV-visible (UV-vis) spectroscopy was carried out with the 
supernatant phase of the centrifuged sample which showed no absorption in the visible 
spectrum. This suggested that the PDI was attached to the NDs, rather than dissolved 
in the basic water, as it had been at the start of the reaction. 
The zeta potential of PDI-NDs significantly decreased to -19.2 ± 4.87 mV suggesting 
a decrease in vacant amino groups on the ND surface thus suggesting the attachment 
of PDI was successful. The reaction was also confirmed using FTIR spectroscopy 
where new stretches are seen around 1580 and 1350 cm-1 for PDI-NDs which are not 
seen for the unmodified NDs (Figure 4.6).  The stretch at 1580 cm-1 can be attributed 
to the presence of aromatic C=C and the stretch at 1350 cm-1 is related to the C=O of 
free carboxylic acid groups, thus suggesting the presence of the PDI derivative.396 
Furthermore, the stretch at 1650 cm-1 is characteristic of C=O amide bond.136 The 
broad stretch at 3300-3500 cm-1 is associated with free amine groups on the ND 
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surface; this can be seen in the unmodified NDs and the PDI-NDs, suggesting that not 
all the amine groups had reacted.  
The suspensions were prone to aggregation, partly due to the high concentration of the 
suspension (1 mg/ml) and hence dilutions were used for all characterisation and cell 
experiments. A concentration of 0.1 mg/ml was used for DLS following guidance from 
the manufacturer and the concentration for cell experiments was determined by 
assessing cytotoxicity.  Ahead of DLS analysis, all samples were diluted and sonicated 
for 10 minutes using an ultrasonic bath. The particle size of PDI-NDs was similar to 
the unmodified NDs at 1771 ± 213 nm and the polydispersity index was 0.363 (Figure 
4.7). 
















Figure 4.6: FTIR spectra of detonation NDs and PDI-NDs (dried). 
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Figure 4.7: Number particle size distribution of detonation PDI-NDs (0.1 mg/ml). The 
different colours represent 3 measurement scans with DLS. 
4.3.1.3 Optical Properties of PDI-NDs 
The optical properties of the PDI-NDs were assessed using UV-vis spectroscopy and 
fluorescence spectrometry. The UV-vis spectrum of the PDI derivative showed peaks 
at 440, 470 and 510 nm, as shown in Figure 4.8. When the PDI-NDs were analysed, 
there was extremely high background signal due to the inherent light scattering 
properties of the NDs; this is consistent with results found in the literature.387 The peak 
was also significantly lower; however. this is likely due to the amount of PDI in PDI-
NDs compared to equivalent mass concentration of pure PDI and thus peak intensity 
is not considered important in this case. Higher concentrations of PDI-NDs could 
increase peak intensity but at the expense of increased light scattering.  
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Figure 4.8: UV-vis spectra of PDI (0.1 mg/ml, 0.06 mM NaOH) and detonation PDI-
NDs and NDs (0.1 mg/ml, neutral water).  
The fluorescence properties of the PDI-NDs were assessed and compared with that of 
the free PDI dye and a sample of just NDs. Figure 4.9a show the emission spectra for 
pure PDI which demonstrates high emission intensity at 600 nm which is consistent 
with the literature.258 When NDs and PDI-NDs were analysed at the same excitation 
wavelength, a 590 nm emission filter was needed to counteract the light scattering 
effects (Figure 4.9b). Emission spectra of NDs showed very low fluorescence, mostly 
associated with background signal and effects from the emission filter; however, for 
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Figure 4.9: Emission spectra (λex = 500 nm) for (a) pure PDI (0.06 mM NaOH solution) 
and (b) PDI-NDs and NDs (0.1 mg/ml, water). For PDI-NDs and NDs, an emission 
filter was used to block emission below 590 nm to counteract the effect of light 
scattering.  
4.3.2 In vitro Evaluation of Detonation PDI-NDs as Fluorescent Probes 
4.3.2.1 The Effect of Detonation PDI-NDs on Cell Viability 
It was first essential to confirm the high biocompatibility reported for detonation NDs 
and whether PDI conjugation affected this. MSCs were seeded at a density of 2x104 
cells/well in a 96-well plate and left to grow and adhere for 24 hours. After this, the 
media was aspirated and replaced with fresh media containing various concentrations 
of unmodified detonation NDs and PDI-NDs. MSCs were then incubated for a further 
24 hours before carrying out the CellTiter-Glo® luminescent cell viability assay; The 
assay principle involves cellular ATP released from lysed cells which react with 
luciferin/luciferase, leading to light emission at 562 nm. Cell viability was measured 
as the amount of ATP released from treated cells as a percentage of the ATP released 




























Figure 4.10: The effect of unmodified detonation NDs and PDI-NDs on ATP 
production in MSCs. Cells were seeded at a density of 2x104 cells/well (96-well plate) 
and incubated for 24 hours before dosing with NDs for a further 24 hours. The error 
bars represent standard deviation of biological repeats (n=3).  
Both unmodified NDs and PDI-NDs have limited effect on the viability of MSCs up 
to concentrations of 300 µg/ml. The cell viability was slightly lower for PDI-ND; 
however, cell viability remained above 80% up to 300 µg/ml.  
4.3.2.2 Assessing Cellular Uptake of Detonation PDI-NDs with Flow Cytometry 
It was possible that the low cytotoxicity could be due to limited cellular uptake, 
particularly due to the large particle aggregates. Therefore, uptake was assessed by 
flow cytometry and confocal fluorescence microscopy. For flow cytometry, MSCs 
were seeded at a density of 2x105 cells/well and incubated for 24 hours ahead of 
dosing. The media was aspirated and replaced with fresh media containing NDs at 
concentrations of 25, 50 or 100 µg/ml; unmodified NDs as well as PDI-NDs were 
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included. Flow cytometry was then carried out on live cell suspensions in PBS (10,000 
cells were counted for each sample), as shown in Figure 4.11. 


































































Figure 4.11: Live cell flow cytometry of MSCs in PBS labelled with various 
concentrations of detonation (a) PDI-NDs and (b) unmodified detonation NDs for 24 
hours. The fluorescence intensity of MSCs labelled with both PDI-NDs and 
unmodified detonation NDs at concentrations of (c) 25 µg/ml and (d) 100 µg/ml is also 
shown. Fluorescence intensity was measured using FL3 filter (670 nm LP), where 
10,000 events were counted, and the fluorescence gating used for all experiments is 
displayed in (a). 
The results show an increase in fluorescence intensity for cells labelled with PDI-NDs 
compared to the untreated cells and this intensity increased slightly as the 







could be due to more cells being labelled though the width of the peaks remained 
constant suggesting the concentration did not affect the amount of PDI-NDs taken up 
per cell. The change in fluorescence intensity when labelling cells with unmodified 
NDs was only small in comparison to untreated cells (Figure 4.11b). When comparing 
cells labelled with PDI-NDs and NDs, the fluorescence intensity is higher for PDI-
NDs (Figures 4.11c-d) 
The flow cytometry data was also represented as dot plots, shown in Figure 4.12, 
showing the change in the side and forward scatter of cells for unlabelled and labelled 
MSCs. The forward scatter indicates the size of the cell and side scatter is related to 
the cell complexity or granularity.397 There is an increase in the side scatter for MSCs 
labelled with both PDI-NDs and unmodified NDs which suggests a change in cell 
granularity; this confirms that the change in fluorescence intensity is due to particle 
uptake.  
The percentage of cells labelled cells was determined using Flowing software and the 
gate shown in Figure 4.11a. Any events found within this gate were counted as cells 
labelled with nanoparticles. When examining the percentage of cells which had been 
labelled with each type of particle (Figure 4.12d), >70% of the cells have taken up 
PDI-NDs compared to <30% with unmodified NDs at all concentrations. However, as 
the changes in side scatter suggest similar cell granularity for both types of particle, 
the differences in percentage of cells positive may be associated with the higher 
fluorescence of PDI-NDs compared to unmodified NDs.  
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Figure 4.12: Flow cytometry dot plots showing changes in front and side scatter for 
(a) untreated MSCs and MSCs labelled with detonation (b) PDI-NDs and (c) 
unmodified detonation NDs at a concentration of 25 µg/ml. The bar chart (d) shows 
the percentage of cells positive with PDI-NDs and unmodified detonation NDs at 
various concentrations using gate shown previously in Figure 4.11a (n=2 and the error 
bars represent the range).   Fluorescence intensity was measured using FL3 filter (670 









4.3.2.3 Assessing Cellular Uptake of Detonation PDI-NDs with Confocal 
Fluorescence Microscopy 
Flow cytometry provided information on the proportion of fluorescent cells and degree 
of intensity per cell. However, confocal fluorescence microscopy was required to 
further assess the uptake of PDI-NDs into MSCs, as it was possible that particles could 
be associated with the surface rather than inside the cells. With confocal fluorescence 
microscopy, various planes can be imaged through the cell to confirm the 
internalisation and distribution of particles.  
Confocal fluorescence microscopy was carried out on fixed samples after 24hr dosing. 
Cells were stained with DAPI and AlexaFluor® 488 phalloidin to show the nucleus 
(blue) and actin cytoskeleton (green), respectively. Multiple images were taken at 
different focal planes and combined to form z-stack images with a greater depth of 
field. This highlighted that particles were inside cells and not just associated with the 
cell surface.     
Unmodified NDs could not be detected with the microscope however PDI-NDs could 
be visualised (red), as shown in Figure 4.13.  The pattern of labelling within the cells 
is consistent with an endosomal location398, 399 and it appears that the majority of cells 
were labelled, which agrees with the flow cytometry data where >70% of cells had 




Figure 4.13: Confocal fluorescence microscope image of MSCs labelled with 
detonation (a) PDI-NDs and (b) unmodified detonation NDs (right). Cells were dosed 
at a concentration of 50 µg/ml for 24 hours and then were fixed and stained with DAPI 
(blue nuclei) and AlexaFluor ® 488 phalloidin (green, actin cytoskeleton). PDI-NDs 
can be seen in red within the MSCs. The master gain of the microscope was 800 V to 
increase the brightness and visualise the PDI-NDs.  
The fluorescence of PDI-NDs did not appear bright, particularly when compared to 
the polymer-stabilised nanoparticles from chapter 2. The intensity of the 640 nm laser 
had to be increased in order for the PDI-NDs to be visualised, which was not the case 
for the polymer-stabilised nanoparticles. In addition to this, the PDI-ND aggregates 
can be seen clearly in Figure 4.13a. 
4.3.3 PDI Conjugation to Larger NDs Prepared by HPHT 
Due to the aggregation observed with detonation PDI-NDs, the PDI derivative (Figure 
4.5) was also conjugated to the surface of HPHT NDs, which had been modified to 
have carboxylic acid surface functionality. Again, PDI-NDs were fully characterised 
and in vitro cell studies were carried out to determine their cytotoxicity, cellular uptake 




4.3.3.1 Characterisation of HPHT NDs 
Due to the extreme aggregation of the detonation NDs, slightly larger NDs were 
investigated that had an estimated particle sizes of 50 nm. These NDs had been 
prepared by milling of ND powders and modified to contain carboxylic acid groups on 
the surface for conjugation to PDI. The carboxylation process was carried out using a 
well-known procedure which involved treatment of the NDs with concentrated 
H2SO4/HNO3.
392  
The particle size was difficult to determine with SEM as the NDs were also prone to 
aggregation. An SEM image of COOH-NDs is shown in Figure 4.14 showing a large 
particle aggregate but individual NDs can be distinguished.  
 
Figure 4.14: SEM image of NDs prepared by HPHT. 
NDs were diluted and sonicated in an ultrasound bath ahead of DLS analysis. The 
measured hydrodynamic diameter of the particles was 67 ± 19 nm with a low particle 
size distribution of 0.065 (Figure 4.15). Hence, as there was limited aggregation in 
aqueous suspension, these NDs were taken forward for PDI conjugation and in vitro 
cell studies.   
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Figure 4.15: Number particle size distribution of HPHT NDs with carboxylic acid 
groups on the surface (0.1 mg/ml). The different colours represent 3 measurement 
scans with DLS. 
The presence of carboxylic acid groups on the surface of the NDs was confirmed by 
measuring the zeta potential. COOH-NDs had a zeta potential of -57.6 ± 12.1 mV 
which is significantly more negative than NDs with hydrogen/hydroxyl terminating 
groups (-33.4 ± 6.35 mV). FTIR analysis showed broad stretches in the fingerprint 
region up to 1800 cm-1 (Figure 4.16). This is commonly seen and likely due to 
overlapping peaks relating to the various bonding stretches within the ND structure, 
e.g. C-C and those associated with NV defects.136 Hence, the broad stretch from 1650-
1850 cm-1 suggests that carboxylic acid groups are present on the surface.  
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Figure 4.16: FTIR of HPHT NDs with carboxylic acid surface groups. 
4.3.3.2 PDI Conjugation 
PDI was attached to the surface of the COOH-NDs using the same protocol as for the 
detonation NDs with EDC/sulfo-NHS, only this time to form an anhydride bond rather 
than amide. The suspension of PDI-NDs was cloudy pink in colour compared to the 
grey colour of the NDs before PDI conjugation. Furthermore, after centrifugation, the 
supernatant was colourless suggesting PDI had been successfully attached.  
The particle size distribution remained relatively consistent with the unreacted COOH-
NDs at 85 ± 39 nm (Figure 4.17) and the polydispersity index was 0.136. The zeta 
potential was -54.3 ± 8.23 nm which was similar to without the PDI. For PDI-NDs 
prepared with detonation NDs with amine surface functionality, there was a decrease 
in zeta from +23.6 ± 9.82 mV to -19.2 ± 4.87 mV. However, in this case, as the COOH-
NDs already had a negative zeta potential, it is not unusual that this did not change 
with the addition of PDI. The FTIR spectrum of the larger PDI-NDs (Figure 4.18) was 
similar to that of PDI-NDs prepared with detonation NDs; The stretch at 1580 cm-1 is 
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consistent with C=C and the stretches at 1350 cm-1 and 1650 cm-1 can be associated 
with C=O of PDI. There is also broad absorption in the fingerprint region associated 
with various bonding stretches within the ND structure.  


















Figure 4.17: Number particle size distribution of HPHT PDI-NDs (0.1 mg/ml). The 
different colours represent 3 measurement scans with DLS. 

















Figure 4.18: FTIR spectra of HPHT NDs and PDI-NDs. 
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4.3.3.3 Absorbance/Fluorescence Properties 
The UV-vis absorbance profile of the larger HPHT PDI-NDs was similar to detonation 
PDI-NDs in that there was a large background signal due to the light scattering 
properties of the NDs. A slight peak can be seen around 460 nm which is similar to 
that of PDI alone, as shown in Figure 4.19.  

















Figure 4.19: UV-vis spectra of HPHT PDI-NDs (0.1 mg/ml, water) and PDI (0.06 mM 
NaOH). 
The fluorescence properties were also assessed using 590 nm emission filter to try and 
counteract the light scattering effects of the NDs. The characteristic emission peak for 

































Figure 4.20: Emission spectra (λex = 500 nm) of PDI-NDs and NDs (0.1 mg/ml water). 
An emission filter was used to block emission below 590 nm to counteract the effects 
of light scattering. 
4.3.4 In vitro Evaluation of Larger HPHT PDI-NDs as Fluorescent Probes 
4.3.4.1 The Effect of HPHT PDI-NDs on Cell Viability 
The cytotoxicity of the PDI-NDs prepared from larger HPHT NDs was investigated. 
The same experimental protocol was used as for the detonation NDs: MSCs were 
seeded at a density of 2x104 cells/well in a 96-well plate and left to grow and adhere 
for 24 hours. After this, the media was aspirated and replaced with fresh media 
containing various concentrations of unmodified HPHT NDs and PDI-NDs. MSCs 
were then incubated for a further 24 hours before carrying out the CellTiter-Glo® 
luminescent cell viability assay. Cell viability was measured as the amount of ATP 
released from treated cells as a percentage of the ATP released from the control. 
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Figure 4.21 shows that initially the HPHT PDI-NDs appeared to have a greater 
cytotoxic effect on MSCs compared to the detonation NDs. Even at a relatively low 
concentration of 25 µg/ml, the average cell viability decreases below 80% compared 
to detonation NDs where >80% viability was seen up to concentrations of 300 µg/ml 
(Figure 4.10). However, while viability decreased to ~75% at a concentration of 25 
µg/ml, no further decrease in viability was observed as the concentration was increased 
to 400 µg/ml, with viability at all concentrations from 25-400 µg/ml remaining 
between 70-80%.  























Figure 4.21: The effect of HPHT PDI-NDs on ATP production in MSCs. Cells were 
seeded at a density of 2x104 cells/well (96-well plate) and incubated for 24 hours 
before dosing with NDs for a further 24 hours. The error bars represent standard 
deviation of biological repeats (n=3).  
4.3.4.2 Assessing Cellular Uptake of HPHT PDI-NDs with Flow Cytometry 
Cellular uptake of HPHT PDI-NDs was assessed using flow cytometry and confocal 
fluorescence microscopy. Flow cytometry of cells labelled with HPHT PDI-NDs was 
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carried out as for cells labelled with the detonation PDI-NDs. Briefly, MSCs were 
seeded at a density of 2x105 cells/well and incubated for 24 hours ahead of dosing. The 
media was aspirated and replaced with fresh media containing HPHT PDI-NDs at 
concentrations of 25, 50 or 100 µg/ml. Flow cytometry was then carried out on live 
cell suspensions in PBS (10,000 cells were counted for each sample), as shown in 
Figure 4.22. 
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Figure 4.22: Live cell flow cytometry of MSCs in PBS labelled with HPHT PDI-NDs, 
where the (a) fluorescence intensity at various dosing concentrations and (b) dot plots 
of side scatter vs. front scatter (25 µg/ml) are displayed. The fluorescence intensity 





µg/ml. Fluorescence intensity was measured using FL3 filter (670 nm LP), where 
10,000 events were counted.  
There was an increase in fluorescence intensity for MSCs labelled with HPHT PDI-
NDs compared to untreated cells suggesting that the fluorescent particles had been 
successfully taken up. This was also confirmed with an increase in side scatter 
suggesting a change in cell granularity compared to untreated cells (Figure 4.12a). The 
fluorescence intensity increased only slightly with increasing concentration of HPHT 
PDI-NDs and the peak width remained similar. Thus, it is unlikely that dosing at higher 
particle concentrations increased the number of particles taken up per cell. 
Furthermore, the percentage of the cell population that was labelled with >90% for all 
concentrations (Figure A16, Appendix).  
The fluorescence intensity of both sets of PDI-NDs (detonation and HPHT) was 
compared and greater fluorescence was seen for those prepared with HPHT NDs 
(Figure 4.22c-d). This suggests that there is greater cellular uptake of these particles, 
possibly due to reduced aggregation.  
4.3.4.3 Assessing Cellular Uptake of HPHT PDI-NDs with Confocal Fluorescence 
Microscopy 
Similar to the detonation NDs, confocal fluorescence microscopy was again utilised to 
assess whether PDI-NDs were internalised or associated with the surface of MSCs. 
Imaging was carried out on fixed samples after 24hr dosing. Cells were stained with 
DAPI and AlexaFluor® 488 phalloidin to show the nucleus (blue) and actin 
cytoskeleton (green), respectively. Multiple images were taken at different focal planes 
and combined to form z-stack images with a greater depth of field. Figure 4.23 shows 
z-stack images which demonstrate that particles were inside cells and not just 
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associated with the cell surface. The HPHT PDI-NDs (red) can be visualised within 
MSCs as aggregates, likely in endosomal locations. The degree of cell labelling 
appears to be similar to the detonation PDI-NDs, where the majority of cells were 
labelled.  
 
Figure 4.23: Confocal fluorescence microscope image of MSCs labelled with HPHT 
PDI-NDs (red). Cells were dosed at a concentration of 50 µg/ml for 24 hours and then 
were fixed and stained with DAPI (blue nuclei) and AlexaFluor ® 488 phalloidin 
(green, actin cytoskeleton). The master gain of the microscope was 800 V to increase 
the brightness and visualise the PDI-NDs. 
4.3.5 NDs with Nitrogen-Vacancy Defects  
Nitrogen-vacancy (NV) defects can be introduced into the ND structure by high energy 
irradiation. NV NDs were also investigated as fluorescent probes in the present study 
in order to compare their performance to PDI-NDs. 
4.3.5.1 Characterisation of NV NDs 
Two NV ND samples were evaluated which had estimated particle sizes of 40 nm 
(NV-40) and 90 nm (NV-90). Table 4.1 summarises the DLS measurements where the 
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particle size was similar to the expected size (Figure 4.24) and a low polydispersity 
index was measured (~0.1) suggesting a narrow particle size distribution. Both NV 
NDs had a negative zeta potential but NV-40 was more negative. The negative zeta 
potential of the particles is expected due to hydrogen or hydroxyl terminating groups 
from the synthesis. The difference in zeta potential between the NV NDs can be 
explained by considering the particle sizes; zeta potential is calculated from 
electrophoretic mobility which is size-dependent.   
Table 4.1: DLS analysis of NV NDs. 












NV-40 40 39 ± 11 0.11 -46 ± 1 
NV-90 90 63 ± 21 0.13 -35 ± 1 
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Figure 4.24: Number particle size distribution of (a) NV-40 and (b) NV-90 NDs (0.1 





The absorption properties were investigated with UV-vis spectroscopy. However, as 
for detonation NDs, the light scattering effects of the NDs were apparent. Figure 4.25 
shows the absorption profile of the NV NDs, where greater light scattering is seen for 
the larger NV-90 NDs. 



















Figure 4.25: UV-vis spectra of NV NDs (water, 0.1 mg/ml).  
The fluorescence properties of the NV NDs are shown in Figure 4.26. The light 
scattering properties of the NDs proved to be an issue again and so a filter was added 
to block emission below 590 nm. This enabled the detection of the peak associated 
with NV- at ~700 nm, which was more pronounced for NV-90 NDs (Figure 4.26b); 
these results agree with similar experiments in the literature.400 NDs without NV defect 
were also analysed using the same excitation wavelengths and only background signal 






















































Figure 4.26: Emission spectra (λex = 560 nm) for (a) NV-40 and (b) NV-90 NDs (0.1 
mg/ml water). An emission filter was used to block emission below 590 nm to 
counteract the effects of light scattering. 
4.3.6 In vitro Evaluation of NV ND as Fluorescent Probes 
4.3.6.1 The Effect of NV NDs on Cell Viability 
The CellTiter-Glo® assay was carried out to see whether NV NDs had an effect on the 
viability of MSCs. The protocol was carried out in the same way as for PDI-NDs. 
Previously, concentrations of up to 300 µg/ml were well-tolerated by MSCs for 
detonation and HPHT PDI-NDs.  For the NV NDs, cell viability decreased with 
increasing concentration and NV-40 NDs appeared to have a greater cytotoxic effect 
than NV-90 NDs, as shown in Figure 4.27. The HPHT PDI-NDs had >80% viability 
at 200 µg/ml which is in line with the NV-90 which have a similar particle size. Cell 






























Figure 4.27: The effect of NV NDs on ATP production in MSCs. Cells were seeded at 
a density of 2x105 cells/well for 24 hours, NDs were then incubated with MSCs for a 
further 24 hours ahead of measuring ATP. The error bars represent the range (n=2). 
In order to ascertain whether the greater cytotoxic effect of NV-40 NDs was due to 
particle size or number, the assay was repeated and cells were dosed by number of NV 
NDs rather than mass concentrations. The number of NDs was calculated using the 
average density of commercial NDs (3.5 g cm-1),401, 402 where 1.8x1010 particles 
correlates to approximately 10.7 µg/ml. Figure 4.28 highlights that NV NDs had a 
similar effect on cell viability when similar particle numbers were used, hence 
suggesting that  the increased cytotoxicity of NV-40 NDs observed previously was due 
to the cells being exposed to a greater number of particles. Therefore, it is likely that 






























Figure 4.28: The effect of NV NDs on ATP production in MSCs. Cells were seeded at 
a density of 2x104 cells/well for 24 hours, NDs were then incubated with MSCs for a 
further 24 hours ahead of measuring ATP. The error bars represent the range (n=2). 
4.3.6.2 Assessing Cellular Uptake of NV NDs with Flow Cytometry 
Flow cytometry was used to assess the uptake of NV NDs into MSCs. As for PDI-
NDs, MSCs were incubated with NV NDs for 24 hours ahead of flow cytometry on 
live cell suspensions in PBS. With both types of NV NDs there was an increase in 
fluorescence intensity with increasing ND concentrations; however, this was less 
pronounced with NV-40 NDs, as shown in Figure 4.29. More specifically, as the 
concentration was increased, the mean fluorescence intensity increases which suggests 
that the percentage of the population that is fluorescent has also increased. 
The difference between NV-40 and NV-90 NDs was more obvious when comparing 
the percentage of cells positive with NDs in a bar chart (Figure 4.30). The percentage 
of labelled cells increased with increasing concentrations for both sets of ND; 
however, following labelling with NV-90 NDs, a greater proportion of the MSC 
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population became fluorescent. Above 50 µg/ml, >80% of the cell population were 
labelled with NV-90 NDs. 






































































Figure 4.29: Live cell flow cytometry of MSCs in PBS labelled with various 
concentrations of (a) NV-40 and (b) NV-90 NDs for 24 hours. The fluorescence 
intensity of MSCs labelled with both NV NDs at concentrations of (c) 25 µg/ml and 
(d) 100 µg/ml is also shown. Fluorescence intensity was measured using FL3 filter 
(670 nm LP), where 10,000 events were counted, and the fluorescence gating used for 
all experiments is displayed in (a). 


























Figure 4.30: Comparison of the percentage of cells positive with various 
concentrations of NV-40 and NV-90 NDs using gate shown in Figure 26a. 
Fluorescence intensity was measured using FL3 filter (670 nm LP), where 10,000 
events were counted. 
Following the cytotoxicity results, which highlighted differences when MSCs were 
dosed based on mass concentration and estimated number of NDs, a flow cytometry 
experiment was carried out on MSCs which had been dosed with various estimated 
numbers of NV NDs. In this case, there was very little change in fluorescence intensity 
between untreated cells and those dosed with various numbers of NV-40 NDs, as 
shown in Figure 4.31. The difference to the mass-based dosing is likely because 
1.8x1010 particles correlates to approximately 10.7 µg/ml. However, for NV-90 NDs, 
fluorescence intensity increased with increasing number of NDs. 
When comparing the percentage of cells positive, uptake of NV-90 NDs increased with 
increasing number of NDs (Figure 4.32). At the highest number (1.8x1010), >40% of 
cells had taken up NV-90, which is consistent with the equivalent mass-based dosing 
concentration of ~10 µg/ml. The flow cytometry data suggests that NV-90 NDs have 
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more intense fluorescence than NV-40 NDs. Higher numbers of NV-40 NDs were 
required to see increases in fluorescence intensity and even then, it was not as high as 
NV-90 NDs.  






































Figure 4.31: Live cell flow cytometry of MSCs in PBS labelled with various numbers 
of (a) NV-40 and (b) NV-90 NDs for 24 hours. Fluorescence intensity was measured 
using FL3 filter (670 nm LP), where 10,000 events were counted, and the fluorescence 
gating used for all experiments is displayed in (a). 





















Figure 4.32: Comparison of the percentage of cells positive with various numbers of 
NV-40 and NV-90 NDs using gate shown in Figure 28. Fluorescence intensity was 




4.3.6.3 Assessing Cellular Uptake of NV NDs with Confocal Fluorescence 
Microscopy 
As for other flow cytometry experiments, 2x104 cells were seeded into chamber slides 
and left to grow and adhere for 24 hours ahead of dosing with NDs (100 µg/ml). Cells 
were subsequently fixed and stained with DAPI and AlexaFluor® 488 phalloidin to 
show the nucleus and actin cytoskeleton, respectively. ND-90 NDs were much more 
abundant and brighter compared to NV-40 NDs when imaged at the same laser 
intensity (Figure 4.33). This is particularly significant, as for the same mass 
concentration, there would be much more NV-40 NDs exposed to the cells compared 
with NV-90 NDs. Hence, the more effective visualisation of the NV-90 NDs is likely 
attributed to more intense fluorescence, which is consistent with the flow cytometry 
analysis (Figure 4.29).  
  
Figure 4.33: Confocal fluorescence microscope images of MSCs dosed with (a) NV-
40 and (b) NV-90 NDs. MSCs were seeded in chamber slides (2x104 cells/well) and 
left to grow and adhere for 24 hours before dosing with 100 µg/ml ND for a further 24 
hours. Cells were fixed with 4% PFA and stained with DAPI (blue) and AlexaFluor® 





When comparing NV NDs to PDI-NDs, a lower laser intensity was required to image 
NV NDs suggesting PDI-NDs have relatively weaker fluorescence. Furthermore, the 
staining pattern observed in Figure 4.33 shows NV NDs as small spherical particles 




















4.4 Discussion  
Two types of fluorescent ND were evaluated in this study: NDs functionalised with an 
organic fluorophore and NDs with NV defects. The NV NDs have been widely studied 
in the literature as fluorescent probes for various biomedical applications.142, 384 One 
major disadvantage is the high cost associated with forming the NV centres and hence 
an alternative way to enhance the optical properties of NDs would be to harness the 
ease of surface modification of NDs. Three types of ND were provided by Element 6 
Ltd. for this study: fluorescent NV NDs (40 nm and 90 nm) and non-fluorescent NDs 
prepared by either detonation (5-10 nm) or HPHT (50 nm).  
The non-fluorescent NDs were first characterised with SEM and DLS to investigate 
particle size. Detonation NDs were found to be their expected particle size of 5-10 nm 
using TEM (Figure 4.2). However, when analysing the aqueous ND suspension with 
DLS, a particle size of just under 2000 nm and a high polydispersity index of 0.152 
was measured. This suggests that that NDs exist mainly as aggregates in aqueous 
medium. Aggregation of detonation NDs is a problem widely observed in the literature 
and hence larger HPHT NDs were also investigated in this study.375, 376  
The HPHT NDs used in this study were found to be ~70 nm with DLS and had a low 
polydispersity index of 0.065. The particle size was slightly larger than expected and 
can be explained by the knowledge that DLS measures hydrodynamic diameter; HPHT 
NDs had a negative zeta potential (-57.6 ± 12.1 mV) due to the carboxylic surface 
functionality which is likely to affect the hydration shell. SEM of HPHT NDs 
suggested these NDs were also prone to aggregation (Figure 4.14).   
FTIR spectroscopy was used to confirm the presence of amino groups and carboxylic 
acid groups on the detonation and HPHT NDs, respectively (Figure 4.4 and 4.16). 
172 
 
Broad absorption was observed in the fingerprint region up to ~1800 cm-1 which is 
characteristic of NDs.136 The absorption can be explained by overlapping stretches due 
to the many bonding stretches present in the NDs structure. The amino and carboxylic 
acid groups were utilised for carbodiimide coupling to the fluorescent dye, PDI. 
4.4.1 PDI Conjugation to Detonation NDs 
A fluorescent PDI derivative has absorbance in the visible region and was used in order 
to optimise the probe. The detonation NDs had been provided with amino groups on 
the surface for carbodiimide coupling to the free carboxylic acid groups in the PDI 
derivative. EDC and Sulfo-NHS were employed to improve the efficiency of the 
coupling reaction, particularly because of their good solubility in water which is ideal 
for the biomedical applications of the probes.403, 404  
The coupling experiment was carried out in basic water (0.06 mM NaOH) due to the 
limited solubility of the PDI derivative in neutral water.391 Although neutral pH is 
optimal for EDC, the basic pH was necessary for solubilising the PDI derivative. 
Sulfo-NHS was included to improve reaction efficiency by reducing the formation of 
the stable N-acylurea side product, as shown in Figure 4.34. Firstly, the PDI derivative 
containing the carboxylate functionality was mixed with EDC/sulfo-NHS to form the 
amine reactive sulfo-NHS ester which can then go on to react with the amino groups 
on the NDs surface. The reaction was carried out at room temperature and left 
overnight for amide formation. PDI-NDs were then washed with centrifugation to 
remove EDC/sulfo-NHS and resuspended in neutral water. The supernatant from 
centrifugation had no absorbance in the visible spectrum and hence suggested PDI was 
successfully attached, rather than still dissolved in the basic water. The resultant 




Figure 4.34: Schematic of the reaction of EDC to form an amide showing  the 
production of unfavourable side product, N-acylurea, and alternative reaction pathway 
with sulfo-NHS.393 The same reaction scheme occurs if another carboxylic acid is 
introduced instead of an amine; this time to form an anhydride 
Focussing first on the detonation NDs, the attachment of PDI was confirmed with 
FTIR where stretches could be seen which corresponds to the carboxylic acid groups 
and aromatic structure of PDI (Figure 4.6), as well as a new peak associated with amide 
bond (1650 cm-1). There was also stretches associated with free amine groups however 
the zeta potential significantly decreased from +23.6 ± 9.82 mV for the unmodified 
NDs to -19.2 ± 4.87 mV, indicating a reduction in the amount of free amino groups on 
the surface. The PDI-NDs still appeared to aggregate as the particle size remained 
~2000 nm in DLS, as discussed in Figure 4.7.  
174 
 
UV-vis spectrometry and fluorescence analysis also suggested the presence of PDI, as 
small peaks could be seen which correspond to the wavelengths associated with PDI 
alone. It should be noted that the absorbance/fluorescence data is not ideal due to the 
high refractive index (RI) of NDs resulting in significant scattering.137, 387 Peaks at 470 
and 500 nm can be seen in the UV-vis spectrum (Figure 4.8) and an emission peak 600 
nm were observed after excitation at 500 nm (Figure 4.9). These wavelengths are 
consistent with that of free PDI. Hence, despite the stability issues, the probes were 
taken forward for in vitro cell studies, as the optical properties appeared promising. 
Furthermore, the high biocompatibility reported in the literature suggested NDs will 
be well-tolerated by cells, despite the aggregation.135 
The murine MSC cell line was used for in vitro studies, where cells were labelled by 
incubation with media containing particles for 24 hours. NDs and PDI-NDs had a 
limited cytotoxic effect in MSCs up to concentrations of 300 µg/ml. This is consistent 
with the literature where the high biocompatibility of NDs in various cell lines has 
been demonstrated.135-137 The conjugation of PDI did not affect cell viability which 
suggests the centrifuge washes were effective in removing EDC/sulfo-NHS. The 
concentration of 300 µg/ml is particularly high, especially compared to polymer-
stabilised PDI nanoparticles prepared in Chapter 2 where cell viability decreased 
below 80% at a labelling concentration of 20 µg/ml (Figure 2.22).  
Flow cytometry and confocal fluorescence microscopy were then used to assess 
cellular uptake as it was possible that the low cytotoxic effect could be attributed to 
limited uptake, particularly as DLS suggested NDs existed predominantly as large 
aggregates. MSCs were labelled with NDs and PDI-NDs for 24 hours and flow 
cytometry was carried out on live cell suspensions in PBS. The MSCs labelled with 
PDI-NDs exhibited increased fluorescence at 670 nm compared to untreated MSCs 
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(Figure 4.11). Cells labelled with unmodified NDs showed a slight increase in 
fluorescence but it was not as noteworthy as with the PDI-NDs. Both PDI-NDs and 
unmodified NDs showed very little change in fluorescence intensity with increasing 
dosing concentrations and the width of the peaks did not change; this suggests that 
increasing the dosing concentration did not affect the amount of NDs taken up per cell.  
During the flow cytometry experiment, there was a change in the laser side scatter 
between the untreated cells and both PDI-NDs and unmodified NDs (Figure 4.12). 
Side scatter is related to cell granularity, which is an indication of cellular uptake thus 
suggesting that the cells had taken up both unmodified NDs and PDI-NDs. It is also 
worth noting that the high RI of NDs may also affect laser scattering. The side scatter 
was similar for PDI-NDs and unmodified NDs which suggests that there was a similar 
amount of cellular uptake for both sets of particles. The difference in fluorescence 
intensity but similar side scatter suggests that PDI-NDs have greater fluorescence at 
670 nm than unmodified NDs.  
Confocal fluorescence microscopy was also carried out to visualise the PDI-NDs 
within the cells. PDI-NDs could be visualised in the majority of cells, which is 
consistent with the flow cytometry data where >80% of cells had taken up particles at 
100 µg/ml however unmodified NDs were not visible. PDI-NDs could only be 
visualised within cells when the 640 nm laser intensity was increased. Hence, the 
fluorescence is relatively low compared to polymer-stabilised nanoparticles in Chapter 
2. This could be partly due to a lower PDI concentration (MSCs were dosed based on 
the overall mass concentration of PDI-NDs) but also the light scattering effects of the 




4.4.2 PDI Conjugation to HPHT NDs 
Although the detonation NDs had low cytotoxicity, the aggregation was not ideal. 
Hence, larger NDs prepared by milling of larger HPHT diamond powders were 
investigated. Carboxylic acid groups were introduced to the NDs surface using an acid 
treatment which has been widely employed in the literature.392, 405, 406 A negative zeta 
potential (-57.6 ± 12.1 mV) was measured for COOH-NDs which confirmed the 
presence of carboxylic acid groups which exist as COO- groups in aqueous medium. 
This is significantly more negative than NDs with hydrogen/hydroxyl terminating 
groups which had a zeta potential of -33.4 ± 6.35 mV. FTIR also showed a broad 
stretch from 1650-1850 cm-1 which is indicative of carboxylic acid functionality, likely 
amongst other overlapping peaks due to the ND structure.136   
PDI was then conjugated to the surface using the exact same method as for the 
detonation NDs only this time to form an anhydride, rather than an amide bond. The 
PDI-NDs were washed by centrifugation to remove EDC/sulfo-NHS and resuspended 
in neutral water to form a cloudy pink suspension. The basic water supernatant did not 
have absorption in the visible region suggesting PDI had attached to the NDs. 
PDI conjugation was also confirmed with FTIR, where peaks at 1580, 1350 and 1650 
cm-1 were observed which can be attributed to C=O and aromatic C=C bonds in the 
PDI (Figure 4.18). In this case, a peak associated with a new anhydride bond could not 
be located however FTIR broad absorption was seen from in the fingerprint region up 
to ~1700 cm-1.  This is a common occurrence for NDs due to overlapping peaks 
associated with the various bonding stretches within the ND structure.136 The zeta 
potential was ~-57 mV for both the PDI-NDs and unmodified NDs. For the detonation 
NDs, a decrease in zeta potential had been observed which suggested a reduction in 
the amount of free amino groups. However, in this case, it is not unexpected that the 
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zeta potential remained similar as the carboxylic acid groups in the unmodified NDs 
are likely to exist as COO- in aqueous suspension. The particle size and polydispersity 
index of PDI-NDs remained relatively unchanged compared to the unmodified HPHT 
NDs.  
Light scattering effects resulted in broad absorption in the UV-vis spectrum for HPHT 
PDI-NDs, similarly to detonation NDs. A shoulder in the absorption profile occurs 
around 470 nm, which is consistent with the peak absorption for PDI. There was also 
fluorescence at 600 nm in the emission spectrum of HPHT PDI-NDs which further 
proved that PDI conjugation was successful. Therefore, the particles were taken 
forward for in vitro cell studies. 
MSCs were labelled with HPHT PDI-NDs for 24 hours, in the same way as for the 
detonation PDI-NDs. It initially appeared that HPHT PDI-NDs were slightly more 
cytotoxic than the detonation PDI-NDs as the average cell viability dipped below 80% 
at some of the lower concentrations, however the standard deviation was quite high. 
Cell viability did not decrease with increasing dosing concentrations and >80% 
viability was observed at 200 and 300 µg/ml. 
Cellular uptake was assessed using flow cytometry and confocal fluorescence 
microscopy. The flow cytometry was carried out in the same way as with the 
detonation PDI-NDs. The fluorescence intensity at 670 nm increased compared to the 
untreated cells; however, increasing the dosing concentration only moved the peak 
slightly (Figure 4.22). Cellular uptake was also confirmed from seeing a change in cell 
granularity by measuring the side scatter compared to untreated MSCs. When 
comparing the detonation and HPHT NDs, it appeared that HPHT PDI-NDs had 
greater fluorescence intensity. This could be due to increased cellular uptake or 
brighter fluorescence, both of which may be attributed to less particle aggregation.  
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Confocal fluorescence microscopy enabled the visualisation of the HPHT PDI-NDs 
within MSCs. The degree of labelling seemed similar to that of detonation NDs 
(~80%); this may mean that the cellular uptake is similar but the fluorescence of HPHT 
PDI-NDs is stronger. As for the detonation PDI-NDs, the laser intensity has to be 
increased in order to visualise the HPHT PDI-NDs. This was not the case for the 
polymer-stabilised nanoparticles from Chapter 2 and so NV NDs were investigated to 
see if they had a stronger fluorescent signal for cell tracking.  
4.4.3 NV NDs 
Despite the higher cost, NDs with NV defect were evaluated for comparison with PDI-
NDs. NV ND with expected particle sizes of 40 nm (NV-40) and 90 nm (NV-90) were 
obtained from Element 6 Ltd. The particle size was confirmed by DLS and the low 
polydispersity index (~0.1) for both samples indicated an even particle size 
distribution. The zeta potential of both NDs was negative; however, NV-40 was more 
negative which can be explained by the fact that the measurement is derived from 
electrophoretic mobility which is size-dependent. In addition to this, there has long 
since been an issue with standardising ND synthesis and so many of the properties of 
NV NDs vary. This is due to the large number of factors which influence the defects, 
such as particle size, the percentage of graphitic form of carbon, surface functionality, 
ND density and RI of the layers.138 Hence, the difference in zeta potential could be 
related to the number of NV centres near the surface.  
The absorption properties of the NV NDs were investigated with UV-vis spectroscopy 
(Figure 4.25). The light scattering properties were evident which is consistent with 
data reported in the literature and can be explained by the knowledge that NDs have 
high RI of 2.42.137, 387. For the PDI-NDs, the peak absorption of the PDI could be 
identified however there were no peaks in the NV NDs UV-vis spectra. NV NDs 
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usually have absorbance at ~560 nm which corresponds to emission at ~700 nm, a 
characteristic of the major defect (NV-) which can be seen in Figure 4.26.373 Following 
this result, the optical properties were later assessed in cells to explore this further.  
Similarly, NV NDs were evaluated in in vitro cell studies to assess cytotoxicity (ATP 
assay), labelling efficiency (flow cytometry) and intracellular localisation (confocal 
fluorescence microscopy). Both NV-40 and NV-90 NDs appeared to be slightly more 
cytotoxic than PDI-NDs; however, cell viability remained >70% at all concentrations 
(up to 100 µg/ml, shown in Figure 4.27). It was found that cell viability decreased with 
increasing concentrations and it appeared that NV-40 NDs were more cytotoxic. This 
was investigated further by dosing MSCs by ND number rather than mass 
concentration, which was estimated based on an approximate density of 3.5 g cm-3 for 
commercial NDs and assuming perfect spherical morphology.401, 402 In this case, it was 
found that NV-40 and NV-90 NDs had a similar effect on cell viability suggesting that 
the amount of NDs, rather than the particle size, caused the cytotoxic effect. Much 
higher cell viability was seen in this experiment, compared with mass concentration 
dosing, as the numbers of NDs used did not reach the higher dosing concentrations 
previously (1.8x1010 NDs = ~10 µg/ml).  
Flow cytometry showed greater increases in fluorescence intensity and a higher 
percentage of fluorescent cells when MSCs were dosed with NV-90 NDs (Figure 
4.29). At the highest concentration of 100 µg/ml, 88% and 57% of the cell population 
were labelled with NV-90 and NV-40 NDs, respectively. When comparing MSCs 
dosed with different numbers of NDs, rather that mass concentration, MSCs dosed 
with NV-40 NDs displayed negligible fluorescence.  When cells were labelled with 
1.8 x 1010 NV-90 NDs, >40% cell uptake was observed, which is consistent with 
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equivalent mass-based dosing concentration of 10 µg/ml. The flow cytometry results 
from dosing by ND numbers suggested that NV-90 NDs had stronger fluorescence. 
The NV NDs were subsequently visualised in MSCs using confocal fluorescence 
microscopy. NV-90 NDs could be seen in the majority of cells whereas NV-40 NDs 
were more difficult to see (Figure 4.33). There are two possible reasons for this 
difference: either fewer NV-40 NDs are taken up by cells or they emit lower levels of 
fluorescence. It is most likely the latter as for confocal imaging, MSCs were dosed at 
100 µg/ml so there should be more NV-40 NDs than NV-90 NDs. In addition to this, 
cellular uptake has been observed for all NDs in this study and is widely reported in 
the literature. Therefore, it is likely that NV-40 NDs emit lower levels of fluorescence 
than NV-90 NDs. This statement agrees with the literature as larger NDs tend to have 















A selection of NDs have been evaluated as fluorescent probes: PDI-NDs (detonation 
and HPHT) and NV NDs (NV-40 and NV-90). NV-90 NDs have shown to be superior 
to the smaller NV-40 NDs in terms of fluorescence intensity, cellular uptake and 
cytotoxicity. Additionally, NV-90 performed better than non-irradiated NDs and PDI-
NDs.  
Non-irradiated NDs have weak fluorescence intensity due to the fewer number of NV 
centres. PDI-NDs, prepared by attaching PDI fluorophore to the surface of non-
irradiated NDs, were prepared as it was thought it would provide a cheaper alternative 
to NV NDs. However, the processing of small NDs results in significant aggregation 
which could not be combatted by surface modification in the present study. Initially, 
it appeared that HPHT NDs would be less prone to aggregation than detonation NDs; 
however, NV-90 NDs still performed better in flow cytometry and aggregates of 
HPHT NDs could be seen in confocal images.  Future work could involve 
functionalising the surface of NDs with stabilisers, such as PEG.378  
The results herein suggest that NV NDs of 90 nm size can be used as effective 
fluorescent probes for the tracking of MSCs. Other common fluorescent probes, such 
as other carbon-based materials and quantum dots (QD), rely on surface coatings to 
reduce cytotoxicity. The high fluorescence of the 90 nm NV NDs, in combination with 
the capacity for high dosing due to the inherent biocompatibility, pose 90 nm NV NDs 
as promising candidates for many biomedical applications; particularly for 
determining the fate and biodistribution of administered cells using fluorescent 
imaging techniques. Furthermore, these particles could be used for tracking cells in 




Despite this, there are still further challenges which will need to be met in order to see 
clinical translation of ND probes. Even though ND-90 had the best performance, this 
study has highlighted the difficulties in working with NDs, specifically when 
characterising surface chemistry and preventing reaggregation. Furthermore, the 




























Chapter 5: General Discussion and Perspectives 
The aim of the present work was to investigate the use of perylene diimide (PDI) based 
nanoparticles in cell and hydrogel tracking. Regenerative medicine therapies (RMT) 
have great potential as treatments for a variety of diseases and injuries however clinical 
translation is hindered by lack of safety and efficacy data.20, 44 Encapsulation of RMTs 
in protective hydrogels can increase cell survival by providing a scaffold for cell 
growth; this is particularly relevant in the treatment of spinal cord injury (SCI) where 
hydrogels can increase local retention and prevent cell sedimentation.33, 34 Herein, PDI 
nanoparticles have been investigated for their ability to label mesenchymal stromal 
cells (MSC) and their encapsulating collagen hydrogels for cell and hydrogel tracking 
in vivo with multispectral optoacoustic tomography (MSOT). Furthermore, PDI has 
also been combined with nanodiamonds to assess their biocompatibility and 
performance as fluorescent probes. 
PDI stands out as an excellent candidate for designing photoacoustic (PA) probes due 
to its high molar extinction coefficient meaning that it can be detected by both 
photoacoustic imaging (PAI) and fluorescence imaging. Furthermore, PDI exhibits 
extremely high photostability, setting it apart from other small molecule dyes such as 
cyanine dyes. In the present study, a near-infrared (NIR) absorbing PDI derivative was 
prepared following well-established procedures from commercially available 
perylene-3,4,9,10-tetracarboxylic dianhydride, (PTCDA). A brominated PTCDA 
derivative was first prepared using a protocol from Sengupta et al.237 Following this, 
the diimide was formed and the bay bromine substituents were substituted for 
pyrrolidine groups as reported by Sukul et al.236 This resulted in a red-shift to the NIR 
region with peak absorbance at 710 nm. The synthesis was carried out successfully on 
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a larger scale to yield enough NIR PDI for all experiments; each step of the procedure 
was fully characterised with 1H NMR, FTIR and UV-vis spectroscopy.  
NIR PDI was then used to prepared nanoparticles for cell and hydrogel labelling. A 
nanoprecipitation method was employed as a simple route to prepare stable 
nanosuspensions. This method took advantage of the hydrophobicity of NIR PDI, 
dissolving first in acetone before adding to water in the presence of a stabiliser. Two 
polymer stabilisers were investigated: our novel star hyperbranched block copolymer 
(SHBP) and poly(vinyl alcohol) (PVA).275 All nanoparticles prepared with SHBP 
stabiliser had a particle size of ~150-170 nm and PVA nanoparticles were sized slightly 
smaller at ~115 nm; both of which were suitable for cell labelling. 
The NIR absorbance of the PDI nanoparticles was confirmed by UV-vis spectroscopy 
and MSOT of the nanoparticle solutions in phantoms. Absorbance at 710 nm was 
observed in both UV-vis spectroscopy and MSOT and the nanoparticle solutions could 
be effectively visualised with MSOT when irradiated at 710 nm. PDI nanoparticles 
were then used to label MSCs by incubating cells with the nanoparticles over a 24hr 
period. The CellTiter-Glo® assay was carried out and it was observed that PDI 
nanoparticles were well-tolerated by MSCs up to a concentration of 15 µg/ml for all 
batches; however, when the ratio of PDI:SHBP was varied, it was found that higher 
amounts of stabiliser resulted in a decrease in cell viability. PVA-stabilised 
nanoparticles had a limited cytotoxicity up to the highest dosing concentration (40 
µg/ml).  
The cellular uptake of PDI nanoparticles was assessed with flow cytometry and 
confocal fluorescence microscopy. All PDI nanoparticles were efficiently taken up by 
MSCs and the highest uptake was seen for PDI-SHBP nanoparticles with a PDI:SHBP 
ratio of 1:1. PDI nanoparticles could also be visualised inside MSCs using confocal 
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fluorescence microscopy and the pattern of labelling was consistent with endosomal 
location. The PDI nanoparticles predominantly existed as small, spherical 
nanoparticles although some rod-like structures were observed in both confocal 
fluorescence microscopy and scanning electron microscopy (SEM). This effect was 
independent of the type or amount of stabiliser used and is more likely to be associated 
with experimental parameters in the nanoprecipitation method, for example, the rate 
of addition of PDI/stabiliser or the rate of solvent evaporation. Future work could 
investigate this further by gaining greater control over the rate of solvent addition (i.e. 
automation) however it was out of the scope of the present study. Furthermore, the 
rod-like structures were in the minority compared to those of spherical morphology 
and they did not appear to affect the viability of the cells.  
The results in Chapter 2 have demonstrated a straightforward route for preparing NIR-
absorbing PDI nanoparticles. These particles exhibit high absorbance at 710 nm and 
can be efficiently detected with MSOT. Moreover, the nanoparticles are efficiently 
taken up by MSCs with limited cytotoxic effect at a labelling concentration of 15 
µg/ml. PDI nanoparticles with SHBP stabiliser (PDI: SHBP 1:1) stand out due to 
having the most efficient cellular uptake and these particles have also been explored 
in rodent models previously in our group.274 In the present study, PVA-stabilised PDI 
nanoparticles were also identified as viable candidates for cell tracking as although 
cellular uptake was slightly lower, these particles had a limited cytotoxic effect up to 
a dosing concentration of 40 µg/ml. The tuneability and photostability of the PDI, 
coupled with the ease of nanoparticle preparation and limited toxicity are key 
advantages that PDI nanoparticles have over other probes on the market such as gold 
nanoparticles, QDs and cyanine dyes.245  
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The PDI nanoparticles (PDI:SHBP 1:1 and PVA) were also investigated for their 
ability to label encapsulating hydrogels (Chapter 3). Collagen constructs were 
prepared following a well-established procedure as collagen is a component of the 
extracellular matrix (ECM) and has previously been applied to SCI.32 MSCs were 
included in the collagen premix to enable cell encapsulation during the gelation 
procedure. Collagen gelation was initiated by both pH and temperature; NaOH was 
added to the collagen (previously stored in acetic acid solution) and the gels were 
incubated at 37 °C (previously stored on ice). The incorporation of MSCs caused a 
contraction of the collagen gel which is a phenomenon widely observed in the 
literature.42, 339  PDI nanoparticles were also included in the gel premix in order to label 
the gels.  
The MSCs had been engineered to express luciferase and hence cell viability could be 
determined by measuring the bioluminescent signal after the addition of luciferase. A 
signal could be observed in all of the gels 1-week post-synthesis, although cell viability 
was generally lower in gels labelled PVA-stabilised nanoparticles. There was no 
bioluminescent signal from the control gels containing nanoparticles but no cells, thus 
confirming the signal was associated with cells and not nanoparticles. The total flux 
of each gel could be quantified which highlighted that overall, there was greater flux 
at 1 week for unlabelled gels and gels labelled with PDI-SHBP nanoparticles thus 
suggesting the cells were viable and proliferating. For gels labelled with PDI-PVA 
nanoparticles, signal was relatively low or decreased from 1 day to 1 week which 
suggested that these nanoparticles had a cytotoxic effect when incorporated into gels. 
The experiments also highlighted that cells remained inside the gels for 1 week and 
did not migrate out to the well.  
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The gels were then analysed with MSOT to check that the PDI nanoparticles could 
effectively provide contrast in the gels. It was found that SHBP-stabilised 
nanoparticles had greater MSOT signal in gels compared to PVA-stabilised 
nanoparticles. This result was unusual as MSOT of the nanoparticle suspensions 
produced similar MSOT signal. The difference could be due to the fact that the MSOT 
only images one slice of the gels and it is not known whether PDI nanoparticles are 
homogenous throughout the gel. Furthermore, for both sets of gels, the MSOT signal 
was lower at 1-week compared to 1-day. Both of these observations suggested 
nanoparticles were leaching from the gels and it was possible that the extent of 
leaching was more pronounced for PVA-stabilised nanoparticles. This may be 
associated with the knowledge that SHBP is a more complex, branched polymer with 
hydrophilic and hydrophobic regions and thus may have more of an interaction with 
the amphoteric collagen compared to the simpler linear PVA chains.274, 275, 408, 409  
The leaching was investigated in an experiment where gels were prepared in 96-well 
plates and moved to a new well every few days and fluorescence imaging was carried 
out after 1 week. A fluorescent signal was observed for all gels that contained 
nanoparticles but only background signal was observed for the MSC control gel 
without nanoparticles; this confirmed that the nanoparticle fluorescent signal was 
being detected. Fluorescence was also observed in all the wells that had previously 
contained a labelled gel thus showing that the nanoparticles leach from the gels. When 
this was quantified as the total flux of each well, the amount of fluorescent signal in 
each well was similar and it was difficult to quantify the extent of leaching for each 
nanoparticle concentration. Future work should investigate this further by dialysing 
the gels and taking UV-vis spectroscopy measurements of the surrounding medium.  
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The SHBP-stabilised PDI nanoparticles could effectively label collagen hydrogels and 
be detected with MSOT and hence can be used to track gel fragmentation in the short 
term; however, the labelled constructs would need to be optimised for longer studies 
to monitor hydrogel degradation over time. Future work should look to optimise the 
constructs to limit nanoparticle leaching; studies in the literature have shown that 
increasing collagen concentration will decrease the pore size of the gel thus limiting 
space for diffusion of molecules.342, 343 This will need to be carefully considered in 
order to avoid compromising cell viability in the gels. An alternative option would be 
to modify the PDI nanoparticles to increase the interaction with the collagen, for 
example by increasing electrostatic interactions or by covalent conjugation.341, 408  
In a separate study (Chapter 4), a different red PDI derivative was attached to the 
surface of nanodiamonds (NDs). This red PDI derivative was used in order to optimise 
the probes with the idea that the protocols could be applied to NIR PDI in the future. 
Furthermore, the high fluorescence of the red PDI derivative combined with the high 
biocompatibility of NDs is ideal for tracking cells in organoids in vitro and detecting 
administered cells ex vivo using fluorescence microscopy. The performance of the 
PDI-NDs was compared to commercially available fluorescence NDs with nitrogen-
vacancy (NV) defects. NV NDs have been explored for fluorescence imaging 
applications however a major drawback is the cost associated with the high energy 
processes required to produce the defects.142  
PDI was conjugated to the surface of detonation NDs and milled high-pressure high-
temperature (HPHT) NDs via carbodiimide coupling. This produced pink cloudy 
suspensions where changes in the FTIR spectra and measured zeta potential indicated 
PDI attachment. The optical properties of the NDs also confirmed PDI attachment as 
peaks associated with PDI could be identified; however, the light scattering effect of 
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the NDs was apparent. When measuring the particle size distribution of the detonation 
NDs, particle sizes of ~2000 nm were measured suggesting severe aggregation, which 
is consistent with detonation NDs in the literature.375, 376 Hence why HPHT NDs were 
also investigated which had a particle size of ~70 nm and NV NDs with particle sizes 
of 40 nm (NV-40) and 90 nm (NV-90) were also explored. Analysis of the 
fluorescence properties of NV NDs identified emission peaks associated with the NV- 
defect.400 
All of the NDs were assessed in vitro for labelling of MSCs. Extremely low 
cytotoxicity was observed for all PDI-NDs, where >80% of cells were viable at dosing 
concentrations of up to 300 µg/ml. When comparing to PDI nanoparticles from 
Chapter 2, where cell viability decreased >20 µg/ml, there is a huge difference and 
hence highlights the high biocompatibility of NDs.135 For NV NDs, the highest 
labelling concentration was 100 µg/ml where the cell viability was >70% for all 
concentrations. It appeared that NV-40 NDs were more cytotoxic however further 
experiments of dosing by number rather than mass concentration suggested that this 
was due to a higher number of NDs and not a particle size effect.   
The cellular uptake of the NDs was assessed with flow cytometry and confocal 
fluorescence microscopy. For PDI-NDs, increases in fluorescence intensity and side 
scatter of cells (related to cell granularity) suggested the particles had been taken up. 
There was a slight increase for unmodified NDs suggesting good cellular uptake 
however the low fluorescence here suggested the attachment of PDI increased 
fluorescence in cells labelled with PDI-NDs. The increase in fluorescence intensity 
was greater for HPHT PDI-NDs compared to detonation PDI-NDs which may be due 
to greater uptake or brighter fluorescence, both of which can be associated with less 
particle aggregation. For NV NDs, NV-90 NDs showed greater increases in 
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fluorescence intensity and a higher percentage of cells fluorescent compared to NV-
40 NDs, this is consistent with the literature where larger NDs have more NV 
defects.372 
Confocal fluorescence microscopy was carried out on MSCs which had been labelled 
with NDs and subsequently fixed and stained. PDI-NDs could be visualised within 
MSCs however the excitation laser had to be increased which was not the case for NV 
NDs; this suggested the fluorescence of PDI-NDs was relatively weak. NV-90 NDs 
exhibited bright fluorescence in MSCs however NV-40 NDs were more difficult to 
visualise which can be attributed to their weaker fluorescence.  
Overall, the findings of Chapter 4 suggest that NV-90 NDs can be used as effective 
fluorescent probes for labelling of MSCs as they have limited cytotoxicity, good 
cellular uptake and bright fluorescence. The study also highlighted the potential for 
the use of HPHT PDI-NDs however optimisation would be required to stabilise these 
NDs and increase PDI loading. Once optimised, NIR PDI could be attached to the 
surface using the same protocols and the probes could be utilised in cell tracking with 
MSOT. Moreover, the extremely high biocompatibility demonstrated herein suggest 
PDI-NDs could be used for labelling cells for ex vivo fluorescence microscopy; the use 
of high dosing concentrations could counteract problems associated with signal 
dilution upon cell division.142 This poses NDs as a great alternative to common 
fluorescent probes, such as metal-based QDs, where surface coatings are required to 
prevent toxicity.121 Furthermore, the extremely low toxicity of the NDs stands out from 
other carbon-based materials, such as graphene, MWCNTs, fullerene and carbon dots, 





In conclusion, PDI derivatives hold great promise for the design of novel probes for 
cell tracking with MSOT and fluorescence imaging. MSOT can be used for the 
tracking of administered cells and encapsulating hydrogels in rodent models where one 
of the key advantages is the ability to spectrally unmix the signals amongst multiple 
endogenous and exogenous absorbers. The versatility of PDI derivatives is therefore 
highly advantageous for MSOT, as a library of PDI derivatives with different 
absorption profiles have been synthesized. Two PDI nanoparticle systems have been 
investigated herein: PDI nanoparticles by nanoprecipitation (Chapter 2) and PDI-NDs 
(Chapter 4). The nanoprecipitation method stands out as a facile way to prepare PDI-
based probes where different PDI derivatives could be used to prepare probes for 
simultaneous cell and hydrogel tracking with MSOT.  
We have previously published a study for tracking of MSCs in rodent models with PDI 
nanoparticles (Chapter 2);274 however, the hydrogel construct explored in Chapter 3 
will need further optimisation to prevent nanoparticle leaching and enable longitudinal 
tracking of hydrogel integrity. Furthermore, the present work has shown that 
combining PDI with NDs (Chapter 4) will enable high dosing concentrations due to 
the biocompatibility of the NDs and hence future work should look into stabilising 
these particles against aggregation. NDs could be used as a versatile PDI-based probe 
for MSOT which could also be used for ex vivo fluorescence microscopy; moreover, 
the surface chemistry of NDs is widely explored to enable conjugation of other contrast 
agents, thus posing NDs as an interesting candidate for designing multimodal 
probes.388, 389  Whilst PDI nanoparticles prepared by nanoprecipitation perform the best 
in the present study, particularly due to high MSOT signal and limited aggregation, 
further optimisation could also present PDI-NDs as viable candidates for cell tracking. 
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5.2 Future Work 
At present, the labelled collagen gels are being tested in vivo in our group to investigate 
cell viability and MSOT signal in rodent models. Future work on this project should 
aim to investigate the stability and homogeneity of the nanoparticles in the gel, and 
look to prevent nanoparticle leaching by increasing the interaction of the PDI 
nanoparticles with the collagen matrix. This could include looking at altering the 
surface charge of the nanoparticles for increasing electrostatic attraction with the 
collagen, or alternatively increasing the collagen concentration could decrease the pore 
size hindering diffusion of the nanoparticles. Another route could look at covalently 
attaching the PDI nanoparticles to the collagen however all of these options will need 
to carefully consider the effect on cell viability.  
Further work could also be carried out to optimise the PDI-NDs by increasing the 
surface loading of PDI and confirming that the PDI does not come off the surface of 
the NDs with time. It would also be beneficial to investigate other functional groups 
which could be introduced to the surface to prevent aggregation. Once the particles 
have been optimised in terms of signal and stability, a NIR-absorbing PDI derivative 
could be synthesized with appropriate functional groups for conjugation to the ND 
surface. These probes could then be investigated for use in in vivo PA imaging and ex 
vivo fluorescence microscopy in rodent models to obtain preclinical data, such as 
information about biodistribution and nanoparticle clearance.  
On a final note, the design of novel probes for cell and hydrogel tracking will improve 
our understanding of the mechanisms and biodistribution of administered cell-based 
RMTs. In turn, having more safety and efficacy data will aid the design and support 
the clinical translation of RMTs. In order to obtain as much information as possible, a 
multi-pronged approach is needed. Hence, combing PA probes with cells expressing 
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bioluminescent or fluorescent reporter genes would provide information from multiple 
imaging modalities. Moreover, the design of multimodal probes is also of great interest 
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Figure A1: FTIR spectra of perylene-3,4,9,10-tetrabutylester (compound 1a) and 1,7-
dibromoperylene-3,4,9,10-tetracarboxytetrabutylester (compound 1b). 
 


















Figure A2: FTIR spectrum of N,N’-dicyclohexyl-1,7-di(pyrrolidinyl)perylene-
3,4,9,10-tetracarboxy diimide (compound 4). 
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Figure A3: Number particle size distribution of PDI-SHBP nanoparticles (PDI:SHBP 
2:1) measured by DLS. The different colours represent 3 measurement scans with 
DLS. 


















Figure A4: Number particle size distribution of PDI-SHBP nanoparticles (PDI:SHBP 







Figure A5: SEM images of PDI-SHBP nanoparticles prepared with PDI:SHBP ratios 
of (a) 2:1 and (b) 3:1. 
  






































Figure A6: Live cell flow cytometry of MSCs in PBS labelled with PDI-SHBP 
nanoparticles with PDI:SHBP ratio of (a) 2:1 and (b) 3:1, where the percentage of 
cells positive was >92% for all concentrations.  Fluorescence intensity was measured 






























Figure A7: The percentage of cells positive with PDI nanoparticles (SHBP- and PVA-
stabilised) at various concentrations using gate shown previously in Figure 11a (n=2 
and the error bars represent the range). 
  
Figure A8: Confocal fluorescence microscope images of MSCs labelled with PDI-
SHBP nanoparticles (a) 2:1 and (b) 3:1. Cells were fixed and stained with DAPI (blue 






Figure A9: MSOT images at 710 nm of gels labelled with SHBP nanoparticles at 











Figure A10: MSOT images at 710 nm of gels labelled with PVA nanoparticles at 











Figure A11: MSOT images at 710 nm of gels labelled with SHBP nanoparticles at 











Figure A12: MSOT images at 710 nm of gels labelled with PVA nanoparticles at 



















































































































Figure A13: Repeat of MSOT of gels prepared and imaged 1-day post-synthesis, where 
the MSOT mean pixel intensity across a range of wavelength is shown for gels 
encapsulating 2x105 cells and labelled with (a) PDI-SHBP and (b) PVA-nanoparticles. 


















































































































Figure A14: Repeat of MSOT of gels prepared and imaged 1-week post-synthesis, 
where the MSOT mean pixel intensity across a range of wavelength is shown for gels 
encapsulating 2x105 cells and labelled with (a) PDI-SHBP and (b) PVA-nanoparticles. 








































































































































Figure A15: Quantification of the radiant efficiency of gels and wells during 
fluorescence imaging.  Gels were labelled with (a) SHBP-stabilised and (b) PVA-
stabilised PDI nanoparticles and (c) unlabelled control gel was included which 
contained MSCs, as well as a unlabelled gels without MSCs. Gels were moved to a 




























Figure A16: The percentage of cells positive with HPHT PDI-NDs at various 
concentrations using gate shown previously in Figure 4.11 in Chapter 4 (n=2 and the 
error bars represent the range). 





















Figure A17: Emission spectrum (λex = 560 nm) of NDs (0.1 mg/ml water). An 
emission filter was used to block emission below 590 nm to counteract the effects of 
light scattering. 
